

[Netformulary](#)

[KNOW](#)

[Traffic Light Classifications](#)

Comments, feedback and requests for further information to nwcb.medsqueries@nhs.net with TAG in the subject line

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	(L-) Carnitine	<i>(Various - Carnitor®)</i>	NHSE	Carnitine Deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	(Para-)aminosalicylic acid	<i>(Granupas®)</i>	NHSE	Tuberculosis	Not recommended for routine use	NICE has not issued any guidance.
RED	Abacavir	<i>(Ziagen®)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Abacavir + dolutegravir + lamivudine	<i>(Triumeq®)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Abacavir and lamivudine	<i>(Generics are available)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Abaloparatide	<i>(Eladynos®)</i>	NHSE	Male and juvenile osteoporosis	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLUE	Abaloparatide	Eladynos®)	ICB	osteoporosis after menopause	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available	TA991 – August 2024
RED	Abatacept	(Orencia®)	ICB	Rheumatoid arthritis - 1st line biologic after failure of non-biologic DMARDs - as per NICE TA 280	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA280 - Apr 13
RED	Abatacept	(Orencia®)	NHSE	Treatment of Juvenile Idiopathic Arthritis (JIA) as per NICE TA 373	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA373 - Dec 15
RED	Abatacept	(Orencia®)	ICB	Rheumatoid arthritis - after other DMARDs including a TNF inhibitor - as per NICE TA 195	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
BLACK	Abatacept	(Orencia®)	ICB	Psoriatic arthritis after DMARDs as per NICE TA 568 terminated appraisal	Not commissioned. No NHS prescribing in primary or secondary care	TA568 - Mar 19
BLACK	Abatacept	various, plus biosimilars	ICB	moderate rheumatoid arthritis after conventional DMARDs have failed	Not commissioned. No NHS prescribing in primary or secondary care	TA715 – July 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Abatacept (subcutaneous)	(Orencia® (subcutaneous))	ICB	First line biologic option for moderate to severe active rheumatoid arthritis in adults who responded inadequately to one or more DMARDS (including MTX)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Abemaciclib	(Verzenios®)	NHSE	Locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults - as per NICE TA 563	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA563 - Feb 19
RED	Abemaciclib	(Verzenios®)	NHSE	Breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA579 - May 2019
RED	Abemaciclib	Verzenios®	NHSE	®) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA810 – July 2022
RED	Abemaciclib (Verzenios®) with fulvestrant	Verzenios®	NHSE	hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA725 – September 2021
RED	Abiraterone	(Zytiga®)	NHSE	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (in combination with prednisone or prednisolone) - as per NICE TA 387	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA387 - Apr 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Abiraterone	Zytiga®	NHSE	newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA721 – August 2021
RED	Abiraterone acetate	(Zytiga®)	NHSE	Castration resistant metastatic prostate cancer previously treated with docetaxel - as per NICE TA 259	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA259 - Jun 12
BLUE	Abrocitinib	Cibinqo®	ICB	moderate to severe atopic dermatitis	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA814 – August 2022
RED	Acalabrutinib	Calquence®	NHSE	chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA689 – April 2021
RED	Acamprosate	(Campral EC / generics are available)	NCC	Maintenance of abstinence in alcohol-dependent patients. Prescribing of treatments for alcohol misuse, including acamprosate and disulfiram (and also nalmefene) are the responsibility of the specialist since local alcohol misuse services are not commissioned from GPs practices	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG115 - Feb 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	ACE Inhibitors - cor pulmonale	(Various)	ICB	Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do (x).	Not recommended for routine use	CG101 - Jul 10
Double Red	ACE inhibitors with Angiotensin-II Receptor Antagonists (ARBs)	(Various)	ICB	NICE Do Not Do (Not a licensed indication).	Not recommended for routine use. Specialist prescribing only	CG182 - Jul 14
RED	Acitretin	(Neotigason®)	ICB	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	ActiPatch®	(ActiPatch®)	ICB	Relief of musculoskeletal pain	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Treatment of adults with psoriasis as per NICE TA 146 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA146 - Jun 08
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Severe active Crohn's disease which has not responded to conventional therapy - as per NICE TA 187	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA187 - May 10
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Rheumatoid arthritis - after other DMARDs including a TNF inhibitor - as per local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA195 - Aug 10

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Treatment of psoriatic arthritis (including switching between treatments) - as per local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA199 - Aug 10
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Moderate to severe ulcerative colitis (primary) - as per NICE TA 329	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA329 - Feb 15
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Juvenile idiopathic rheumatoid arthritis (JIA) - option in children with chronic anterior uveitis - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA373 - Dec 15
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Treatment of children and young people with polyarticular juvenile idiopathic arthritis and for enthesitis-related juvenile idiopathic arthritis as per NICE TA 373	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA373 - Dec 15
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Ankylosing spondylitis - as per local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Adalimumab	(Humira® / Biosimilar)	ICB	2nd line anti-TNF in patients with joint or skin autoimmune disease who develop IBD on etanercept - as per local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Adalimumab	(Humira® / Biosimilar)	ICB	Treatment of (non-radiographic) axial spondyloarthritis - as per local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Moderate to severe hidradenitis suppurativa - as per NICE TA 392	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA392 - Jun 16
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Plaque psoriasis in children and young people - as per NICE TA 455	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA455 - Jul 17
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Anti-TNF Alpha treatment option for paediatric patients with severe refractory uveitis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA460 - Jul 17
RED	Adalimumab	(Humira®)	NHSE	Anti-TNF treatment option for adult patients with severe refractory uveitis - as per NHS England policy and NICE TA 460 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA460 - Jul 17
RED	Adalimumab	various, plus biosimilars	ICB	moderate rheumatoid arthritis after conventional DMARDs have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA715 – July 2021
RED	Adalimumab	(Humira® / Biosimilar)	NHSE	Behcet's syndrome (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Adalimumab	<i>(Humira® / Biosimilar)</i>	NHSE	Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Adalimumab	<i>(Humira® / Biosimilar)</i>	ICB	Weekly use for treatment of psoriasis in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE TA146 does not cover weekly use
RED	Adalimumab (biosimilar)	<i>(Imraldi® / Amjevita®)</i>	ICB	Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Adalimumab (biosimilar)	various	ICB	weekly use for dose escalations in NICE-approved rheumatology indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Adefovir	<i>Hepsera®</i>	NHSE	Hepatitis B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG165 - Oct 17
Double Red	ADHD drugs - various	<i>(Various)</i>	ICB	First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication).	Not recommended for routine use - Specialist initiation only	CG72 - Feb 16
Double Red	ADHD drugs - various	<i>(Various)</i>	ICB	Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication).	Not recommended for routine use - Specialist initiation only	CG72 - Feb 16
BLACK	Afamelanotide	Scenesse®	NHSE	erythropoietic protoporphyria	Not commissioned. No NHS prescribing in primary or secondary care	HST27 – July 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Afatinib ▼	(Giotrif® ▼)	NHSE	Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer - as per NICE TA 310	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA310 - April 2014
BLACK	Afatinib ▼	(Giotrif® ▼)	NHSE	Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA444 - May 17
RED	Aflibercept	(Eylea®)	ICB	Treatment of Wet Age-related Macular Degeneration	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA294 - Jul 13
RED	Aflibercept	(Eylea®)	ICB	Wet Age-related Macular Degeneration (AMD)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA294 - Jul 13
RED	Aflibercept	(Eylea®)	ICB	Wet Age-related Macular Degeneration (AMD) in new patients	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA294 - Jul 13
RED	Aflibercept	(Eylea®)	ICB	Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA305 - Feb 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Aflibercept	(Zaltrap®)	NHSE	Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil-based therapy) - as per NICE TA 307 - NICE Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	TA307 - Mar 14
RED	Aflibercept	(Eylea®)	ICB	Treatment of visual impairment caused by diabetic macular oedema (DMO)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA346 - Jul 15
RED	Aflibercept	(Eylea®)	ICB	Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA409 - Sep 16
RED	Aflibercept	(Eylea®)	ICB	Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA486 - Nov 17
RED	Aflibercept	(Eylea®)	ICB	Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Aflibercept	(Eylea®)	ICB	Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Aflibercept (switched to Ranibizumab (Lucentis®))	(Eylea®)	ICB	Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NG82 - Jan 18
RED	Agalsidase alfa and beta	(Replaga® (alpha) / Fabrazyme® (beta))	NHSE	Fabry disease (α-galactosidase A deficiency)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Agomelatine	(Valdoxan®)	ICB	4th line use in depression where other treatments have failed or not been tolerated (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA231 - Sep 11
RED	Albumin bound paclitaxel	Abraxane®	NHSE	with gemcitabine for untreated metastatic pancreatic cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA476 - Sep 17
RED	Albutrenpenonacog alfa	(Idelvion)	NHSE	Haemophilia B - as per NHS England policy SSC1652	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Aldesleukin	(Proleukin)	NHSE	Cancer - metastatic renal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Alectinib	(Alecensa®)	NHSE	Untreated ALK-positive advanced non-small-cell lung cancer - as per NICE TA 536	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA536 - Aug 18
RED	Alectinib	Alecensa®	NHSE	adjuvant treatment of ALK-positive non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1014 – November 2024
BLACK	Alectinib ▼	(Alecensa® ▼)	NHSE	Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA438 - Mar 17
RED	Alemtuzumab	(Lemtrada®)	NHSE	Chronic lymphocytic leukaemia (CLL) - as per NHS England policy 2013	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Alemtuzumab	(Lemtrada®)	NHSE	Pre-transplant immunosuppression	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Alemtuzumab	(MabCampath®)	NHSE	Behcet's syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Alemtuzumab ▼	(Lemtrada® ▼)	NHSE	Treatment of adults with relapsing-remitting multiple sclerosis (RRMS) - as per NICE TA 312	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA312 – May 2014, updated May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Alendronate / Vitamin D3 combination	(Fosavance®)	ICB	Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency	Not recommended for routine use	NICE has not issued any guidance.
ADVICE	Alfacalcidol	(AlfaD®, One-Alpha®)	ICB	Preparation for hyperparathyroidectomy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Alglucosidase alfa	(Myozyme®)	NHSE	Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase) - as per NHS England	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Alimemazine (Trimeprazine)	(Generics)	ICB	Sedative in children / general antihistamine	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Alipogene tiparvovec	(Glybera®)	NHSE	(Gene therapy treatment for) Lipoprotein lipase deficiency - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Alirocumab ▼	(Praluent® ▼)	ICB	Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 393	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA393 - Jun 16
BLACK	Aliskiren ▼	(Rasilez® ▼)	ICB	Treatment of essential hypertension - as per NICE CG 127	Not commissioned. No NHS prescribing in primary or secondary care	CG127 - Sep 11
Double Red	Alisporivir	((aka Debio 025 / DEB025 / UNIL-025))	NHSE	Viral Hepatitis C - as per NHSE policy	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Alitretinoin	(Toctino®)	ICB	Treatment of severe chronic hand eczema - as per NICE TA 177	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA177 - Aug 09
BLACK	Alpelisib	Piqray®	NHSE	with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA652 – October 2020
RED	Alpelisib	Piqray®	NHSE	with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA816 – August 2022
Double Red	Alpha blockers - various	(Various)	ICB	Treatment of cor pulmonale - as per NICE CG 101 .	Not recommended for routine use	CG101 - Jul 10
RED	Alpha-mannosidase - recombinant human	(Lamazym®)	NHSE	Alpha Mannosidase deficiency - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Alteplase	(Actilyse®)	ICB	Treatment of acute ischaemic stroke - as per NICE TA 264	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA264 - Sep 12
Double Red	Amantadine Hydrochloride	(Lysovir®)	ICB	Treatment and prophylaxis of influenza	Not recommended for routine use	TA168 - Feb 09
RED	Ambrisentan	(Volibris® ▼)	NHSE	Pulmonary Arterial Hypertension - specialist centre only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Amifampridine (phosphate) ▼	(Firdapse® ▼)	NHSE	Treatment of myasthenias - Lambert-Eaton syndrome - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Amikacin - liposomal for inhalation	(Arikace®)	NHSE	Gram-negative bacterial infection in Cystic Fibrosis .	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Amikacin (for inhalation)	(Amikin®)	NHSE	Gram-negative bacterial infection in Cystic Fibrosis	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Aminobenzoic acid (capsules and powder)	(Potaba®)	ICB	Peyronie's disease, Scleroderma	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
SCA	Amiodarone	(Cordarone X®)	ICB	Supraventricular and ventricular arrhythmias	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	CG180 - Jun 14
BLACK	Amivantamab	n/a	NHSE	EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Not commissioned. No NHS prescribing in primary or secondary care	TA850 – December 2022
BLACK	Amorolfine	(Loceryl and other equivalent preparations)	ICB	Fungal nail infections	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Amphotericin B, itraconazole & voriconazole	(Various)	NHSE	Chronic Pulmonary Aspergillosis (CPA) - specialist centre only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Anagrelide ▼	(Xagrid® ▼ / Agrelin® / Agrylin®)	ICB	Thrombocythaemia	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	NICE has not issued any guidance.
RED	Anakinra	Kineret®	NHSE	Still's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA685 – March 2021
RED	Anakinra	(Kineret®)	NHSE	Cryopyrin-associated periodic syndrome (CAPS)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Anakinra	(Kineret®)	NHSE	Rheumatoid arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NG100 - Oct 2020
RED	Anakinra	(Kineret®)	NHSE	Juvenile Idiopathic Arthritis (JIA)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Anakinra	(Kineret®)	NHSE	Periodic fevers and autoinflammatory conditions	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Anastrozole	(Arimidex®)	ICB	Breast cancer - as per NICE CG81	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG81 - Nov 06

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Anastrozole	(Arimidex®)	ICB	Post menopausal Women at moderate or High or moderate risk of breast Cancer unless they have severe osteoporosis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG164 - updated Nov 2019
BLACK	Andexanet alfa	Ondexxya®	ICB	for reversing anticoagulation from edoxaban	Not commissioned. No NHS prescribing in primary or secondary care	TA697 – May 2021
RED	Andexanet alfa	Ondexxya®	ICB	for reversing anticoagulation from apixaban or rivaroxaban	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA697 – May 2021
BLACK	Angiotensin II	Giapreza®	ICB	vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA859 – Jan 2023
Double Red	Angiotensin-II receptor antagonists with ACE inhibitors	(Various)	ICB	with ACE inhibitors (Not a licensed indication).	Not recommended for routine use	CG182 - Jul 14
RED	Anidulafungin	(Ecalta®)	NHSE	Fungal infection - invasive candidiasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Anifrolumab	N/A	NHSE	active autoantibody-positive systemic lupus erythematosus (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA793 – June 2022
Double Red	Antacids - various	(Various)	ICB	Long term frequent use in functional dyspepsia - as per NICE CG 184 - Do Not Do	Not recommended for routine use	CG184 - Aug 04

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Antibiotic prophylaxis	<i>(Various)</i>	ICB	Infective endocarditis and interventional procedure (dental/non dental) - as per NICE CG 64	Not recommended for routine use	CG64 - Jul 16
RED	Antibiotics - intravenous / inhalation	<i>(Various)</i>	NHSE	Cystic fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Antibiotics (oral for children)	<i>(Various)</i>	ICB	Fever in children without apparent source - as per NICE CG 160 - Do Not Do	Not recommended for routine use	NG143 - Nov 19
RED	Anti-D immunoglobulin	<i>(Various)</i>	ICB	Routine anti-D prophylaxis (RAADP) - as per NICE TA 156	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA156 - Aug 08
Double Red	Antidepressants (including SSRIs)	<i>(Various)</i>	ICB	(Routine use) for the treatment of alcohol misuse alone - as per NICE CG 115 - Do Not Do	Not recommended for routine use	CG115 - Feb 11
RED	Antihaemophilic Factor	<i>((von Willebrand Factor Complex))</i>	NHSE	As per BCSH Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Antihistamines (oral)	<i>(Various)</i>	ICB	(Routine use) for Atopic eczema in children - as per NICE CG 57	Not recommended for routine use	CG57 - Dec 07
RED	Antilymphocyte globulin		NHSE	Aplastic anaemia, as per BCSH guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Antioxidant - ubiquinone aka ubidecarenone	<i>(Co Enzyme Q10)</i>	ICB	Any indication (Various indications).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Antioxidant nutritional supplements (many brands)	<i>(Ocuvite PreserVision ICAPS MacuLEH, Viteyes Vitalux)</i>	ICB	Eye health - including to prevent or slow the progression of AMD, or prevent cataracts (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Anti-Pseudomonas aeruginosa antibody	<i>()</i>	NHSE	Cystic fibrosis - NHSE policy - IFR approval	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Antipsychotics	<i>(Various)</i>	ICB	Combined use (except for short periods) - as per NICE CG 178	Not recommended for routine use	CG178 - Mar 14
BLACK	Antipsychotics	<i>(Various)</i>	ICB	Borderline personality disorder (medium to long term treatment) - as per NICE CG 78 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG78 - Jan 09
BLACK	Antipsychotics	<i>(Various)</i>	ICB	Treatment of ADHD in children, young people and adults - as per NICE CG 72 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG72 - Feb 16
Double Red	Antipsychotics	<i>(Various)</i>	ICB	Generalised Anxiety Disorder - as per NICE CG 113 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG113 - Jan 11
BLACK	Antipsychotics	<i>(Various)</i>	ICB	Loading doses of antipsychotic medication (aka 'rapid neuroleptisation')	Not commissioned. No NHS prescribing in primary or secondary care	CG178 - Mar 14
RED	Antiretroviral therapy (ART)	<i>(Various)</i>	NHSE	Treatment as Prevention (TasP) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Antithrombin III	()	NHSE	As per BCSH Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	BCSH guidelines
RED	Antithymocyte immunoglobulin	(Thymoglobulin e®)	NHSE	Aplastic anaemia, organ transplant - as per BCSH guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	BCSH guidelines
BLACK	Antivirals	(Various)	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
RED	Apalutamide	Erleada®	NHSE	with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA740 – October 2021
RED	Apalutamide	Erleada®	NHSE	with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA741 – October 2021
RED	Apixaban	(Eliquis®)	ICB	Thromboprophylaxis post hip and knee surgery	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA245 - Jan 12

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Apixaban	(Eliquis®)	ICB	Treatment of calf vein deep vein thrombosis (as per NICE TA 341)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA341 - Jun 15
ADVICE	Apixaban	(Eliquis®)	ICB	Treatment and secondary prevention of DVT & PE	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA341 - Jun 15
Double Red	Apixaban	(Eliquis®)	ICB	Combined use with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not recommended for routine use	NG185 - Nov 2020
RED	Apomorphine	(APO-go®)	ICB	Patients with Parkinson's disease with disabling motor fluctuations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLUE	AposHealth		ICB	knee osteoarthritis	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available	MTG76 - April 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Apraclonidine eye drops	(Iopidine®)	ICB	Short-term adjunctive therapy of chronic glaucoma in patients on maximally tolerated medical therapy who require additional intraocular pressure (IOP) reduction to delay laser treatment or glaucoma surgery.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Apremilast	(Otezla® ▼)	NHSE	Paediatric indications - NHSE policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Apremilast ▼	(Otezla® ▼)	ICB	Treatment of moderate to severe plaque psoriasis that has not responded to systemic therapy, or where systemic therapy is contraindicated or not tolerated - as per NICE TA 419 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA419 - Nov 16
RED	Apremilast ▼	(Otezla® ▼)	ICB	Active psoriatic arthritis in adults - as per NICE TA 433	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA433 - Feb 17
RED	Aprepitant	(Emend®)	NHSE	Prevention of nausea and vomiting in patients on highly emetogenic chemotherapy - as per NHS England policy (A licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Aripiprazole	(Abilify®)	ICB	Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA292 - Jul 13

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Aripiprazole	(Abilify®)	ICB	Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG82 - Mar 09
BLACK	Armour Thyroid / any unlicensed thyroid products	(Armour Thyroid)	ICB	Any indication	Not commissioned. No NHS prescribing in primary or secondary care	RMOC guidance - June 2019
ADVICE	Aromatase inhibitors (Various)	(Various)	ICB	Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG81 - Nov 06
RED	Arsenic trioxide	(Trisenox®)	NHSE	Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults - as per NICE TA 526	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA526 - Jun 18
RED	Asciminib	Scemblix®	NHSE	chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA813 – August 2022
RED	Asfotase alfa	Strensiq®	NHSE	paediatric-onset hypophosphatasia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST23 – March 2023
Double Red	Aspirin	()	ICB	Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's	Not recommended for routine use	NG17 - May 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Aspirin	()	ICB	Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's	Not recommended for routine use	NG28 - May 17
Double Red	Asunaprevir (with Daclatasvir)	()	NHSE	Viral Hepatitis (B&C) and Respiratory Syncytial Virus	Not recommended for routine use	NICE has not issued any guidance.
RED	Atacicept	()	NHSE	Systemic Lupus Erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ataluren ▼	(<i>Translarna®</i> ▼)	NHSE	Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST22 - Feb 2023
RED	Atazanavir	(<i>Reyataz®</i>)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Atazanavir and Cobicistat	(<i>Evotaz®</i>)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Atezolizumab	(<i>Tecentriq®</i>)	NHSE	Locally advanced or metastatic non-small-cell lung cancer after chemotherapy - as per NICE TA 520	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA520 - May 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Atezolizumab	(Tecentriq®)	NHSE	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - as per NICE TA 525	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA525 - Jun 18
RED	Atezolizumab	Tecentriq®	NHSE	monotherapy for untreated advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA705 – June 2021
RED	Atezolizumab	Tecentriq®	NHSE	untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA739 – October 2021
BLACK	Atezolizumab	TECENTRIQ®	NHSE	with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer as per TA618 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA618 - Jan 20
RED	Atezolizumab	Tecentriq®	NHSE	adjuvant treatment of resected non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA823 – October 2022
RED	Atezolizumab ▼	(Tecentriq® ▼)	NHSE	with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA638 - July 2020
RED	Atezolizumab ▼	(Tecentriq® ▼)	NHSE	with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA639 - July 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Atezolizumab ▼	(Tecentriq® ▼)	NHSE	with bevacizumab for treating advanced or unresectable hepatocellular carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA666 – December 2020
RED	Atezolizumab ▼	(Tecentriq® ▼)	NHSE	Cancer - various (Various indications).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Atidarsagene autotemcel	Libmeldy	NHSE	metachromatic leukodystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST18 - March 2022
ADVICE	Atogepant	Aquipta®	ICB	preventing migraine	Specialist will initiate and provide the first 12 weeks of medication to the patient.	TA973 – May 2024
SCA	Atomoxetine	(Strattera®)	ICB	Attention Deficit Hyperactivity Disorder in Adults for new treatment of symptoms that can be confirmed from childhood	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NG87 - Mar 18
SCA	Atomoxetine	(Strattera® ▼)	ICB	Attention Deficit Hyperactivity Disorder in Children & Adolescents	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG87 - Mar 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Atypical antipsychotics (except clozapine)	(Various (except Clozaril® (Red))	ICB	Psychosis and schizophrenia in adults - As per NICE CG 178	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of one month.	CG82 - Mar 09
RED	Autologous anti-CD19-transduced CD3+ cells	Tecartus®	NHSE	Relapsed or refractory mantle cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA677 – February 2021
RED	Autologous chondrocyte implantation	(Spherox®)	NHSE	For treating symptomatic articular cartilage defects of the knee - as per NICE TA 508	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA508 - Mar 18
RED	Autologous serum eye drops	()	NHSE	Dry eye	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Avacopan	Tavneos®	NHSE	Anca-positive vasculitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Avacopan	Tavneos®	NHSE	severe active granulomatosis with polyangiitis or microscopic polyangiitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA825 – September 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Avalglucosidase alfa	AVAL®	NHSE	Pompe disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA821 – August 2022
BLACK	Avanafil ▼	(Spedra® ▼)	ICB	Use of regular, daily doses for penile rehabilitation in prostate cancer/post radical prostatectomy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Avapritinib	Ayvakyt®	NHSE	advanced systemic mastocytosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1012 – November 2024
BLACK	Avapritinib	N/A	NHSE	unresectable or metastatic gastrointestinal stromal tumours (terminated)	Not commissioned. No NHS prescribing in primary or secondary care	TA730 – September 2021
RED	Avatrombopag	(Doptelet®)	ICB	treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA626 - Jun 2020
RED	Avatrombopag	Doptelet®	ICB	primary chronic immune thrombocytopenia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA853 – December 2022
RED	Avelumab	(Bavencio®)	NHSE	Metastatic Merkel cell carcinoma - as per NICE TA 517	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA517 - Apr 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Avelumab	(Bavencio®)	NHSE	axitinib for untreated advanced renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA645 – September 2020
RED	Avelumab	Bavencio®	NHSE	untreated metastatic Merkel cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA691 – April 2021
RED	Avelumab	Bavencio®	NHSE	maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA788 – May 2022
RED	Avorlastat	()	NHSE	Hereditary angioedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Axicabtagene ciloleucel	Yescarta®	NHSE	diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA872 – February 2023
BLACK	Axicabtagene ciloleucel	(Yescarta®)	NHSE	relapsed or refractory follicular lymphoma	Not commissioned. No NHS prescribing in primary or secondary care	TA894 – June 2023
RED	Axicabtagene ciloleucel	(Yescarta®)	NHSE	relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA895 – June 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Axitinib	(<i>Inlyta</i> ®)	NHSE	Advanced renal cell carcinoma after failure of prior systemic treatment - as per NICE TA 333	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA333 - Feb 2015
BLACK	Axonics sacral neuromodulation system		ICB	Overactive bladder and faecal incontinence	Not commissioned. No NHS prescribing in primary or secondary care	MIB 164 - December 2018
Double Red	Aymes Actagain protein shot	Aymes Actagain	ICB	hypoproteinaemia	Not recommended for routine use.	NICE has not issued any guidance.
RED	Azacitidine	(<i>Vidaza</i> ®)	NHSE	Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia - as per NICE 218	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA218 - Mar 11
BLACK	Azacitidine	(<i>Vidaza</i> ®)	NHSE	Acute myeloid leukaemia with more than 30% bone marrow blasts in people of 65 years or older who are not eligible for haematopoietic stem cell transplant - as per NICE TA 399	Not commissioned. No NHS prescribing in primary or secondary care	TA399 - July 16
RED	Azacitidine (oral)	Onureg®	NHSE	maintenance treatment of acute myeloid leukaemia after induction therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA827 – October 2022
SCA	Azathioprine	(<i>Imuran</i> ®)	ICB	As a steroid-sparing effect in patients with Autoimmune Diseases in whom steroids cannot be reduced or are contraindicated, and for maintaining remission in vasculitis	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Azathioprine	<i>(Generics are available)</i>	ICB	Steroid-sparing effect in ulcerative colitis and Crohn's disease (Not a licensed indication).	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.
RED	Azelastine and Fluticasone nasal spray	Dymista®	ICB	moderate to severe seasonal and perennial rhinitis if monotherapy with antihistamine or corticosteroid is inadequate	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Azilsartan	<i>(Edarbi®)</i>	ICB	Essential hypertension	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Aztreonam (nebulised)	<i>(Cayston®)</i>	NHSE	Gram negative infections in cystic fibrosis - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NG78 - Oct 17
BLACK	B Braun Diveen	()	ICB	Urinary stress incontinence	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Baclofen (via intrathecal pump)	<i>(Lioresal®)</i>	NHSE	Muscle spasm in neurological conditions as per NICE guidance	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG145 - Jul 12
BLACK	Baloxavir marboxil	N/A	ICB	acute uncomplicated influenza <i>(terminated appraisal)</i>	Not commissioned. No NHS prescribing in primary or secondary care	TA732 – October 2021
BLACK	Bamboo bedding (incl sheets, pillow cases)	<i>(Symmetrikit® bamboo sheet and cushion covers)</i>	ICB	Care of very disabled patients with severe physical needs	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Bardoxolone Methyl		NHSE	Pulmonary arterial hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Baricitinib	Olumiant®	ICB	Moderate to severe atopic dermatitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA681 – March 2021
BLACK	Baricitinib	Olumiant®	ICB	severe alopecia areata	Not commissioned. No NHS prescribing in primary or secondary care	TA926 – October 2023
BLACK	Baricitinib	Olumiant®	n/a	juvenile idiopathic arthritis in people 2 years and over	Not commissioned. No NHS prescribing in primary or secondary care	TA982 – June 2024
RED	Baricitinib ▼	(<i>Olumiant®</i> ▼)	ICB	(with or without methotrexate) for active moderate to severe rheumatoid arthritis in adults - as per NICE TA 466 and locally commissioned treatment	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA466 - Aug 17
RED	Basiliximab	(<i>Simulect®</i>)	NHSE	Option for induction therapy in the prophylaxis of acute organ rejection in adults, children and adolescents undergoing renal transplantation - as per NICE TAs 481 and 482	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA481 - Oct 17
RED	Basiliximab	(<i>Simulect®</i>)	NHSE	Option for induction therapy in the prophylaxis of acute organ rejection in adults, children and adolescents undergoing renal transplantation - as per NICE TAs 481 and 482	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA482 - Oct 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Bazedoxifene plus conjugated oestrogens	(<i>Duavive</i> ®)	ICB	Management of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestin-containing therapy is not appropriate	Not recommended for routine use	NICE has not issued any guidance.
Double Red	Beclabuvir	()	NHSE	Hepatitis C	Not recommended for routine use	NICE has not issued any guidance.
ADVICE	Beclometasone dipropionate 5mg MR tablets	(<i>Clipper</i> ®)	ICB	Second-line oral corticosteroid option in the treatment of flares in mild-moderate ulcerative colitis in adults - as per local pathway	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Bedaquiline ▼	(<i>Sirturo</i> ® ▼)	NHSE	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bee and wasp venom	(<i>Pharmalgen</i> ®)	NHSE	Bee and wasp venom allergy - as per NICE TA 246 - specialist centre only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA246 - Feb 12
RED	Begelomab	(<i>Begedina</i> ®)	NHSE	Graft versus Host Disease (GvHD)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Belatacept	(<i>Nulojix</i> ®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Belatacept	(Nulojix®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17
BLACK	Belimumab	N/A	NHSE	lupus nephritis (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA806 – July 2022
RED	Belimumab	Benlysta®	NHSE	active autoantibody-positive systemic lupus erythematosus (replaces TA397)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA752 – December 2021
BLACK	Belladonna adhesive plaster	()	ICB	As a counter irritant for pain relief	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Belumosudil	Rezurock®	NHSE	chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA949 – February 2024
RED	Belzutifan	Welireg®	NHSE	tumours associated with von Hippel-Lindau disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1011 – October 2024
ADVICE	Bempedoic acid (alone or with ezetimibe)	Nilemdo® (bempedoic acid) or Nustendi® (combination product)	ICB	primary hypercholesterolaemia or mixed dyslipidaemia	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA694 – April 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Bendamustine	(Levact®)	NHSE	Treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab - as per NICE TA 206 (terminated)	Not commissioned. No NHS prescribing in primary or secondary care	TA206 - Oct 10
RED	Bendamustine	(Levact®)	NHSE	First-line treatment of chronic lymphocytic leukaemia (binet stage B or C) - as per NICE TA 216 / NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA216 - Feb 11
RED	Benralizumab	(Fasenra®)	NHSE	Severe eosinophilic asthma (specialist use only) - as per NICE TA 565 (NHSE commissioning responsibility)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA565 - Mar 19
BLACK	Benzodiazepines	(Various)	ICB	Augmentation of an antidepressant with a benzodiazepine for more than 2 weeks - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG90 - Oct 09
BLACK	Benzodiazepines	(Various)	ICB	Panic disorder - as per NICE CG 113 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG113 - Jan 11
BLACK	Benzodiazepines	(Various)	ICB	Ongoing treatment of alcohol dependence - as per NICE CG 115	Not commissioned. No NHS prescribing in primary or secondary care	CG115 - Feb 11
BLACK	Benzodiazepines	(Various)	ICB	Generalised Anxiety Disorder (long term use) - as per NICE CG 113 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG113 - Jan 11
RED	Beractant	(Survanta®)	NHSE	Respiratory distress syndrome neonates	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Berotrastat	Orladeyo®	NHSE	preventing recurrent attacks of hereditary angioedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA738 – October 2021
BLACK	Beta-carotene (supplements containing)	(Various)	ICB	Secondary prevention of MI / reduce cardiovascular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG172 - Nov 13
RED	Betaine	(Cystadane® oral powder (orphan drug))	NHSE	Homocystinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Betamethasone plaster	BETESIL®	ICB	Treatment of inflammatory skin disorders that do not respond to less potent corticosteroids	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Bevacizumab	(Avastin®)	NHSE	Treatment of non-small-cell lung cancer - as per NHS England policy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA148 - Jun 08
BLACK	Bevacizumab	(Avastin®)	NHSE	First-line treatment of advanced and/or metastatic renal cell carcinoma - as per NHS England policy	Not commissioned. No NHS prescribing in primary or secondary care	TA178 - Aug 09
RED	Bevacizumab	(Avastin®)	NHSE	With oxaliplatin and either 5-FU plus folinic acid or capecitabine for metastatic colorectal cancer - as NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA212 - Dec 10
RED	Bevacizumab	(Avastin®)	NHSE	First-line treatment of metastatic breast cancer (in combination with a taxane) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA214 - Feb 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Bevacizumab	(<i>Avastin</i> ®)	NHSE	Treatment of metastatic colorectal cancer after 1st-line chemotherapy - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA242 - Jan 12
BLACK	Bevacizumab	(<i>Avastin</i> ®)	NHSE	First-line treatment of metastatic breast cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA263 - Aug 12
RED	Bevacizumab	(<i>Avastin</i> ®)	NHSE	(with paclitaxel & carboplatin) 1st-line for advanced ovarian cancer - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA284 - May 13
RED	Bevacizumab	(<i>Avastin</i> ®)	NHSE	(with gemcitabine & carboplatin) - treatment of the first recurrence of platinum-sensitive advanced ovarian cancer - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA285 - May 13
BLACK	Bevacizumab	(<i>Avastin</i> ®)	NHSE	Treatment for relapsed, platinum resistant epithelial ovarian, fallopian tube or primary peritoneal cancer - as per NICE TA 353 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA353 - Aug 15
BLACK	Bevacizumab	(<i>Avastin</i> ®)	NHSE	Epidermal growth factor receptor mutation-positive non-small-cell lung cancer - as per NICE TA 436 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA436 - Mar 17
BLACK	Bevacizumab	(<i>Avastin</i> ®)	NHSE	(with carboplatin, gemcitabine and paclitaxel) for first recurrence of platinum-sensitive advanced ovarian cancer - as per NICE TA 560 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA560 - Feb 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Bevacizumab	(Avastin®)	NHSE	pre-treatment before vitrectomy for proliferative diabetic retinopathy (neovascular)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Bevacizumab	(Avastin®)	ICB	Early (pre-NICE criteria) treatment of wet AMD and related conditions (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Bevacizumab	(Avastin®)	NHSE	Neurofibromatosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bevacizumab	(Avastin®)	ICB	Choroidal neovascularisation (CNV) secondary to conditions other than age-related macular degeneration (AMD) or pathological myopia (PM) - as per local agreement during 2014-15 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bevacizumab	(Avastin®)	ICB	(Short term) treatment of neovascular glaucoma in rubeosis iridis - as per locally commissioned agreement (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bevacizumab	(Avastin®)	ICB	Radiation retinopathy macular oedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Bevacizumab gamma	Lytenava®	ICB	wet age-related macular degeneration	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1022 – December 2024
RED	Bexarotene	(Targretin®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Bezafibrate	(Bezalip; Fibrazate)	ICB	Prevention of CVD - as per NICE CG 181 "Do Not Do"	Not recommended for routine use	CG181 - Jul 14
BLACK	Bezlotoxumab	(Zinplava®)	ICB	Prevention of recurrent clostridium difficile infection (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA601 - Sep 19
RED	Bictecravir (in combination with emtricitabine and tenofovir alafenamide)	Biktarvy®)	NHSE	HIV	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bimagrumab	((BYM338))	NHSE	Inclusion body myositis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bimekizumab	Bimzelx®	ICB	active psoriatic arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA916 – October 2023
RED	Bimekizumab	Bimzelx®	ICB	axial spondyloarthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA918 – October 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Bimekizumab	Bimzelx®	ICB	moderate to severe plaque psoriasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA723 – September 2021
RED	Binimetinib	(Mektovi®)	NHSE	(with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA562 - Feb 19
BLACK	Bioidentical HRT	(Bioidentical hormone replacement therapy)	ICB	Menopausal symptoms	Not commissioned. No NHS prescribing in primary or secondary care	NG23 - Nov 13
RED	Biotin (vitamin H)	(Qizenday®, Cerenday®, MD1003)	NHSE	various	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Birch bark extract	n/a	NHSE	epidermolysis bullosa	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST28 – September 2023
RED	Bivalirudin	(Angiox®)	ICB	Treatment of ST-segment-elevation myocardial infarction - as per NICE TA 230	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA230 - Jul 11
RED	Blinatumomab	(Blincyto®)	NHSE	Acute lymphoblastic leukaemia in remission with minimal residual disease activity	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA589 - Jul 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Blinatumomab	N/A	NHSE	previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA686 – March 2021
RED	Blinatumomab ▼	<i>(Blincyto® ▼)</i>	NHSE	Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults as per NICE TA 450	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA450 - Jun 17
RED	Blisibimod	()	NHSE	Systemic lupus erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Boceprevir	<i>(VICTRELIS®)</i>	NHSE	Treatment of genotype 1 chronic hepatitis C - as per NICE TA 253	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA253 - Apr 12
RED	Bortezomib	<i>(Velcade®)</i>	NHSE	Multiple myeloma (first line) - as per NICE 228	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA228 - Jul 11
RED	Bortezomib	<i>(Velcade®)</i>	NHSE	Induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation - as per NICE TA 311	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA311 - Apr 14
RED	Bortezomib	<i>(Velcade®)</i>	NHSE	Previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable as per NICE TA 370	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA370 - Dec 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Bortezomib	(Velcade®)	NHSE	Relapsed Multiple Myeloma - as per NHS England policy & NICE TA 453 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA453 - Jul 17
RED	Bortezomib	(Velcade®)	NHSE	Treatment of refractory antibody mediated rejection post kidney transplant - as per NHS England policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bosentan	(Tracleer®)	NHSE	Treatment of digital ulceration in systemic sclerosis - as per NHS England policy (A licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bosentan	(Tracleer®)	NHSE	Pulmonary arterial hypertension - as per NHS England policy - specialist centres only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Bosutinib	(Bosulif®)	NHSE	Previously treated chronic myeloid leukaemia - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA401 - Aug 16
BLACK	Bosutinib	(Bosulif®)	NHSE	Untreated chronic myeloid leukaemia in adults - as per NICE TA 576 (terminated appraisal) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA576 - Apr 19
RED	Botulinum neurotoxin type A	(Xeomin®)	ICB	Chronic sialorrhoea	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA605 - Oct 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Botulinum Toxin Type A	(Botox®)	ICB	Prophylaxis of headaches in adults with chronic migraine - as per locally agreed policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA260 - Jun 12
RED	Botulinum Toxin Type A	(Dysport®)	ICB	Neurogenic and non neurogenic detrusor overactivity in paediatric patients who have not responded to antimuscarinic treatment - as per locally agreed policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(Botox®)	ICB	Oesophageal spasm and nutcracker oesophagus - as per locally agreed policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(Botox®)	ICB	(severe) Focal hyperhidrosis - as per locally agreed policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(Botox®)	ICB	Overactive bladder / detrusor overactivity - as per locally agreed policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(Botox®)	ICB	Chronic anal fissure - as per locally agreed policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Botulinum Toxin Type A	(<i>Botox® - 200 units injection</i>)	ICB	Treatment of achalasia and gastroparesis - as per locally agreed policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(<i>Dysport®</i>)	ICB	Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A	(<i>Botox®, Dysport®</i>)	ICB	Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A and B	(<i>Botox®</i>)	NHSE	Intravesical use in spinal cord injury	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Botulinum Toxin Type A and B	(<i>Botox®</i>)	NHSE	Focal spasticity in children	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Brentuximab vedotin	(<i>Adcetris®</i>)	NHSE	CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per NICE TA 524	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA524 - Jun 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Brentuximab vedotin	(Adcetris®)	NHSE	Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA577 - Apr 19
BLACK	Brentuximab vedotin	(Adcetris®)	NHSE	Untreated advanced Hodgkin lymphoma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA594 - Aug 19
RED	Brentuximab vedotin	(Adcetris®)	NHSE	in combination for untreated systemic anaplastic large cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA641 – August 2020
RED	Brentuximab vedotin ▼	(Adcetris® ▼)	NHSE	CD30-positive Hodgkin lymphoma - as per NICE TA 446	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA446 - Jun 17
RED	Brentuximab vedotin ▼	(Adcetris® ▼)	NHSE	For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA478 - Oct 17
RED	Brexucabtagene autoleucel	Tecartus®	NHSE	relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA893 – June 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Brigatinib	(Alunbrig®)	NHSE	For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA571 - Mar 19
RED	Brigatinib	Alunbrig®	NHSE	ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA670 – January 2021
RED	Brimapitide		NHSE	Acute sensorineural hearing loss	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Brimonidine tartrate gel	(Mirvaso®)	ICB	Treatment of facial erythema (rosacea)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Brincidofovir	((CMX001))	NHSE	CMV infection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Brivaracetam	Briviact	ICB	epilepsy as alternative to levetiracetam	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Brodalumab	(Kyntheum®)	ICB	Moderate to severe plaque psoriasis - as per NICE TA 511	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA511 - Mar 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Brolucizumab	Beovu®	ICB	Wet age-related macular degeneration	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA672 – February 2021
BLUE	Brolucizumab	Beovu®	ICB	diabetic macular oedema	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA820 – August 2022
BLACK	Bromocriptine	()	ICB	Pharmacological neuroprotective therapy in Parkinson's disease (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Bromocriptine mesilate	(<i>Parlodel®</i>)	ICB	First-line use in Parkinson's disease - as per NICE NG 17	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
ADVICE	Budenofalk	(<i>Budenofalk®</i>)	ICB	Crohn's disease in adults	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Budenofalk (Budesonide 3mg caps & 9mg granules)	(<i>Budenofalk®</i>)	ICB	Collagenous colitis in adults	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Budesonide (oral viscous slurry)	Pulmicort respules	ICB	eosinophilic oesophagitis in paediatrics	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance
BLACK	Budesonide orodispersible tablets	(<i>Jorveza®</i>)	ICB	Eosinophilic oesophagitis in adults - treatment for maintenance of remission	Not commissioned. No NHS prescribing in primary or secondary care	TA708 – June 2021
ADVICE	Budesonide orodispersible tablets	(<i>Jorveza®</i>)	ICB	Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	TA708 – June 2021
RED	Budesonide orodispersible tablets	(<i>Jorveza®</i>)	ICB	Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA708 – June 2021
RED	Bulevirtide	Hepcludex®	NHSE	chronic hepatitis D	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA896 – June 2023
ADVICE	Buprenorphine (transdermal)	(<i>Butec®, Transtec® patches</i>)	ICB	Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLUE	Buprenorphine Long-Acting Injection	Buvidal®)	ICB	opioid substitution treatment	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	RMOC - April 2021
ADVICE	Bupropion	(Zyban®)	NCC	GP prescribable after consultant/specialist recommendation where the specialist is a smoking cessation adviser (level 2 or 3).	Formulary - Drugs that can be initiated by Prescriber in Primary Care	NG92 - Mar 18
BLACK	Bupropion	(Zyban®)	ICB	ADHD and other mental health conditions	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Burosumab	Crysvita®)	NHSE	X-linked hypophosphataemia in adults	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA993 – August 2024
Double Red	Buspirone	(Generics are available)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do	Not recommended for routine use	CG90 - Oct 09
RED	Busulfan	(Myleran®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Butyrophenones (benperidol and haloperidol)	(Various)	ICB	NICE Do Not Do - Use in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	C1 Esterase Inhibitors		NHSE	Hereditary angioedema treatment and prophylaxis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Cabazitaxel	(<i>Jevtana</i> ®)	NHSE	Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255	Not commissioned. No NHS prescribing in primary or secondary care	TA255 - May 12
RED	Cabazitaxel	(<i>Jevtana</i> ®)	NHSE	Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA391 - Aug 16
BLACK	Cabergoline	(<i>Cabaser</i> ®)	ICB	First-line use in Parkinson's disease - as per NICE NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
RED	Cabotegravir	Vocabria®	NHSE	with rilpivirine for treating HIV-1	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA757 – January 2022
RED	Cabozantinib	(<i>Cometriq</i> ®)	NHSE	For treating medullary thyroid cancer - as per NICE TA 516	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA516 - Mar 18
RED	Cabozantinib	(<i>Cabometyx</i> ®)	NHSE	Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA542 - Oct 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cabozantinib	Cabometyx®	NHSE	previously treated advanced hepatocellular carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA849 – December 2022
BLACK	Cabozantinib	Cabometyx®	NHSE	previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine	Not commissioned. No NHS prescribing in primary or secondary care	TA928 – November 2023
RED	Cabozantinib	Cabometyx®	NHSE	with nivolumab for untreated advanced renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA964 – April 2024
RED	Cabozantinib ▼	<i>(Cabometyx® ▼)</i>	NHSE	Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy - as per NICE TA 463	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA463 - Aug 17
RED	Calcifidiol		NHSE	Inborn errors in primary bile acid synthesis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Calcium and Ergocalciferol combi tablets	<i>(Generic tablets)</i>	ICB	Prevention of osteoporosis-related fractures and falls	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Calcium channel blockers - various	<i>(Various)</i>	ICB	Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do	Not recommended for routine use	CG101 - Jul 10

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Canagliflozin ▼	(Invokana® ▼)	ICB	In combination therapy for treating type 2 diabetes - as per NICE TA 315	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA315 - Jun 14
ADVICE	Canagliflozin ▼	(Invokana® ▼)	ICB	As a 4th monotherapy option for treating type 2 diabetes - as per NICE TA 390	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA390 - May 16
BLACK	Canakinumab	(Ilaris®)	ICB	Treatment of gouty arthritis attacks and reducing the frequency of subsequent attacks - as per NICE TA 281 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA281 - Apr 13
BLACK	Canakinumab	(Ilaris®)	NHSE	Treatment of systemic juvenile idiopathic arthritis - as per NHS England policy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA302 - Nov 13
BLACK	Cangrelor ▼	(Kengrexal® ▼)	ICB	Treatment for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA351 - Jul 15
RED	Cannabidiol	Epidyolex®	NHSE	seizures caused by tuberous sclerosis complex	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA873 – March 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cannabidiol with clobazam	<i>(Epidyolex®)</i>	NHSE	Seizures associated with Dravet syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA614 - Dec 19
RED	Cannabidiol with clobazam	<i>(Epidyolex®)</i>	NHSE	Seizures associated with Lennox–Gastaut syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA615 - Dec 19
BLACK	Cannabis (all forms, including nabilone)	<i>(excluding sativex)</i>	ICB	All indications - as per local policy (July 2011) and PAC guidance Jan 2020	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Cannabidiol with Dronabinol oromucosal spray	<i>(Sativex®)</i>	ICB	adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Capecitabine	<i>(Xeloda®)</i>	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA191 - Apr 06
RED	Caplacizumab	Cablivi®	NHSE	with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA667 – December 2020
BLACK	Capmatinib	n/a	NHSE	advanced non-small-cell lung cancer with MET exon 14 skipping	Not commissioned. No NHS prescribing in primary or secondary care	TA884 – May 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Capsaicin transdermal patches (Qutenza®)	(Qutenza®)	ICB	Peripheral neuropathic pain in non-diabetic patients (specialist use only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Carbamazepine	(Tegretol®, Carbagen®)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG90 - Oct 09
RED	Carfilzomib (®) with dexamethasone and lenalidomide)	Kyprolis®	NHSE	previously treated multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA695 – April 2021
RED	Carfilzomib ▼	(Kyprolis® ▼)	NHSE	(with dexamethasone) for previously treated multiple myeloma where the patient has had only 1 previous therapy, which did not include bortezomib - as per NICE 457	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA457 - Jul 17
RED	Carfilzomib ▼	(Kyprolis® ▼)	NHSE	with dexamethasone for multiple myeloma in adults, only if they have had only 1 previous therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA657 – November 2020
BLACK	Carfilzomib with daratumumab and dexamethasone	Kyprolis®	NHSE	relapsed or refractory multiple myeloma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA841 – November 2022
RED	Carglumic acid	(Carbaglu®)	NHSE	Treatment hyperammonaemia in urea cycle disorder	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Carmustine implants	(<i>Gladel</i> ®)	NHSE	Treatment of recurrent glioblastoma multiforme - as per NICE TA 149 and NHS England policy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA149 - Jun 08
BLACK	Casirivimab and Imdevimab	Ronapreve	ICB	monoclonal antibody treatment for COVID-19	Not commissioned. No NHS prescribing in primary or secondary care	TA878 – March 2023, updated June 2023
RED	Caspofungin	(<i>Cancidas</i> ®)	NHSE	Systemic candidiasis - - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Catridecacog	(<i>NovoThirteen</i> ®)	NHSE	Congenital factor XIII A-subunit deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ceftriaxone	(<i>Rocephin</i> ®)	ICB	Cellulitis - as per local policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Cemiplimab	(<i>Libtayo</i> ®)	NHSE	Metastatic or locally advanced cutaneous squamous cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA592 - Aug 19
BLACK	Cemiplimab	Libtayo®	NHSE	untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA848 – December 2022
BLACK	Cemiplimab	(<i>Libtayo</i> ®)	NHSE	recurrent or metastatic cervical cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA901 – June 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cemiplimab	Libtayo®	NHSE	advanced cutaneous squamous cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA802 – June 2022
BLACK	Cenegermin eye drops ▼	(<i>Oxervate</i> ▼)	NHSE	Treatment of moderate or severe neurotrophic keratitis - as per NICE TA 532	Not commissioned. No NHS prescribing in primary or secondary care	TA532 - July 18
SCA	Cenobamate	Ontozry®	ICB	focal onset seizures in epilepsy	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	TA753 – December 2021
RED	Ceralifimod	((<i>ONO-4641</i>))	NHSE	Multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Cerebrotech Visor	(<i>Cerebrotech Visor</i>)	ICB	For detecting stroke	Not commissioned. No NHS prescribing in primary or secondary care	MIB165 - Dec 18
RED	Ceritinib	(<i>Zykadia</i> ®)	NHSE	Anaplastic lymphoma kinase positive non-small-cell lung cancer in adults previously treated with crizotinib - as per NICE TA 395	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA395 - Jun 16
RED	Ceritinib ▼	(<i>Zykadia</i> ® ▼)	NHSE	Untreated ALK-positive non-small-cell lung cancer in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA500 - Jan 18
RED	Cerliponase	(<i>Brineura</i> ®)	NHSE	Neuronal Ceroid Lipofuscinosis, type 2 (CLN2) from birth, also known as tripeptidyl peptidase 1 (TPP1) deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST12 - Nov 2019

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Certolizumab pegol	(Cimzia®)	ICB	for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
RED	Certolizumab Pegol	(Cimzia®)	ICB	Treatment of severe (non-radiographic) axial spondyloarthritis - as per NICE TA 383 and locally agreed pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Certolizumab pegol	(Cimizia®)	ICB	Ankylosing spondylitis - as per NICE TA 383 and locally agreed pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Certolizumab pegol	(Cimzia®)	ICB	For treating moderate to severe plaque psoriasis in adults - as per NICE TA 574 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA574 - Apr 19
RED	Certolizumab pegol (with and without MTX)	(Cimzia®)	ICB	Active rheumatoid arthritis in adults after inadequate response or intolerance to other disease-modifying antirheumatic drugs (DMARDs) including at least one tumour necrosis factor-alpha (TNF-alpha) inhibitor	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA415 - Oct 16
RED	Certolizumab pegol (with or without MTX)	(Cimzia ®)	ICB	Psoriatic arthritis (including switching between treatments) after inadequate response to DMARDs - as per NICE TA 445 and locally agreed pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA445 - May 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cetuximab	(Erbix®)	NHSE	Locally advanced squamous cell cancer of the head and neck - as per NICE TA 145 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA145 - Jun 08
RED	Cetuximab	(Erbix®)	NHSE	Treatment of metastatic colorectal cancer after 1st-line chemotherapy - as per NICE TA 242 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA242 - Jan 12
RED	Cetuximab	(Erbix®)	NHSE	First-line treatment of metastatic colorectal cancer under specified circumstances	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA439 - Mar 17
RED	Cetuximab	(Erbix®)	NHSE	Recurrent or metastatic squamous cell head and neck cancer in adults only if started in the mouth - as per NICE TA 473 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA473 - Aug 17
RED	Chenodeoxycholic acid	(Chenodeoxycholic acid sigma-tau)	NHSE	Primary biliary cirrhosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Chenodeoxycholic acid	(Chenodeoxycholic acid sigma-tau)	NHSE	Cerebrotendinous xanthomatosis (CTX)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Chloral hydrate 500mg/5ml oral solution	n/a	ICB	off-label use in treatment of dystonia.	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Chlorambucil	<i>(Leukeran®)</i>	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Chlorhexidine Mouthwash	<i>(Various)</i>	ICB	prophylaxis against infective endocarditis to people at risk of infective endocarditis undergoing dental procedures - as per NICE CG 64 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG64 - Jul 16
RED	Chlormethine gel	Ledaga®	NHSE	mycosis fungoides-type cutaneous T-cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA720 – August 2021
BLACK	Cholesterol and Simvastatin cream	n/a	ICB	disseminated superficial actinic porokeratosis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Cholic acid	<i>(Orphacol®, Kolbam®)</i>	NHSE	Inborn errors in primary bile acid synthesis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Chondroitin	<i>(Various)</i>	ICB	Osteoarthritis - as per NICE CG 177 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG177 - Feb 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ciclosporin	(Ikervis®)	ICB	Severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes (Consultant recommendation only) - as per NICE TA 369	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA369 - Dec 15
SCA	Ciclosporin	(Various brands - to be specified by prescribers)	ICB	Rheumatic and dermatological diseases.	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG100 - Jul 18
RED	Cidofovir	(Vistide®)	NHSE	Cytomegalovirus (CMV) infection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Cilostazol	(Pletal®)	ICB	Treatment of intermittent claudication in people with peripheral arterial disease - as per NICE TA 223	Not commissioned. No NHS prescribing in primary or secondary care	TA223 - May 11
BLACK	Ciltacabtagene autoleucel	n/a	NHSE	relapsed or refractory multiple myeloma	Not commissioned. No NHS prescribing in primary or secondary care	TA889 – May 2023
RED	Cinacalcet	(Mimpara®)	NHSE	Refractory secondary hyperparathyroidism in patients with end-stage renal disease under specific criteria - as per NICE TA 117 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA117 - Jan 07
RED	Cinacalcet	(Mimpara®)	NHSE	Secondary hyperparathyroidism & parathyroid cancer - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA117 - Jan 07

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Cinacalcet	(Mimpara®)	NHSE	Primary hyperparathyroidism where parathyroidectomy is contraindicated, refused by patient or not suitable as per NHSE Commissioning Policy 16034/P	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.
RED	Cipaglucosidase alfa	Pombiliti®	NHSE	with miglustat for treating late-onset Pompe disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA912 – August 2023
Double Red	Ciprofibrate	(Generics are available)	ICB	Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication).	Not recommended for routine use	CG181 - Jul 14
RED	Ciprofloxacin (inhalation)	()	NHSE	Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ciprofloxacin liposomal (inhaled)	()	NHSE	Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Cladribine	(Mavenclad®; Leustat®; Litak®)	NHSE	Pulmonary Langerhans histiocytosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Cladribine	(Mavenclad®)	NHSE	Relapsing-remitting multiple sclerosis - as per NICE TA616	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA616 – December 2019, updated May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Clazakizumab		NHSE	Antibody medicated rejection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Clofarabine	<i>(Evoltra®)</i>	NHSE	Cancer (Various indications).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Clomethiazole	<i>(Heminevrin®)</i>	PHE	Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do	Not recommended for routine use	CG115 - Feb 11
RED	Clopidogrel	<i>(Plavix®, generics approved for use - Sept 2009)</i>	ICB	Prophylaxis pre-elective PCI	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Clopidogrel	<i>(Plavix®, generics approved for use - Sept 2009)</i>	ICB	Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's	Not recommended for routine use	NG17 - May 17
Double Red	Clopidogrel	<i>(Plavix®, generics approved for use - Sept 2009)</i>	ICB	Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's	Not recommended for routine use	NG28 - May 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Clopidogrel (with low dose aspirin)	(Plavix®, generics approved for use - Sept 2009)	ICB	Acute Coronary Syndrome without ST-segment elevation (NSTEMI) (with aspirin)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	TA80 - Jul 04
ADVICE	Clopidogrel (with low dose aspirin)	(Plavix®, generics approved for use - Sept 2009)	ICB	Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay.	NICE has not issued any guidance.
ADVICE	Clopidogrel (with low dose aspirin)	(Plavix®, generics approved for use - Sept 2009)	ICB	ST-elevation myocardial infarction (STEMI) (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month.	NICE has not issued any guidance.
RED	Clozapine	(Clozaril®, Denzapine®, Zaponex®)	ICB	Schizophrenia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG82 - Mar 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cobicistat ▼	(Tybost® ▼)	NHSE	Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Cobimetinib ▼ (in combination with vemurafenib)	(Cotellic® ▼)	NHSE	Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414	Not commissioned. No NHS prescribing in primary or secondary care	TA414 - Oct 16
RED	Co-careldopa intestinal gel	(Duodopa® ▼)	NHSE	Severe Parkinson's disease inadequately controlled by other preparations - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Cochlear implants	(Various)	NHSE	For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA566 - Mar 19
Double Red	Codeine linctus	generic	ICB	Cough suppressant	Not recommended for routine use	NICE has not issued any guidance
BLACK	Co-enzyme Q10	(Healthcrafts, Nature's Best, Lamb, Natrahealth etc)	ICB	All indications - as per NICE NG 71 & CG181 Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG181 - Jul 17
BLACK	Co-enzyme Q11	(Healthcrafts, Nature's Best, Lamb, Natrahealth etc)	ICB	All indications - as per NICE NG 71 & CG181 Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Colecalciferol (Vitamin D)	(Various)	ICB	To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG181 - Jul 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Colesevelam HCl	(<i>Cholestagel®</i>)	ICB	Third-line option for (unlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients).	NICE has not issued any guidance.
Double Red	Colesevelam HCl ▼	(<i>Cholestagel®</i> ▼)	ICB	Hypercholesterolaemia - as per NICE CG 181 Do Not Do	Not recommended for routine use	CG181 - Jul 14
Double Red	Colesevelam hydrochloride	(<i>Cholestagel®</i>)	ICB	Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do	Not recommended for routine use	CG181 - Jul 14
RED	Colestilan	(<i>)</i>	NHSE	Management of hyperphosphataemia in adults on renal dialysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Colestipol hydrochloride	(<i>Colestid®</i>)	ICB	Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG181 - Jul 14
Double Red	Colestyramine	(<i>Questran®</i>)	ICB	Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG181 - Jul 14
RED	Colistimethate sodium (nebulised)	(<i>Colomycin®</i> , <i>Promixin®</i>)	NHSE	Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA276 - Mar 13

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Colistimethate sodium (Nebulised)	(<i>Colomycin®</i> , <i>Promixin®</i>)	ICB	Ps. aeruginosa infection in non-Cystic Fibrosis bronchiectasis	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	NICE has not issued any guidance.
RED	Colistimethate sodium Dry Powder Inhaler	(<i>Colobreathe® Dry Powder Inhaler</i>)	NHSE	Pseudomonas lung infection in cystic fibrosis - as per NICE TA 276 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA276 - Mar 13
BLACK	Combination analgesics with caffeine	()	ICB	Pain relief	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Combination products - new co-drugs	(<i>Various</i>)	ICB	Various (Various indications).	Not recommended for routine use	NICE has not issued any guidance.
RED	Conestat alfa	(<i>Ruconest®</i>)	NHSE	Hereditary angiodema - acute treatment only - as per NHS England policy .	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Co-proxamol	(<i>Distalgesic</i>)	ICB	Pain - as per N&W DROP List (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Corneal epithelial cells (human) with stem cells	(<i>Holoclar</i>)	NHSE	(Holoclar for) Limbal stem cell deficiency after eye burns - as per NICE TA 467	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA467 - Aug 17
BLACK	Crisaborole		ICB	mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA701 – May 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Crizanlizumab	Adakveo®	NHSE	preventing sickle cell crises in sickle cell disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA743 – November 2021
RED	Crizotinib	(<i>Xalkori</i> ®)	NHSE	ROS1-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1021 – December 2024
RED	Crizotinib ▼	(<i>Xalkori</i> ® ▼)	NHSE	Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 406	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA406 - Sep 16
RED	Crizotinib ▼	(<i>Xalkori</i> ® ▼)	NHSE	Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene - as per NICE TA 422	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA422 - Dec 16
RED	Crovalimab	Piasky®	NHSE	paroxysmal nocturnal haemoglobinuria in people 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1019 – November 2024
RED	Cyclic Pyranopterin Monophosphate		NHSE	Molybdenum cofactor deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Cycloidal vibration accessories (Vibro-pulse)	(<i>Vibro-pulse</i> ® accessories)	ICB	Therapy for cellulitis, venous leg ulcers and lower limb oedema	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Cyclophosphamide	(Endoxana®)	NHSE	Use in Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Cysteamine (Mercaptamine)	(Cystagon®; Procysbi®)	NHSE	Neuropathic cystinosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Dabigatran	(Pradaxa®)	ICB	Treatment and secondary prevention of pulmonary embolism as per NICE TA 327 (where warfarin is not appropriate see Full Guidance)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA327 - Dec 14
Double Red	Dabigatran	(Pradaxa®)	ICB	Combined use with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG172 - Nov 13
RED	Dabigatran etexilate	(Pradaxa®)	ICB	Prevention of venous thromboembolism after hip or knee surgery in adults (as per NICE TA 157)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA157 - Sep 08

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Dabigatran etexilate	(Pradaxa®)	ICB	Treatment and secondary prevention of proximal deep vein thrombosis in specified patient groups as per NICE TA 327 and local policy (see Full TAG Guidance)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 3 weeks.	TA327 - Dec 14
RED	Dabigatran etexilate	(Pradaxa®)	ICB	Treatment and secondary prevention of calf vein deep vein thrombosis (as per NICE TA 327)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA327 - Dec 14
RED	Dabrafenib	(Tafinlar®)	NHSE	plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA898 – June 2023
RED	Dabrafenib	Finlee®	NHSE	with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA977 – May 2024
RED	Dabrafenib ▼	(Tafinlar® ▼)	NHSE	Treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma (alone or with trametinib)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA396 - Jun 16
RED	Dabrafenib with trametinib	(Tafinlar® with Mekinist®)	NHSE	Adjuvant treatment of resected BRAF V600 mutation-positive melanoma - as per NICE TA 544	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA544 - Oct 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Daclatasvir ▼	(Daklinza® ▼)	NHSE	For treating chronic hepatitis C in adults (with sofosbuvir or peginterferon alfa, and with ribavirin) as per NICE TA 364	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA364 - Nov 15
BLACK	Daclizumab	(Zinbryta®)	NHSE	Relapsing-remitting multiple sclerosis in adults - as per NICE TA 441 Specialist centre only - currently suspended	Not commissioned. No NHS prescribing in primary or secondary care	TA441 - Apr 17
RED	Dacomitinib	(Vizimpro®)	NHSE	Untreated EGFR mutation-positive non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA595 - Aug 19
BLACK	Danazol	(Danol®)	ICB	Heavy menstrual bleeding - as per NICE CG 44 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG44 - Aug 16
RED	Danicopan	Voydeya®	NHSE	with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1010 – October 2024
ADVICE	Dapagliflozin	(Forxiga®)	ICB	Triple therapy for treating type 2 diabetes in adults - as per NICE TA 418	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA418 - Nov 16
BLACK	Dapagliflozin	(Forxiga®)	ICB	With insulin for treating type 1 diabetes	Not commissioned. No NHS prescribing in primary or secondary care	TA597 - Nov 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Dapagliflozin	Forxiga®	ICB	Chronic heart failure with reduced ejection fraction	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA679 – February 2021
ADVICE	Dapagliflozin	Forxiga®	ICB	chronic heart failure with preserved or mildly reduced ejection fraction	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA902 – June 2023
ADVICE	Dapagliflozin ▼	(Forxiga® ▼)	ICB	Limited use in Type 2 diabetes mellitus - as per NICE TA 288	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA288 - Jun 13
ADVICE	Dapagliflozin ▼	(Forxiga® ▼)	ICB	As monotherapy for treating type 2 diabetes - as per NICE TA 390	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA390 - May 16
BLACK	Dapoxetine	(Priligy®)	ICB	For diagnosed premature ejaculation	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Daratumumab	N/A	NHSE	with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA771 – February 2022
RED	Daratumumab	(Darzalex®)	NHSE	As monotherapy for treating relapsed and refractory multiple myeloma - as per NICE TA783	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA783 – April 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Daratumumab	(Darzalex®)	NHSE	with bortezomib and dexamethasone for previously treated multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA897 – June 2023
RED	Daratumumab	Darzalex®	NHSE	with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA917 – October 2023
RED	Daratumumab	Darzalex®)	NHSE	combination for treating newly diagnosed systemic amyloid light-chain amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA959 – March 2024
RED	Daratumumab	Darzalex®	NHSE	in combination for untreated multiple myeloma when a stem cell transplant is suitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA763 – February 2022
RED	Daratumumab (with bortezomib and dexamethasone)	(Darzalex®)	NHSE	Previously treated multiple myeloma in people who have had 1 previous treatment - as per NICE TA 573	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA573 - Apr 19
BLACK	Daratumumab (with lenalidomide and dexamethasone)	n/a	NHSE	untreated multiple myeloma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA634 – June 2020
BLACK	Daratumumab ▼	(Darzalex® ▼)	NHSE	(with lenalidomide and dexamethasone) for relapsed or refractory multiple myeloma - as per NICE TA 454 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA454 - Jul 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Daratumumab with pomalidomide and dexamethasone	N/A	NHSE	relapsed or refractory multiple myeloma (terminated)	Not commissioned. No NHS prescribing in primary or secondary care	TA726 – September 2021
RED	Darbepoetin alfa	(<i>Aranesp</i> ®)	ICB	Treatment of anaemia in people with cancer having chemotherapy as per NICE TA 323	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA323 - Nov 14
RED	Darbepoetin alfa	(<i>Aranesp</i> ®)	NHSE	Treatment of anaemia renal dialysis as per CG114	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG114 - Nov 11
SCA	Darbepoetin alfa	Aranesp®	ICB	anaemia in chronic kidney disease	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.
RED	Darolutamide	Nubeqa®	NHSE	with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA660 – November 2020
RED	Darolutamide	Nubeqa®	NHSE	with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA903 – June 2023
RED	Darunavir	(<i>Prezista</i> ®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Darunavir and Cobicistat (Rezolsta®)	(Rezolsta®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Darvadstrocel	(Alofisel®)	ICB	Complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease - as per NICE TA 556	Not commissioned. No NHS prescribing in primary or secondary care	TA556 - Jan 19
Double Red	Dasabuvir	(Exviera®)	NHSE	Viral Hepatitis C	Not recommended for routine use	NICE has not issued any guidance.
RED	Dasatinib	(Sprycel®)	NHSE	Chronic myeloid leukaemia (CML) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA425 - Dec 16
RED	Dasatinib	(Sprycel®)	NHSE	Untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults - as per NICE TA 426	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA426 - Dec 16
BLACK	Dasatinib	n/a	NHSE	Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA714 – July 2021
BLACK	Decitabine	(Dacogen®)	NHSE	Acute Myeloid Leukaemia - as per NICE TA 270 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA270 - Dec 12
BLACK	Decitabine	(Dacogen®)	NHSE	Untreated acute myeloid leukaemia - as per NICE TA 548 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA548 - Dec 18
BLACK	Decitabine–ceda zuridine	N/A	N/A	untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Not commissioned. No NHS prescribing in primary or secondary care	TA932 – November 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Deep Brain Stimulation (DBS)	<i>(Deep Brain Stimulation (DBS))</i>	NHSE	Treatment of refractory epilepsy - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Deep Brain Stimulation (DBS)	<i>(Deep Brain Stimulation (DBS))</i>	NHSE	Treatment of Chronic Neuropathic Pain - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Deferasirox	<i>(Exjade®)</i>	ICB	For blood transfusion related iron overload in patients with myelodysplastic syndrome (MDS) (Not a licensed indication).	Not recommended for routine use	NICE has not issued any guidance.
RED	Deferasirox	<i>(Exjade®)</i>	NHSE	Iron chelation in thalassaemia and sickle cell	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Deferasirox	<i>(Exjade®)</i>	NHSE	Treatment of chronic iron overload due to frequent blood transfusions (but not for use in MDS) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Deferiprone	<i>(Ferriprox®)</i>	ICB	For blood transfusion related iron overload in patients with myelodysplastic syndrome (MDS) (Not a licensed indication).	Not recommended for routine use	NICE has not issued any guidance.
RED	Deferiprone	<i>(Ferriprox®)</i>	NHSE	Chronic iron overload related to frequent blood transfusions (not for use in MDS) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Deferiprone	(Ferriprox®)	NHSE	Iron chelation in thalassaemia and sickle cell	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Defibrotide	(Defitelio®)	NHSE	Treatment of hepatic veno-occlusive disease in adults and children undergoing haematopoietic stem cell transplant - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Degarelix	(Firmagon®)	ICB	Advanced hormone-dependent prostate cancer - as per NICE TA 404	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA404 - Aug 16
ADVICE	DEKAs essential/plus		ICB	for use when recommended by specialists for patients with cystic fibrosis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Delamanid	(Delyba®)	NHSE	Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Denosumab	(Prolia®)	ICB	Treatment of therapy-induced bone loss in non-metastatic prostate cancer - as per NICE TA 194 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA194 - Jan 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Denosumab	(<i>Prolia</i> ®)	ICB	Prevention of osteoporotic fractures in postmenopausal women as per NICE TA 204	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	TA204 - Oct 10
RED	Denosumab	(<i>Prolia</i> ®)	ICB	Prevention of osteoporotic fractures in men	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Denosumab	(<i>XGEVA</i> ®)	ICB	Preventing skeletal-related events in multiple myeloma - as per NICE TA 549 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA549 - Dec 18
RED	Denosumab ▼	(<i>XGEVA</i> ® ▼)	ICB	Prevention of skeletal-related events in adults with bone metastases from solid tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA265 - Oct 12
BLACK	Deodorants (stoma)	(<i>Various</i>)	ICB	Odour management related to stoma	Not commissioned. No NHS prescribing in primary or secondary care	Norfolk and Waveney Fair Usage Policy
BLACK	Depigmenting cream	(<i>Pigmanorm</i> ®)	ICB	Melasma (Chloasma)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Desferrioxamine	(<i>Desferal</i> ®)	ICB	For blood transfusion related iron overload in patients with myelodysplastic syndrome (MDS) (Not a licensed indication).	Not recommended for routine use	NICE has not issued any guidance.
RED	Desferrioxamine mesilate	(<i>Desferal</i> ®)	NHSE	Anaemia related to chronic iron overload (not for use in MDS) - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Desferrioxamine mesilate	<i>(Desferal®)</i>	NHSE	Iron chelation in thalassaemia and sickle cell	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Desloratadine	<i>(Generics are available)</i>	ICB	Allergy (not for NHS provision - self care recommended)	Not recommended for routine use	NICE has not issued any guidance.
RED	Deucravacitinib	SOTYKTU®	ICB	moderate to severe plaque psoriasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA907 – June 2023
RED	Dexamethasone	<i>n/a</i>	ICB	To prevent prescribing in primary care as a treatment for covid-19	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Dexamethasone intravitreal implant	<i>(Ozurdex®)</i>	ICB	Non-infectious uveitis in the posterior segment of the eye in adults - as per NICE TA 460	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA460 - Jul 17
RED	Dexamethasone intravitreal implant	<i>(Ozurdex®)</i>	ICB	Treatment of diabetic macular oedema (DMO) in line with NICE TA824	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA824 – September 2022
RED	Dexamethasone intravitreal implant ▼	<i>(Ozurdex®)</i>	ICB	Macular oedema secondary to retinal vein occlusion - as per NICE TA 229	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA229 - Jul 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Dexamfetamine sulfate ▼	(see Shared Care Agreement)	ICB	Narcolepsy in adults - All patients will be initiated by specialist centre in Cambridge. No new initiations in Norfolk and Waveney	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.
SCA	Dexamfetamine sulfate ▼	(Use generic)	ICB	Attention Deficit Hyperactivity Disorder in Adults for new treatment of symptoms that can be confirmed from childhood (Not a licensed indication).	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NG87 - Mar 18
SCA	Dexamfetamine sulfate ▼ (currently under review)	(Generic)	ICB	Attention Deficit Hyperactivity Disorder in children and adolescents	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG87 - Mar 18
BLACK	Dexamfetamine sulphate ▼	(Generics are available)	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
BLACK	Dexibuprofen	(Seractil®)	ICB	Analgesia / musculoskeletal pain	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Dexrazoxane (Cardioxane®)	(Cardioxane®)	NHSE	Anthracycline cardiotoxicity	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Dexrazoxane (Savene®)	(Savene®)	NHSE	Anthracycline extravasation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Diaminopyridine (-3,4) (amifampridine base)	(Generic)	NHSE	Treatment of myasthenias - as per NHS England policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Diaminopyridine (-3,4) (amifampridine base)	(Generic)	NHSE	Lambert Eaton Myasthenic Syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Diazepam	(Generic)	ICB	Chronic use for spasticity in adults with cerebral palsy - NICE Do Not Do as per NG 119	Not recommended for routine use	NG119 - Jan 19
RED	Dibotermin alfa	(InductOs®)	NHSE	Complex spinal surgery - as per NHS England Policy 16063/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Dibotermin alfa (RH bone morphogenetic protein-2)	(InductOs 12)	ICB	Acute tibial fractures with Grade IIIB fractures	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Dichlorphenamide		NHSE	Primary hypo and hyperkalaemic periodic paralysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Diclofenac medicated plaster	<i>(Flector Tissugel medicated plaster 140mg)</i>	ICB	Pain relief	Not recommended for routine use	NICE has not issued any guidance.
Double Red	Dicycloverine	<i>(Generics available)</i>	ICB	GI indications	Not recommended for routine use	NICE has not issued any guidance.
ADVICE	Diethylstilboestrol	various	ICB	treatment of prostate cancer	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Difelikefalin	Kapruvia®	NHSE	pruritus in people having haemodialysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA890 – May 2023
Double Red	Digoxin	<i>(Generics available)</i>	ICB	Cor pulmonale	Not recommended for routine use	CG101 - Jul 10
RED	Dimethyl fumarate (Skilarence®)	<i>(Skilarence®)</i>	ICB	Treatment of moderate to severe plaque psoriasis in adults - as per NICE TA 475 and locally commissioned pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA475 - Sep 17
RED	Dimethyl Fumarate (Tecfidera®)	<i>(Tecfidera®)</i>	NHSE	For treatment of adults with active relapsing-remitting multiple sclerosis (RRMS) - as per NICE TA 320	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA320 - Aug 14
RED	Dinutuximab beta	<i>(Qarziba®)</i>	NHSE	High-risk neuroblastoma in people aged 12 months and over - as per NICE TA538	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA538 - Aug 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Dipipanone 10mg / cyclizine 30mg	Diconal®)	ICB	treatment of acute pain	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Diroximel fumarate	Vumerity®	NHSE	relapsing–remitting multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA794 – June 2022
RED	Disulfiram	<i>(Generics are available)</i>	NCC (Prescribing via CGL)	Maintenance of abstinence in alcohol-dependent patients. Prescribing of treatments for alcohol misuse, including acamprostate and disulfiram (and also nalmefene) are the responsibility of the specialist since local alcohol misuse services are not commissioned from GPs practices	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG115 - Feb 11
RED	Docetaxel	<i>(Taxotere®)</i>	NHSE	Non-small cell lung cancer - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Docetaxel	<i>(Taxotere®)</i>	NHSE	Substitute for paclitaxel causing peripheral neuropathy in ovarian cancer - as per NHS England policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Docetaxel	<i>(Taxotere®)</i>	NHSE	Advanced breast cancer - as per NICE CG 80	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG80 - Feb 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Dolutegravir ▼	(Tivicay® ▼)	NHSE	(in combination with other antiretroviral drugs) Treatment of HIV-1 infection in adults and adolescents - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Domagrozumab		NHSE	Duchenne muscular dystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Donepezil	(Aricept®; Generics available)	ICB	Mild to moderate Alzheimer's dementia - as per NICE TA 217	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	TA217 - Mar 11
RED	Doravirine	()	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Dornase alfa	(Pulmozyme®)	NHSE	Cystic fibrosis - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Dornase alfa	(Pulmozyme®)	NHSE	Primary Ciliary Dyskinesia (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Dostarlimab	Jemperli®	NHSE	previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA779 – March 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Dostarlimab	Jemperli®	NHSE	platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA963 – April 2024
BLACK	Dosulepin hydrochloride	(Prothiaden®)	ICB	Depression - as per NICE CG 90 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG90 - Oct 09
Double Red	Doxepin	()	ICB	Antidepressant	Not recommended for routine use	NICE has not issued any guidance.
Double Red	Doxepin	(Xepin)	ICB	Urticaria in dermatology	Not recommended for routine use	NICE has not issued any guidance.
RED	Doxorubicin HCl (pegylated liposomal) (PLDH)	(Caelyx)	NHSE	As monotherapy or with platinum for treatment of advanced recurrent ovarian cancer - as per NICE TA 389	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA389 - Apr 16
ADVICE	Doxylamine succinate + Pyridoxine	(Xonvea®)	ICB	(with pyridoxine hydrochloride 10mg in a delayed-release formulation) for the treatment of nausea and vomiting in pregnancy in women who do not respond to conservative management (third-line option)	Only to be initiated in hospital. Can continue in primary care once patient is stable and treatment has been proven to be effective. Not to be initiated in primary care	NICE has not issued any guidance.
RED	Dried Prothrombin (complex)	()	NHSE	Licensed indications incl treatment and peri-operative prophylaxis of haemorrhage in patients with congenital deficiency of factors II, VII, IX, or X if purified specific coagulation factors not available	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Drisapersen	((PRO051 / GSK2402968))	NHSE	Duchenne Muscular Dystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Dronedarone	(<i>Multaq®</i>)	ICB	Non-permanent Atrial Fibrillation - for use only where amiodarone is contraindicated or has previously not been tolerated (except lung toxicity due to amiodarone)	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	TA197 - Aug 10
ADVICE	Dulaglutide ▼	(<i>Trulicity® ▼</i>)	ICB	Type 2 diabetes mellitus - third line option	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Duloxetine	(<i>Yentreve®</i>)	ICB	Moderate to Severe Stress Urinary Incontinence (SUI) - (but not first- line as per NICE CG 171 Do Not Do)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG171 - Oct 06
BLUE	Dundee sunscreen	n/a	ICB	photosensitivity disorders where the patient is sensitive to visible light, most commonly solar urticaria and porphyrias, particularly erythropoietic protoporphyria	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Dupilumab	Dupixent®	NHSE	severe asthma with type 2 inflammation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA751 – December 2021
BLACK	Dupilumab	N/A	N/A	eosinophilic oesophagitis in people 12 years and over	Not commissioned. No NHS prescribing in primary or secondary care	TA938 – December 2023
BLACK	Dupilumab	N/A	N/A	moderate to severe prurigo nodularis	Not commissioned. No NHS prescribing in primary or secondary care	TA955 – March 2024
RED	Dupilumab ▼	(Dupixent® ▼)	ICB	For adults with severe atopic dermatitis who have failed to respond, or who are intolerant of or ineligible for all approved therapies - as per NICE TA 534	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA534 - Aug 18
BLACK	Dupilumab ▼	(Dupixent® ▼)	ICB	chronic rhinosinusitis with nasal polyps (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA648 – September 2020
RED	Dupilumab ▼	(Dupixent® ▼)	NHSE	Asthma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Durvalumab		NHSE	in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA662 – November 2020
RED	Durvalumab	Imfinzi®	NHSE	maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA798 – June 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Durvalumab	Imfinzi®	NHSE	with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA944 – Jan 2024
BLACK	Duvelisib	N/A	NHSE	relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA717 – July 2021
BLACK	Duvelisib	N/A	NHSE	relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA811 – July 2022
RED	Ecallantide	(Kalbitor®)	NHSE	Hereditary angiodema - acute treatment only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Eculizumab	(Soliris®)	NHSE	treating refractory myasthenia gravis (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA636 – June 2020
BLACK	Eculizumab	(Soliris®)	NHSE	relapsing neuromyelitis optica (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA647 – September 2020
RED	Eculizumab	(Soliris®)	NHSE	C3 glomerulopathy (post transplant) - as per NHSE policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Eculizumab	(Soliris®)	NHSE	Paroxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Eculizumab	(Soliris®)	NHSE	Treatment of refractory antibody mediated rejection post kidney transplant - as per NHS England policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Eculizumab	(Soliris®)	NHSE	Atypical haemolytic uremic syndrome (aHUS)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST1 - Jan 2015
RED	Edasalonexent		NHSE	Duchenne muscular dystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Edoxaban ▼	(Lixiana® ▼)	ICB	Treatment and secondary prevention of pulmonary embolism as per NICE TA 354 (where warfarin is not appropriate see Full Guidance)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA354 - Aug 15
ADVICE	Edoxaban ▼	(Lixiana® ▼)	ICB	Treatment and prevention of proximal deep vein thrombosis in specified patient groups (see Full Guidance)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 3 weeks.	TA354 - Aug 15
RED	Edoxaban ▼	(Lixiana® ▼)	ICB	Treatment of calf vein deep vein thrombosis (as per NICE TA 354)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA354 - Aug 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Edoxaban ▼	(Lixiana® ▼)	ICB	Combined use with with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG172 - Nov 13
RED	Edtratide	((hCDR1))	NHSE	Systemic lupus erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Efalex	(Efalex)	ICB	Dyslexia - (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Efavirenz	(Sustiva®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Efralococog alfa ()	()	NHSE	Haemophilia A - as per NHS England policy SSC1652	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Eftrenonacog alfa ()	()	NHSE	Haemophilia B - as per NHS England SSC1652	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Eladocagene exuparovec	Upstaza®	NHSE	aromatic L-amino acid decarboxylase deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST26 – April 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Elafibranor	Iqirvo®	NHSE	previously treated primary biliary cholangitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1016 – November 2024
RED	Elbasvir-grazoprevir ▼	(Zepatier® ▼)	NHSE	Genotype 1 or 4 chronic hepatitis C in adults - as per NICE TA 413	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA413 - Oct 16
BLACK	Electronic cigarettes	(e-cigarettes)	ICB	Tobacco dependence / smoking reduction or cessation - as per Public Health guidance (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG92 - Mar 18
RED	Eliglustat ▼	(Cerdelga® ▼)	NHSE	Treatment of Type 1 Gaucher disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST5 - Jun 17
RED	Elosulfase alpha ▼	(Vimizim® ▼)	NHSE	Treatment of Mucopolysaccharidosis IV Type A (MPS IVA) (Morquio A syndrome) as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST19 - April 2022
BLACK	Elotuzumab ▼	(Empliciti® ▼)	NHSE	Multiple myeloma - as per NICE TA 434 (Terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA434 - Mar 17
RED	Elranatamab	Elrexio®	NHSE	relapsed and refractory multiple myeloma after 3 or more treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1023 – December 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Eltrombopag	(Revolade®)	ICB	Treatment of chronic immune (idiopathic) thrombocytopenic purpura - as per NICE TA 293	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA293 - Jul 13
RED	Eltrombopag	(Revolade®)	NHSE	ITP in children	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA293 - Jul 13
BLACK	Eltrombopag	(Revolade®)	ICB	Severe aplastic anaemia refractory to immunosuppressive therapy - as per NICE TA 382 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA382 - Jan 16
BLUE	Eltrombopag	(Revolade®)	ICB	Thrombocytopenia which affects the initiation or maintenance of optimal interferon therapy in adults with chronic Hepatitis C	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	NICE has not issued any guidance.
RED	Elvitegravir	(Part of Genvoya®; Stribild®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per NHS England Policy 16043/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Elvitegravir/cobicistat/emtricitabine/tenofovir ▼	(Stribild® ▼)	NHSE	HIV infection - as per NHS England policy 16043/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Elvucitabine	()	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Emapalumab		NHSE	Haemophagocytic lymphohistiocytosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Emicizumab		NHSE	As per BCSH guidelines for specialised indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Empagliflozin	(Jardiance ▼)	ICB	treating type 2 diabetes in people 10 to 17 years (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA1006 – September 2024
ADVICE	Empagliflozin	Jardiance®	ICB	chronic heart failure with reduced ejection fraction	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA773 – March 2022
ADVICE	Empagliflozin	Jardiance®	ICB	chronic heart failure with preserved or mildly reduced ejection fraction	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA929 – November 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Empagliflozin ▼	(Jardiance® ▼)	ICB	In combination therapy for treating type 2 diabetes - as per NICE TA 336	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA336 - Mar 15
ADVICE	Empagliflozin ▼	(Jardiance ▼)	ICB	As 4th line monotherapy option for treating type 2 diabetes - as per NICE TA 390	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA390 - May 16
RED	Emricasan	()	NHSE	Non alcoholic steatohepatitis (NASH) fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Emtricitabine	(Emtriva®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Emtricitabine and tenofovir	(Truvada®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Emtricitabine and Tenofovir alafenamide fumarate	(Descovy®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Emtricitabine, Rilpivirine, tenofovir alafenamide	(Odefsey®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Encorafenib	(Braftovi®)	NHSE	(with binimetinib (Mektovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA562 - Feb 19
RED	Encorafenib	Braftovi®	NHSE	Plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA668 – January 2021
BLACK	Enfortumab vedotin	N/A	NHSE	previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA797 – June 2022
RED	Enfuvirtide	(Fuzeon®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Entecavir	(Baraclude®)	NHSE	Chronic hepatitis B - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG165 - Jun 13
RED	Entrectinib	Rozlytrek®)	NHSE	ROS1-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA643 – August 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Entrectinib	Rozlytrek®)	NHSE	NTRK fusion-positive solid tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA644 – August 2020
RED	Enzalutamide	(<i>Xtandi</i> ®)	NHSE	Metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 316	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA316 - Jul 14
RED	Enzalutamide	(<i>Xtandi</i> ®)	NHSE	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - as per NICE TA 377	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA377 - Jan 16
BLACK	Enzalutamide		n/a	non-metastatic prostate cancer after radical prostatectomy or radiotherapy	Not for prescribing in primary or secondary care	TA994 – August 2024
RED	Enzalutamide	Xtandi®	NHSE	hormone-sensitive metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA712 – July 2021
RED	Epcoritamab	Tepkinly®)	NHSE	relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA954 – March 2024
BLACK	Epifix®	(<i>Epifix</i> ®)	ICB	Chronic wounds (A licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	MIB139 - Jan 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Epinephrine (Adrenaline) inhaler (Primatene Mist®)	(Primatene Mist®)	ICB	Asthma - reliever therapy (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Eplontersen	Wainzua®	NHSE	hereditary transthyretin-related amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1020 – November 2024
RED	Epoetin alpha, beta, theta and zeta		NHSE	Dialysis-induced anaemia (renal dialysis only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Epoprostenol	(Flolan®)	NHSE	Acute respiratory distress syndrome (ARDS) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Epoprostenol (prostacyclin)	(Flolan®)	NHSE	Primary pulmonary hypertension - as per NHS England policy - specialist centre only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Epratuzumab	(Epratucyn®)	NHSE	Systemic lupus erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Eprodinate	(Kiacta® (formerly Fibrillex))	NHSE	Amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Eptifibatide	(Integrilin®)	NHSE	Prevention of MI in unstable angina - as per NICE TA 47	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA47 - Sep 02
RED	Eptinezumab	VYEPTI®	ICB	preventing migraine	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA871 – March 2023
RED	Eptotermin alfa	()	NHSE	Complex spinal surgery	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Erectile dysfunction drugs	(Various)	ICB	Severe distress from erectile dysfunction seeking treatment on the NHS	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLUE	Erenumab	Aimovig®	ICB	Preventing migraine	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA682 – March 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ergocalciferol / Vitamin D Injections		ICB	Vitamin D deficiency	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Eribulin	(Halaven®)	NHSE	Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) - as per NICE TA 423	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA423 - Dec 16
RED	Eribulin	(Halaven®)	NHSE	Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA423 - Dec 16
BLACK	Eribulin	(Halaven®)	NHSE	Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515	Not commissioned. No NHS prescribing in primary or secondary care	TA515 - Mar 18
BLACK	Erlotinib	(Tarceva®)	NHSE	Monotherapy for maintenance treatment of non-small-cell lung cancer - as per NICE TA 227 and NHS England policy	Not commissioned. No NHS prescribing in primary or secondary care	TA227 - Jun 11
RED	Erlotinib	(Tarceva®)	NHSE	First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA258 - Jun 12
BLACK	Erlotinib	(Tarceva®)	NHSE	Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy	Not commissioned. No NHS prescribing in primary or secondary care	TA374 - Dec 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Erlotinib	(<i>Tarceva®</i>)	NHSE	Treating locally advanced or metastatic NSCLC that doesn't test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA374 - Dec 15
ADVICE	Ertugliflozin	(<i>Steglatro®</i>)	ICB	As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA572 - Mar 19
RED	Erythropoietin (epoetin / darbepoetin)	(<i>Various</i>)	ICB	Treatment of anaemia in people with cancer having chemotherapy as per NICE TA 323 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA323 - Nov 14
RED	Erythropoietin / Epoetin	(<i>Eprex</i>)	ICB	Treatment of transfusion-dependent anaemia in myelodysplasia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Erythropoietin / Epoetin	(<i>Eprex®, NeoRecormon® and others</i>)	NHSE	Dialysis-induced anaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG114 - Nov 11
Double Red	Erythropoietin / Epoetin	(<i>Eprex®, NeoRecormon® and others</i>)	ICB	Anaemia in renal failure pre-dialysis.	Not recommended for routine use	NG8 - Jun 15
BLACK	Esketamine	Spravato®	ICB	nasal spray for treatment-resistant depression	Not commissioned. No NHS prescribing in primary or secondary care	TA854 – December 2022
BLACK	Esketamine	Spravato®	ICB	major depressive disorder in adults at imminent risk of suicide (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA899 – June 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Eslicarbazepine	Zebinix®	ICB	Epilepsy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Eslicarbazepine	Zebinix®	ICB	Trigeminal neuralgia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Esomeprazole	<i>(Generic)</i>	ICB	Limited use where other PPI options have been ineffective; Barrett's oesophagus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
Double Red	Esomeprazole	<i>(Nexium®, Emozul®, Generic available)</i>	ICB	First line PPI option for licensed indications -	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Estradiol / Dienogest	<i>(Qlaira®)</i>	ICB	Contraception	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Estramustine phosphate	<i>(Estracyt®)</i>	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Etamsylate	<i>(Dicynene®)</i>	ICB	Heavy menstrual bleeding - as per NICE CG 44 and the BNF	Not commissioned. No NHS prescribing in primary or secondary care	NG88 - Mar 18
RED	Etanercept	<i>(Enbrel® / Benepali® ▼)</i>	ICB	Psoriasis - as per NICE TA 103 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA103 - Jul 06

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	Rheumatoid arthritis - after other DMARDs including a TNF inhibitor - as per NICE TA 195 and local policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA195 - Aug 10
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	Active and progressive psoriatic arthritis - as per NICE 199 and local policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA199 - Aug 10
RED	Etanercept	(Enbrel® / Benepali® ▼)	NHSE	Idiopathic juvenile arthritis - polyarticular, psoriatic and enthesitis-related JIA as per NICE TA 373 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA373 - Dec 15
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - as per NICE TA 375 and local policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	Ankylosing spondylitis - as per NICE TA 383	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	Axial spondyloarthritis (severe, non-radiographic) where NSAIDs not effective or not tolerated - as per NICE TA 383 and local policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Etanercept	(Enbrel® / Benepali® ▼)	ICB	Plaque psoriasis in children and young people - as per NICE TA 455	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA455 - Jul 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Etanercept	various, plus biosimilars	ICB	moderate rheumatoid arthritis after conventional DMARDs have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA715 – July 2021
RED	Etanercept	(<i>Enbrel® / Benepali® ▼</i>)	NHSE	Behcet's Disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Etelcalcetide ▼	(<i>Parsabiv® ▼</i>)	NHSE	Secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis - as per NICE TA 448	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA448 - Jun 17
RED	Eteplirsen	(<i>Exondys 51</i>)	NHSE	Duchenne Muscular Dystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Ethambutol	<i>various</i>	ICB	Non-TB related mycobacterium infections	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	NICE has not issued any guidance.
BLACK	Etilefrine		ICB	Priapism in sickle cell crisis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Etonogestrel / ethinylestradiol	(NuvaRing®)	ICB	Medium acting reversible contraception where oral and transdermal options are not suitable	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	NICE has not issued any guidance.
RED	Etoposide	(Vepesid®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Etranacogene dezaparvovec	Hemgenix®	NHSE	moderately severe or severe haemophilia B	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA989 – July 2024
RED	Etrasimod	Velsipity	ICB	moderately to severely active ulcerative colitis in people aged 16 and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA956 - March 2024
RED	Etravirine	(Intence)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Etrolizumab	((RG7413))	NHSE	Paediatric indications (IBD) where adult TA available	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Everolimus	(<i>Certican</i> ®)	NHSE	Treatment for preventing organ rejection in liver transplantation - as per NICE TA 348	Not commissioned. No NHS prescribing in primary or secondary care	TA348 - Jul 15
RED	Everolimus	(<i>Afinitor</i> ®)	NHSE	(with exemestane) for advanced HER2-negative, hormone-receptor-positive breast cancer in postmenopausal women - as per NICE TA 421 and NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA421 - Dec 16
RED	Everolimus	(<i>Afinitor tablets</i> ® ▼)	NHSE	2nd line for advanced renal cell carcinoma - as per NICE TA 432	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA432 - Feb 17
RED	Everolimus	(<i>Afinitor</i> ®)	NHSE	Unresectable or metastatic neuroendocrine tumours in people with progressive disease in adults as per NICE TA 449	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA449 - Jun 17
BLACK	Everolimus	(<i>Certican</i> ®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17
BLACK	Everolimus	(<i>Certican</i> ®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17
RED	Everolimus	(<i>Votubia</i> ®)	NHSE	Subependymal giant cell astrocytoma (SEGA) associated with tubular sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Everolimus	(<i>Votubia</i> ®)	NHSE	Renal angiomyolipoma associated with tubular sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Evinacumab		NHSE	Homozygous familial hypercholesterolaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Evinacumab	Evkeeza®	NHSE	homozygous familial hypercholesterolaemia in people 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1002 – September 2024
RED	Evolocumab	(<i>Repatha</i> ® ▼)	NHSE	Homozygous familial hypercholesterolaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Evolocumab ▼	(<i>Repatha</i> ® ▼)	ICB	For treating primary hypercholesterolaemia and mixed dyslipidaemia - as per NICE TA 394	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA394 - Jun 16
RED	Exagamglogene autotemcel	Casgevy®	NHSE	transfusion-dependent beta-thalassaemia in people 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1003 – September 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Exemestane	(Aromasin®)	ICB	Adjuvant treatment of oestrogen-receptor-positive early breast cancer - as per NICE TA 112 and CG80/81	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA112 - Nov 06
ADVICE	Exemestane	(Aromasin®)	ICB	Advanced breast cancer in postmenopausal women in whom anti-oestrogen therapy has failed - as per NICE CG 81	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Exenatide	(Byetta®)	ICB	Co-use with insulin under specified criteria for T2DM - as per local policy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Exenatide	(Byetta® and Bydureon® ▼)	ICB	3rd line use in Type 2 diabetes with metformin + sulphonylurea - as per NICE CG 28	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NG28 - Dec 15
ADVICE	Exenatide (prolonged-release)	(Bydureon®)	ICB	in combination with oral antidiabetic therapy for type-2 diabetes - as per NICE TA 248	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA248 - Feb 12

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ex-vivo expanded autologous human corneal epithelial cells containing stem cells (Holoclar)		NHSE	Treatment of adult patients with moderate to severe limbal stem cell deficiency (LSCD), unilateral or bilateral, due to physical or chemical ocular burns	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA467 - Aug 17
RED	Factor IX		NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Factor VII		NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Factor VIIA	<i>NovoSeven</i>	NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Factor VIII	<i>NovoEight®</i>	NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Factor VIII and IX	<i>(Various)</i>	NHSE	Deficiency states (A licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Factor X (Coagadex)		NHSE	Hereditary factor X deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Factor XIII		NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	FactorR VIII Inhibitor Bypassing Factor (FEIBA)		NHSE	Specialist indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Fampridine	(Fampyra®)	NHSE	Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Farco-fill Protect		ICB	Indwelling urinary catheterisation	Not commissioned. No NHS prescribing in primary or secondary care	MIB 121 – September 2017
RED	Faricimab	Vabysmo®	ICB	visual impairment caused by macular oedema after retinal vein occlusion	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1004 – September 2024
RED	Faricimab	Vabysmo®	ICB	diabetic macular oedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA799 – June 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Faricimab	Vabysmo®	ICB	wet age-related macular degeneration	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA800 – June 2022
RED	Fedratinib	Inrebic®	NHSE	disease-related splenomegaly or symptoms in myelofibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1018 – November 2024
RED	Fenfluramine	Fintepla®	NHSE	seizures associated with Dravet syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA808 – July 2022
Double Red	Fenofibrate	(Lipantil®; Supralip®; Cholib®)	ICB	Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication).	Not recommended for routine use	CG181 - Jul 14
Double Red	Fentanyl I-R - buccal tabs, loz, nasal sprays	(Effentora®, Actiq®, Instanyl®, PecFent®)	ICB	(Acute) breakthrough pain in cancer	Not recommended for routine use	CG140 - July 12
RED	Fentanyl I-R sublingual tabs (Abstral®)	(Abstral®)	ICB	3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Ferric maltol (Feraccru®)	(Feraccru®)	ICB	Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD)	Not recommended for routine use	NICE has not issued any guidance.
RED	Ferric maltol (Feraccru®)	(Feraccru®)	ICB	Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Fibrin sealants	(<i>Fibrin sealants</i>)	NHSE	Haemostatic / tissue glue	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Fibrinogen, dried (Human)	()	NHSE	Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Fibroblast growth factor 1 (FGF1) gene therapy	()	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Fidaxomicin	(<i>Dificlir®</i>)	ICB	Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Filgotinib	Jyseleca®)	ICB	Moderate to severe rheumatoid arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA676 – February 2021
RED	Filgotinib	()	NHSE	Paediatric indications (where adult TA available) - specialist centres only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Filgotinib	Jyseleca®	ICB	moderately to severely active ulcerative colitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA792 – June 2022
RED	Filgrastim	()	NHSE	Barth Syndrome - specialist centres only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Filgrastim	(Various ▼)	NHSE	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per NHS England policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Filibuvir	()	NHSE	Viral Hepatitis (B&C) and Respiratory Syncytial Virus	Not recommended for routine use	NICE has not issued any guidance.
RED	Fingolimod ▼	(Gilenya® ▼)	NHSE	Highly active relapsing remitting multiple sclerosis as per NICE TA 254	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA254 - Apr 12
RED	Fingolimod ▼	(Gilenya® ▼)	NHSE	Highly active, or rapidly evolving severe, relapsing-remitting multiple sclerosis outside NICE TA 254	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA254 - Apr 12
BLACK	Fish oils (omega-3 fatty acids)	(e.g. Omacor®, Maxepa®, Equazen®)	ICB	Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG181 - Jul 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Fish oils (omega-3 fatty acids)	(Various - e.g. Equazen®, Omacor®, Maxepa®)	ICB	Treatment of attention deficit hyperactivity disorder (ADHD) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Fitusiran		NHSE	Haemophilia A and B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Flavoxate hydrochloride	(Urispas®)	ICB	Overactive bladder and urinary incontinence in women - as per NICE CG 171 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG171 - Nov 15
BLACK	Fluconazole (Oral)	(Generics available)	ICB	Vaginal candidiasis in pregnancy - as per NICE CG 62 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG62 - Jan 17
RED	Fludarabine	(Fludara®)	NHSE	B-cell Chronic Lymphocytic Leukaemia - 2nd line treatment - as per NICE TA 29	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA29 - Sep 01
BLACK	Fludarabine	(Fludara®)	NHSE	B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119	Not commissioned. No NHS prescribing in primary or secondary care	TA119 - Feb 07
ADVICE	Fludroxycortide tape	(previously Haelan)	ICB	Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance
BLACK	Fludroxycortide tape	(previously Haelan)	ICB	All unlicensed uses including hypertrophic scars and keloids	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Fluocinolone acetonide intravitreal implant	(Iluvien®)	ICB	Recurrent non-infectious uveitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA590 - Jul 19
RED	Fluocinolone acetonide intravitreal implant	(Iluvien®)	ICB	chronic diabetic macular oedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA953 – March 2024
RED	Fluoride supplements - Toothpaste; dental products	(Duraphat 0.619% DPF; 1.1% DPF Toothpaste)	ICB	Prevention of dental caries in at-risk patients (where the specialist is a dentist)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Folic acid	(Generics are available)	ICB	Secondary prevention of MI / reduce cardiovascular risk post MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG172 - Nov 13
BLACK	Folic Acid	(Generics are available)	ICB	For preventing hypertensive disorders during pregnancy - as per NICE CG 107 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG107 - Aug 10
RED	Fomepizole	(Antizol®)	ICB	Methanol and ethylene glycol poisoning (Poison Centre prescribing only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Fondaparinux sodium	(Arixtra®)	NHSE	Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per regional network policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG94 - Mar 10
BLACK	Fondaparinux sodium	(Arixtra®)	NHSE	Prophylaxis of venous thromboembolism in those undergoing major orthopaedic surgery of the legs - as per NICE DoNotDo recommendation	Not commissioned. No NHS prescribing in primary or secondary care	NG89 - Mar 18
RED	Forigerimod acetate	(Lupuzor®)	NHSE	Systemic lupus erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Fosamprenavir	(Telzir®)	NHSE	HIV infection in combination with other antiretroviral drugs- with low-dose ritonavir	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Foscarnet	(Foscavir®)	NHSE	CMV infection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Foslevodopa–foscarbidopa	Produodopa®		advanced Parkinson's with motor symptoms	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA934 – November 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Fosphenytoin sodium	(Pro-Epanutin®)	ICB	Status epilepticus, seizures with head injury, etc.	Not recommended for routine use	NICE has not issued any guidance.
RED	Fostamatinib	Tavlesse®	ICB	refractory chronic immune thrombocytopenia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA835 – October 2022
Double Red	Fostemsavir	()	NHSE	HIV infection in combination with other antiretroviral drugs	Not recommended for routine use	NICE has not issued any guidance.
RED	FreeStyle Libre BGS device (sensors are "Advice")	(FreeStyle Libre)	ICB	Blood Glucose Monitoring in diabetes - as per NHSE criteria March 2019	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	FreeStyle Libre BGS sensors (BGS device is "Red")	(FreeStyle Libre)	ICB	Blood Glucose Monitoring in diabetes - as per NHSE criteria March 2019	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	NICE has not issued any guidance.
RED	Fremanezumab	Ajovy®	ICB	preventing migraine	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA764 – February 2022
BLACK	Fulvestrant	(Faslodex®)	NHSE	Treatment of locally advanced or metastatic breast cancer - as per NICE TA 503	Not commissioned. No NHS prescribing in primary or secondary care	TA503 - Jan 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Fumaric acid ester	(Fumaderm (unlicensed product))	ICB	Severe psoriasis - specialist use only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Futibatinib	Lytgobi®	NHSE	previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1005 – September 2024
SCA	Galantamine	(Reminyl®)	ICB	Mild to moderate Alzheimer's dementia - as per NICE TA 217	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	TA217 - Mar 11
BLACK	Galaxy UNYCO	(Galaxy UNYCO)	ICB	for temporary stabilisation of lower limb fractures	Not commissioned. No NHS prescribing in primary or secondary care	MIB166 - Dec 18
RED	Galcanezumab	Emgality®	ICB	preventing migraine	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA659 – November 2020
RED	Galsufase	()	NHSE	Mucopolysaccharidosis VI - specialist centre only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Galunisertib		NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Gamolenic Acid (Evening Primrose Oil)	(Various - Epogam (Blacklisted))	ICB	All - not for NHS prescribing (Various indications).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ganciclovir sodium	(Cymevene)	NHSE	Cytomegalovirus infection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ganetespib	()	NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Gefapixant	Lyfnua®	n/a	refractory or unexplained chronic cough (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA969 – April 2024
RED	Gefitinib	(Iressa®)	NHSE	First-line treatment of locally advanced or metastatic non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA192 - Jul 10
BLACK	Gefitinib	(Iressa®)	NHSE	Treating NSCLC that has progressed after chemotherapy (as per NICE TA 374) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA374 - Dec 15
BLACK	Geko wound therapy		ICB	treatment of venous insufficiency and ischemia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Gemcitabine	(Gemzar®)	NHSE	Pancreatic cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA25 - May 01
BLACK	Gemcitabine	(Gemzar®)	NHSE	Treatment of the first recurrence of platinum sensitive ovarian cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA389 - Apr 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Gemcitabine	(<i>Gemzar®</i>)	NHSE	Non-small cell lung carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Gemfibrozil	(<i>Lopid®</i>)	ICB	Prevention CVD - as per NICE CG 181 "Do Not Do"	Not recommended for routine use	CG181 - Jul 14
RED	Gemtuzumab ozogamicin	(<i>Mylotarg®</i>)	NHSE	Untreated de novo CD33-positive acute myeloid leukaemia in people aged ≥15 years - as per NICE TA 545	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA545 - Nov 18
RED	Gentamicin (nebulised)	()	ICB	Ps. aeruginosa infection in non-Cystic Fibrosis bronchiectasis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Gevokizumab	()	NHSE	Uveitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Gilteritinib	Xospata®	NHSE	relapsed or refractory acute myeloid leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA642 – August 2020
RED	Givosiran	Givlaari	NHSE	Hepatic porphyria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST16 - Nov 2021
BLACK	Glasdegib	()	NHSE	with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA646 – September 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Glatiramer	(Copaxone®)	NHSE	Multiple Sclerosis - as per NICE TA 527	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA527 - Jun 18
RED	Glecaprevir-pibrentasvir ▼	(Maviret® ▼)	NHSE	Chronic hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA499 - Jan 18
BLACK	Gliclazide modified release	(Diamicon® MR)	ICB	Type 2 diabetes mellitus	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Glofitamab	Columvi®	NHSE	relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA927 – October 2023
RED	Glucarpidase	(Voraxase)	NHSE	Urgent treatment of methotrexate-induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Glucocorticoids (inc hydrocortisone, prednisolone)	(Generics are available)	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
BLACK	Glucosamine	(Various)	ICB	Osteoarthritis - as per NICE CG 177 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG177 - Feb 14
BLACK	Glucosamine, Glucosamine & Chondroitin	(Alateris and various)	ICB	Osteoarthritis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Gluten-free foods	<i>(Various)</i>	ICB	Gluten sensitive enteropathies in all patients across N+W	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Glycerol phenylbutyrate	<i>(Ravicti® 1.1 g/ml oral liquid)</i>	NHSE	Urea cycle disorders (specialist use only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	GlycoPEGylated Factor IX	<i>(Rebinyn®)</i>	NHSE	Haemophilia B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Glycopyrronium bromide	Glycobromag	ICB	Hyperhidrosis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Glycopyrronium bromide	Adults - Glycobromag first line, Assicco second line. Children - Assicco first line, sialanar second line	ICB	Hypersalivation	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Glycopyrronium bromide 2% in cetomacrogol cream	N/A	ICB	craniofacial hyperhidrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Golimumab	(<i>Simponi</i> ®)	ICB	Treatment of psoriatic arthritis (including switching between treatments) - as per NICE TA 220 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA220 - Apr 11
BLACK	Golimumab	(<i>Simponi</i> ®)	ICB	Treatment of methotrexate-naïve rheumatoid arthritis - as per NICE TA 224 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA224 - Jun 11
RED	Golimumab	(<i>Simponi</i> ®)	ICB	Treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA225 - Jun 11
RED	Golimumab	(<i>Simponi</i> ®)	ICB	2nd line (Biologic) treatment option for moderately to severely active ulcerative colitis after the failure of conventional therapy - as per NICE TA 329 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA329 - Feb 15
RED	Golimumab	(<i>Simponi</i> ®)	ICB	For rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
RED	Golimumab	(<i>Simponi</i> ®)	ICB	Ankylosing spondilitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLUE	Golimumab	(<i>Simponi</i> ®)	ICB	Severe non-radiographic axial spondyloarthritis in adults whose disease has responded inadequately to, or who cannot tolerate, nonsteroidal anti-inflammatory drugs	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA497 - Jan 18
BLACK	Golimumab	(<i>Simponi</i> ®)	ICB	For induction of remission, with or without steroids, in patients with Crohn's disease colitis with moderate-severe disease as a third-line anti-TNF after failure of or adverse reaction to two previous agents (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
SCA	Goserelin	(<i>Zoladex</i> ®)	ICB	Management of endometriosis; pre-operative management of uterine fibroids	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG73 - Sep 17
ADVICE	Goserelin	(<i>Zoladex</i> ®)	ICB	Prostate cancer	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Gosuranemab		NHSE	Supranuclear palsy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Granulocyte-macrophage colony-stimulating factor (leukine® - import)		NHSE	Antibody-positive pulmonary alveolar proteinosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Grass pollen allergen extract	(Grazax®)	ICB	Seasonal allergic hay fever due to grass pollen	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Grazoprevir		NHSE	Hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	GTN patches		ICB	Achilles Tendinopathy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance
SCA	Guanfacine Prolonged-Release ▼	(Intuniv® ▼)	ICB	For children aged 6-17yr with ADHD for whom stimulants are not suitable, not tolerated or have been shown to be ineffective	Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.
RED	Guselkumab	(Tremfya®)	ICB	Moderate to severe plaque psoriasis in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA521 - Jun 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Guselkumab	Tremfya®	ICB	active psoriatic arthritis after inadequate response to DMARDs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA711 – June 2021
RED	Guselkumab	Tremfya®	ICB	treating active psoriatic arthritis after inadequate response to DMARDs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA815 – August 2022
RED	Haem Arginate	(Normosang®)	NHSE	Hepatic porphyria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Haem iron tablets (GlobiFer)	(GlobiFer®, also Forte and Plus)	ICB	Anaemia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Heparin - Low molecular weight (LMWH)	(Various)	ICB	Prevention of DVT during flights (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Heparin - Low Molecular Weight (LMWH)	(Various)	ICB	Use in obstetrics for management of VTE in high risk patients (e.g. overweight, multiparous, or who smoke) and require LMWH post partum (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Heparin - Low Molecular Weight (LMWH)	(Various)	ICB	Unstable angina/coronary artery disease/NSTEMI	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Heparin - Low Molecular Weight (LMWH) (currently under review)	(Various)	ICB	For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.
Double Red	Heparinised saline	(Saline (heparinised))	ICB	Central venous catheter lock in adults - as per RMOC guidance (Feb 2019)	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Heparinoid Cream / Gel	Hirudoid 0.3%, Bruiseze 0.8%, Lasonil	ICB	Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq	(Saizen®, Zomacton®, Nordiflex®, Nutropin Aq)	ICB	Growth hormone deficiency (GHD) - as per East of England PAC policy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	HidraWear dressings	n/a	ICB	Hidradenitis Suppurativa (HS)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	HidraWear underwear	n/a	ICB	Hidradenitis Suppurativa (HS)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	HIV vaccine	(HIV vaccine)	NHSE	HIV infection prophylaxis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	HIV/AIDS treatments	(Various)	NHSE	HIV infection / post exposure prophylaxis (PEP)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Hormone Replacement Therapy (HRT) - systemic	(Various)	ICB	Treatment of urinary incontinence as per NICE CG 171 - NICE Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG171 - Nov 15
RED	Human alpha-1 proteinase inhibitor		NHSE	Emphysema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Human alpha1-proteinase inhibitor		N/A	emphysema	Not commissioned. No NHS prescribing in primary or secondary care	TA965 – March 2024
RED	Human heterologous liver cells (HHLivC)	(Heparesc®)	NHSE	Urea cycle disorders	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Aragam®)	(Aragam®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Flebogamma®)	(Flebogamma®)	NHSE	As per National Demand Management Plan	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human normal immunoglobulin (Gammagard®)	(Gammagard®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Human normal immunoglobulin (Gammanorm®)	(Gammanorm®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human normal immunoglobulin (Gammaplex®)	(Gammaplex®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human normal immunoglobulin (Gamunex®)	(Gamunex®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Hizentra)	(Hizentra®)	NHSE	As per National Demand Management Plan - NHSE policy Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human normal immunoglobulin (Intratect®)	(Intratect®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human normal immunoglobulin (IVIg)	(Privigen®)	NHSE	As per National Demand Management Plan	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Kiovig)	(Kiovig®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Human Normal Immunoglobulin (Octagam)	(Octagam®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Subcuvia®)	(Subcuvia®)	NHSE	As per National Demand Management Plan - NHSE Policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Subgam®)	(Subgam®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Vigam®)	(Vigam®)	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human Normal Immunoglobulin (Vivaglobin®)	(Vivaglobin® (for s-c infusion) (discontinued 2011))	NHSE	As per National Demand Management Plan - NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Human parathyroid hormone-related protein analogue	Natpar® s/c injection	NHSE	Male and juvenile osteoporosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Hyaluronate	various	ICB	Intra-articular injection in osteoarthritis (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Hybrid closed loop systems	N/A	ICB	managing blood glucose levels in type 1 diabetes	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA943 – December 2023
RED	Hydrocortisone	various	ICB	To prevent prescribing in primary care as a treatment for covid-19	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Hydrocortisone granules in capsules	(Alkindi®)	ICB	Cortisol replacement therapy for children (0-6 years) with adrenal insufficiency	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Hydrocortisone MR	(Plenadren® MR tablets)	ICB	Treatment of adrenal insufficiency in adults	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Hydrocortisone MR caps	Efmody	ICB	congenital adrenal hyperplasia (CAH) in patients 12 years old and above.	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Hydroxycarbamide (hydroxyurea) - generic	(Generic)	ICB	Sickle Cell disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Hydroxycarbamide (Hydroxyurea) 500mg capsules	(Generics are available - 500mg capsules only)	ICB	CML / Myeloproliferative disorders requiring cytoreduction (A licensed indication).	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Hydroxycarbamide (hydroxyurea) as Siklos® ▼	<i>(Siklos® (not funded by NHS Norfolk))</i>	ICB	Sickle-cell disease	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	HyQvia (HN Immunoglobulin & Hyaluronidase)	<i>(HyQvia®)</i>	NHSE	As per national Demand Management Plan	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Ibalizumab	<i>(Trogarzo®)</i>	NHSE	HIV in combination with other anti-retroviral drugs	Not recommended for routine use	NICE has not issued any guidance.
ADVICE	Ibandronate / Ibandronic acid	<i>(Oral 50mg tablets - various manufacturers)</i>	ICB	Daily use for two years to improve survival in post-menopausal women with breast cancer receiving chemotherapy (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Ibandronic acid	<i>(Bonviva® Injection)</i>	ICB	Treatment of osteoporosis in postmenopausal women	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA464 - Aug 17
ADVICE	Ibandronic Acid, Ibandronate	<i>(Oral product - Bondronat®)</i>	ICB	Reduction of bone damage in bone metastases in breast cancer	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Ibrutinib	Imbruvica®	NHSE	Waldenstrom's macroglobulinaemia	Not commissioned. No NHS prescribing in primary or secondary care	TA795 – June 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ibrutinib	Imbruvica®	NHSE	with venetoclax for untreated chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA891 – May 2023
RED	Ibrutinib ▼	(Imbruvica® ▼)	NHSE	Previously treated adults with chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - as per NICE TA 429	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA429 - Jan 17
BLACK	Ibrutinib ▼	(Imbruvica® ▼)	NHSE	Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation - as per NICE TA 452 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA452 - Jul 17
RED	Ibrutinib ▼	(Imbruvica® ▼)	NHSE	Waldenstrom's macroglobulinaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA491 - Nov 17
RED	Ibrutinib ▼	(Imbruvica® ▼)	NHSE	Relapsed or refractory mantle cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA502 - Jan 18
BLACK	Ibrutinib ▼ (with bendamustine and rituximab)	(Imbruvica® ▼)	NHSE	Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA437 - Mar 17
BLACK	Ibrutinib with obinutuzumab		NHSE	untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA702 – May 2021
BLACK	Ibrutinib with rituximab	(Imbruvica®)	NHSE	Waldenstrom's macroglobulinaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA608 - Oct 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Ibrutinib with rituximab	(Imbruvica®)	NHSE	untreated chronic lymphocytic leukaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA703 – May 2021
RED	Icatibant	(Firazyr®)	NHSE	Hereditary angioedema - acute treatment	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Icatibant	(Firazyr®)	NHSE	Hereditary angiodema - prophylactic treatment - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Icosapent ethyl	Vazkepa®	ICB	with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA805 – July 2022
RED	Idarubicin HCl	(Zavedos®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Idebenone	(Raxone®)	NHSE	Duchenne muscular dystrophy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Idcabtagene vicleucel	N/A	N/A	relapsed and refractory multiple myeloma after 3 or more treatments	Not commissioned. No NHS prescribing in primary or secondary care	TA936 – November 2023
BLACK	Idelalisib	(Zydelig®)	NHSE	Refractory follicular lymphoma that has not responded to 2 prior lines of treatment in adults	Not commissioned. No NHS prescribing in primary or secondary care	TA604 - Oct 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Idelalisib ▼	(<i>Zydelig</i> ® ▼)	NHSE	Treatment of follicular lymphoma that is refractory to two prior treatments (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA328 - Dec 14
RED	Idelalisib ▼	(<i>Zydelig</i> ® ▼)	NHSE	Chronic lymphocytic leukaemia for adults (in combination with rituximab)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA359 - Oct 15
BLACK	Idelalisib ▼	(<i>Zydelig</i> ® ▼)	NHSE	Chronic lymphocytic leukaemia (with ofatumumab (Arzerra®)) - as per NICE TA 469 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA469 - Aug 17
RED	Idursulfase	(<i>Elaprase</i> ®)	NHSE	Mucopolysaccharidosis - highly specialised criteria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ilprost	(<i>Ventavis</i> ®)	NHSE	Pulmonary arterial hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Imatinib ▼	(<i>Glivec</i> ® ▼)	NHSE	Kit-positive unresectable and /or metastatic GIST	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA209 - Nov 10
RED	Imatinib ▼	(<i>Glivec</i> ® ▼)	NHSE	Adjuvant treatment of gastrointestinal stromal tumours (GIST) after surgery	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA326 - Nov 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Imatinib mesylate (high dose) ▼	(<i>Glivec</i> ® ▼)	NHSE	Imatinib-resistant or intolerant chronic myeloid leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA425 - Dec 16
RED	Imatinib mesylate ▼	(<i>Glivec</i> ® ▼)	NHSE	Untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA426 - Dec 16
RED	Imatinib mesylate ▼	(<i>Glivec</i> ® ▼)	NHSE	Chronic graft versus host disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Imatinib mesylate ▼ (high dose)	(<i>Glivec</i> ® ▼)	NHSE	Imatinib-resistant Chronic Myeloid Leukaemia	Not commissioned. No NHS prescribing in primary or secondary care	TA425 - Dec 16
RED	Imatinib mesylate ▼ (standard dose)	(<i>Glivec</i> ® ▼)	NHSE	Chronic myeloid leukaemia (CML)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA425 - Dec 16
RED	Imetelstat		NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Imiglucerase	(<i>Cerezyme</i> ®)	NHSE	Gaucher's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Imipramine	<i>(Generics available)</i>	ICB	Overactive bladder and urinary incontinence in women - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG171 - Nov 15
ADVICE	Imiquimod Cream	<i>(Aldara® & Zyclara®)</i>	ICB	Non-hypertrophic actinic keratosis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Imlifidase	Idefirix®	NHSE	desensitisation treatment before kidney transplant in people with chronic kidney disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA809 – July 2022
ADVICE	Inclisiran	Leqvio®	ICB	hypercholesterolaemia or mixed dyslipidaemia	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA733 - Oct 2021
BLACK	Independence wound protection pouch and related products	<i>(Rapidcare)</i>	ICB	Haemodialysis patients - protection of line when washing	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Inebilizumab		NHSE	Multiple Sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Infertility drugs	(Various)	ICB	Infertility treatment	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	(Various brands available)	NHSE	Psoriasis - use in children, aligning with NICE TA 134 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA134 - Jan 08
RED	Infliximab	(Various brands available)	NHSE	Ankylosing spondylitis - use in children, aligning with NICE TA 143 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA143 - May 2008
RED	Infliximab	(Various brands available)	NHSE	Acute exacerbations of ulcerative colitis - use in children, aligning with NICE TA 163.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA163 - Dec 2008
RED	Infliximab	(Various brands available)	NHSE	Crohn's disease - use in children, aligning with NICE TA 187	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA187 - May 10
RED	Infliximab	(Various brands available)	NHSE	Treatment of psoriatic arthritis - use in children, aligning with NICE TA 199 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA199 - Aug 10
RED	Infliximab	(Various brands available)	NHSE	Moderately to severely active ulcerative colitis after the failure of conventional therapy - use in children, aligning with NICE TA 329	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA329 - Feb 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Infliximab	(Various brands available)	NHSE	Rheumatoid arthritis - use in children, aligning with NICE TA 130 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
RED	Infliximab	various, plus biosimilars	ICB	moderate rheumatoid arthritis after conventional DMARDs have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA715 – July 2021
RED	Infliximab	(Various brands available)	NHSE	Graft versus host disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	(Various brands available)	NHSE	Sarcoidosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	(Various brands available)	NHSE	Hidradenitis Suppurativa (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	(Various)	NHSE	Connective tissue disease - interstitial lung disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	(Various brands available)	NHSE	Renal indications (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Infliximab	<i>(Remicade®; Biosimilars also available)</i>	NHSE	Behcet's Disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	<i>(Remicade®, Inflectra® ▼, Remsima® ▼)</i>	NHSE	Anti-TNF Alpha treatment option for paediatric patients with severe refractory uveitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	<i>(Remicade® (until end Mar16 only); Remsima® ▼)</i>	NHSE	Treatment of Juvenile Idiopathic Arthritis (JIA) - in patients with uveitis only if etanercept or adalimumab not appropriate or are ineffective (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab	<i>(Cost effective biosimilars available)</i>	ICB	Anti-TNF treatment option for adult patients with severe refractory uveitis - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab (Biosimilar to be used 1st line)	<i>Cost effective biosimilar to be used</i>	ICB	Rheumatoid arthritis - after other DMARDs including a TNF inhibitor - as per NICE TA 195	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA195 - Aug 10
RED	Infliximab (biosimilar)	<i>(Remicade® (until end Mar16 only); Remsima® ▼)</i>	ICB	Treatment of psoriasis in adults - as per NICE TA 134 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA134 - Jan 08

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Infliximab (biosimilar)	<i>(As cost-effective biosimilar of choice)</i>	ICB	Crohn's disease which has not responded to conventional therapy - as per NICE TA 187	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA187 - May 10
RED	Infliximab (biosimilar)	<i>(Remicade® (until end Mar16 only); Remsima® ▼)</i>	ICB	Active and progressive psoriatic arthritis - as per NICE TA 199	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA199 - Aug 10
RED	Infliximab (biosimilar)	<i>(Remicade® (until end Mar16 only); Remsima® ▼)</i>	ICB	Subacute manifestations of moderately to severely active ulcerative colitis - as per NICE TA 329 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA329 - Feb 15
RED	Infliximab (biosimilar)	<i>(Cost effective biosimilar to be used)</i>	ICB	Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - as per NICE TA 375 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA375 - Jan 16
RED	Infliximab (biosimilar)	<i>(Lowest acquisition cost product to be used)</i>	ICB	Ankylosing spondylitis - severe active, where NSAIDs are not effective or not tolerated - as per NICE TA 383	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16
RED	Infliximab (biosimilar)	<i>(Cost effective biosimilars available))</i>	ICB	Axial spondyloarthritis (non-radiographic) - as per NICE TA 383 and NNUH application	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA383 - Feb 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Infliximab (biosimilar)	(Cost -effective biosimilar to be used)	ICB	Immunotherapy toxicity (causing colitis)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab (biosimilar)	(Remicade® (until end Mar16 only); Remsima® ▼)	ICB	Acute exacerbations of ulcerative colitis - as per the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	Dec-08
RED	Infliximab (biosimilar)	(Cost effective product to be used)	ICB	Psoriatic arthritis (switching between treatments)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Infliximab (Remicade®)	(Remicade®)	NHSE	Anti-TNF Alpha treatment option for paediatric patients with severe refractory uveitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Influenza vaccination	(Various)	ICB	Vaccination of non-target patients on the NHS	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Influenza vaccine - intradermal	(Intanza®)	ICB	Influenza vaccination	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Ingenol mebutate topical gel	(Picato®)	ICB	Non-hypertrophic actinic keratosis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Inhaled corticosteroids	(Various)	ICB	Children who wheeze with a cold (viral wheeze / bronchiolitis) (Not a licenced indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG9 - May 15
BLACK	Inositol nicotinate	(Hexopal®)	ICB	Treatment of intermittent claudication in people with peripheral arterial disease	Not commissioned. No NHS prescribing in primary or secondary care	TA223 - May 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Inotersen	Tegsedi®	NHSE	Amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST9 - May 2019
RED	Inotuzumab ozogamicin	(Besponsa®)	NHSE	Relapsed or refractory B-cell acute lymphoblastic leukaemia - as per NICE TA 541	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA541 - Sep 18
BLACK	Insert for female stress incontinence (Contiform)	(Contiform®)	ICB	Female stress urinary incontinence - as per NICE CG 171 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG171 - Nov 15
RED	Inspiratory muscle training devices	(POWERbreath e® Medic, Threshold IMT®, Ultrabreathe®)	ICB	Inspiratory muscle training in COPD, non-CF bronchiectasis, upper spinal cord injuries, Cystic fibrosis, asthma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NG115 - Dec 18
BLACK	Inspiratory muscle training devices	(POWERbreath e® Medic, Threshold IMT®, Ultrabreathe®)	ICB	Fitness / Sports use	Not commissioned. No NHS prescribing in primary or secondary care	NG115 - Dec 18
BLACK	Insulin - Non-basal-bolus regimens	(Various)	ICB	Newly diagnosed Type 1 diabetes - NICE Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	NG17 - May 17
BLACK	Insulin analogues (rapid acting)	(Various)	ICB	Routine use after meals in T1 Diabetes - NICE Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	NG17 - May 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Insulin Aspart (Fiasp®) ▼	(Fiasp® ▼)	ICB	Diabetes mellitus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
Double Red	Insulin degludec	(Tresiba®)	ICB	ROUTINE use in Type 1 and Type 2 diabetes mellitus - see separate entry regarding RESTRICTED USE	Not recommended for routine use	NICE has not issued any guidance.
ADVICE	Insulin degludec	(Tresiba®)	ICB	RESTRICTED use in Type 1 and Type 2 Diabetes mellitus - consultant initiation only	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NG17 - Aug 15
BLACK	Insulin degludec / liraglutide combi (Xultophy®)	(Xultophy®)	ICB	Diabetes mellitus	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Insulin detemir	(Levemir®)	ICB	Diabetes in adults & children >1 yrs	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NG18 - Nov 16
ADVICE	Insulin glargine	(Lantus®)	ICB	Diabetes mellitus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NG18 - Nov 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Insulin glargine 300 units/ml (Toujeo®)	(Toujeo®)	ICB	Restricted use in adults aged ≥18 years with diabetes mellitus under specified criteria - see full guidance	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Insulin Glargine and Lixisenatide solution	(Suliqua®)	ICB	Diabetes mellitus	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Insulin glargine biosimilar 100iu/ml (Abasaglar®)	(Abasaglar®)	ICB	Diabetes mellitus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Insulin glulisine	(Apidra®)	ICB	Diabetes mellitus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Insulin Lispro	Lyumjev®	ICB	adults with type 1 and type 2 diabetes	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Insulin Lispro ▼ 200units/ml (Humalog KwikPen®)	(Humalog KwikPen®)	ICB	A specific group of adults with diabetes mellitus who require more than 20 units of quick-acting insulin per day	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Insulin pump therapy	<i>(Continuous Subcutaneous Insulin Infusion (CSII))</i>	ICB	Type 1 Diabetes under specified circumstances	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Insulin safety needles	<i>(BD-Autoshields, Mylife Clickfine, Autoprotect etc)</i>	ICB	Insulin administration	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Insulin safety needles	<i>(BD-Autoshields, Mylife Clickfine, Autoprotect etc)</i>	ICB	Insulin administration	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Interferon alfa	<i>(Roferon-A®, Viraferon®)</i>	NHSE	In combination with ribavirin for Hepatitis C, and for Hepatitis B - as per NICE 75 and CG 165	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA75 - Sep 10
RED	Interferon alfa	<i>(Roferon-A®, Viraferon®)</i>	NHSE	Adjunct to surgery in malignant melanoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Interferon alfa	<i>(Roferon-A®, Viraferon®)</i>	NHSE	Metastatic renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Interferon alfa	(Roferon-A®, Viraferon®)	NHSE	Chronic myelogenous leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Interferon beta 1a	(Avonex®, Rebif®)	NHSE	Multiple Sclerosis - as per NICE TA 527	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA527 - Jun 18
BLACK	Interferon beta 1b (Betaferon®)	(Betaferon®)	NHSE	Multiple sclerosis - as per NICE TA 527	Not commissioned. No NHS prescribing in primary or secondary care	TA527 - Jun 18
RED	Interferon beta 1b (Extavia®)	(Extavia®)	NHSE	Multiple Sclerosis - as per NICE TA 527	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA527 - Jun 18
RED	Intrathecal drug delivery	(Procedure)	NHSE	Treatment of severe cancer pain	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Intrathecal pumps	(Intrathecal pumps)	NHSE	Treatment of severe chronic (non-cancer) pain	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Intravenous nutrition	(SMOFlipid®)	NHSE	Total Parenteral Nutrition in premature infants with intestinal failure	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ipilimumab	(Yervoy®)	NHSE	Previously treated advanced (unresectable or metastatic) melanoma (stage III or IV) in previously treated people	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA268 - Dec 12
RED	Ipilimumab	(Yervoy®)	NHSE	Previously untreated advanced (unresectable or metastatic) melanoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA319 - Jul 14
BLACK	i-Port advance	n/a	ICB	Blood glucose monitoring as per PAC policy March 2020	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Iptacopan	Fabhalta®	NHSE	paroxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1000 – September 2024
BLACK	IQoro neuromuscular training device	()	ICB	Hiatus hernia - improving symptoms	Not commissioned. No NHS prescribing in primary or secondary care	MIB 176 - March 2019
BLACK	IQoro neuromuscular training device	()	ICB	Stroke-related dysphagia	Not commissioned. No NHS prescribing in primary or secondary care	MIB175 - Mar 19
RED	Irinotecan	(Campto®)	NHSE	Colorectal cancer 2nd line	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA93 - Aug 05
RED	Isatuximab	Sarclisa®	NHSE	with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA658 – November 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Isatuximab with carfilzomib and dexamethasone	N/A	NHSE	relapsed or refractory multiple myeloma (terminated)	Not commissioned. No NHS prescribing in primary or secondary care	TA727 – September 2021
RED	Isavuconazole	(<i>Cresemba</i> ®)	NHSE	Systemic fungal infections	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Isoniazid	<i>various</i>	ICB	Non-TB related mycobacterium infections	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	NICE has not issued any guidance.
RED	Isotretinoin	(<i>Roaccutane</i> ®)	ICB	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Isotretinoin	(<i>Roaccutane</i> ®)	ICB	Acne	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Ivabradine ▼	(<i>Procoralan</i> ® ▼)	ICB	Treatment of chronic heart failure	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period until the patient is stabilise.	TA267 - Nov 12

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ivacaftor ▼	(Kalydeco® ▼)	NHSE	Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor	(IVA–TEZ–ELX; Kaftrio, Vertex®), (TEZ–IVA; Symkevi, Vertex®) and (LUM–IVA; Orkambi, Vertex®)	NHSE	cystic fibrosis	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA988 – July 2024
ADVICE	Ivermectin (oral)		ICB	Scabies	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Ivosidenib	Tibsovo®	NHSE	for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA948 – January 2024
RED	Ivosidenib	Tibsovo®	NHSE	with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA979 – June 2024
RED	Ixazomib	(Ninlaro®)	NHSE	Amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ixazomib	Ninlaro®	NHSE	with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA870 – February 2023
RED	Ixazomib ▼ (with lenalidomide and dexamethasone)	(Ninlaro® ▼)	NHSE	Relapsed or refractory multiple myeloma - as per NICE TA 505 - CDF list	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA505 - Feb 18
RED	Ixekizumab	(Taltz®)	ICB	Active psoriatic arthritis after inadequate response to DMARDs, used alone or with methotrexate - as per NICE TA 537	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA537 - Aug 18
RED	Ixekizumab	Taltz®	ICB	axial spondyloarthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA718 – July 2021
RED	Ixekizumab ▼	(Taltz® ▼)	ICB	3rd line biologic option in moderate to severe plaque psoriasis under certain conditions as per NICE TA 442 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA442 - Apr 17
RED	Jaw rehabilitation devices	(Therabite®)	ICB	Following head and neck radiotherapy or head and neck surgery when recommended by an appropriate Secondary Care Specialist	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ketogenic Diet Therapy	various	ICB	ketogenic diets, epilepsy & neurometabolic disorders as part of tertiary service provided by Addenbrookes	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance
BLACK	Ketoprofen/omeprazole	(Axorid®)	ICB	Patients requiring ketoprofen for OA, RA and ankylosing spondylitis who are at risk of NSAID-associated DU or GU	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Lacosamide	(Vimpat®)	ICB	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Lamivudine	(Epivir, Zeffix (generic also available))	NHSE	Chronic hepatitis B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG165 - Jun 13
RED	Lamivudine	(Epivir, Zeffix (generic also available))	NHSE	HIV	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Lamotrigine	(Lamictal®; Generics are available)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG90 - Oct 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Lamotrigine	(Lamictal®)	ICB	(Relapse of) Bipolar Depression (as alternative to, or in addition to lithium)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should recommend, but GP can take responsibility for all scripts 4 weeks.	NICE has not issued any guidance.
RED	Lanadelumab	(Takhzyro®)	NHSE	Prevention of recurrent attacks of hereditary angioedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA606 - Oct 19
BLACK	Lancet (single use, safety)	All brands except neon-verifine (see above)	ICB	Single use safety lancet	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Lanreotide	(Somatuline LA®)	ICB	Reducing vomiting in terminal bowel obstruction	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Lanreotide	(Somatuline®)	NHSE	Congenital hyperinsulinism (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lanreotide	(Somatuline® LA)	NHSE	Acromegaly	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Lanreotide	(Somatuline LA®)	NHSE	Carcinoid and other neuroendocrine tumours - for new patients	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Lanthanum carbonate	(Fosrenol®)	ICB	Hyperphosphataemia in end-stage chronic renal failure - if on treatment before 1st April 2013	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Lapatinib	(Tyverb®)	NHSE	1st-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2	Not commissioned. No NHS prescribing in primary or secondary care	TA257 - Jun 12
RED	Laquinimod	(Nerventa® (not licensed in the UK))	NHSE	Multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Laronidase	(Aldurazyme®)	NHSE	Treatment of non-neurological manifestations of mucopolysaccharidosis I - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Larotrectinib	(Vitrakvi®)	NHSE	treating NTRK fusion-positive solid tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA630 – May 2020
RED	Latanoprost–netarsudil	Roclanda®	ICB	previously treated primary open-angle glaucoma or ocular hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1009 – October 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Lebrikizumab		NHSE	Asthma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lebrikizumab	Ebglyss®	ICB adults, NHSE children	moderate to severe atopic dermatitis in people 12 years and over	Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA986 – July 2024
RED	Ledipasvir- sofosbuvir ▼	(Harvoni® ▼)	NHSE	For treating chronic hepatitis C as per NICE TA 363	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA363 - Nov 15
SCA	Leflunomide	(Arava®)	ICB	Rheumatoid arthritis and psoriatic arthritis	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	CG79 - Feb 09
BLACK	Lenalidomide	(Revlimid®)	NHSE	With bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA603 - Sep 19
RED	Lenalidomide	Revlimid®	NHSE	After an autologous stem cell transplant for newly diagnosed multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA680 – March 2021
BLACK	Lenalidomide	n/a	NHSE	relapsed or refractory mantle cell lymphoma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA774 – March 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Lenalidomide	(<i>Revlimid</i> ®)	NHSE	POEMS syndrome - as per NHSE policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lenalidomide	(<i>Revlimid</i> ®)	NHSE	Cancer - as per NHSE policy / Cancer Drugs Fund (Various indications).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lenalidomide ▼	(<i>Revlimid</i> ® ▼)	NHSE	Treatment of multiple myeloma in people who have received at least two prior therapies - as per NICE TA 171	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA171 - Jun 09
RED	Lenalidomide ▼	(<i>Revlimid</i> ® ▼)	NHSE	Treatment of myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality - as per NICE TA 322	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA322 - Sep 14
RED	Lenalidomide plus dexamethasone	(<i>Revlimid</i> ®)	NHSE	Multiple myeloma after 1 treatment with bortezomib	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA586 - Jun 19
RED	Lenalidomide plus dexamethasone	(<i>Revlimid</i> ®)	NHSE	Previously untreated multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA587 - Jun 19
RED	Lenalidomide with rituximab	REVLIMID®	NHSE	With rituximab for previously treated follicular lymphoma as per TA627	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA627 - April 20

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Lenograstim	(Granocyte®)	NHSE	Barth Syndrome - Highly specialised criteria by Specialist centres only (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lenograstim	(Granocyte®)	NHSE	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lenvatinib	(Lenvima®)	NHSE	Untreated advanced, unresectable hepatocellular carcinoma in adults - as per NICE TA 551	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA551 - Dec 18
RED	Lenvatinib	Kispplx®	NHSE	with pembrolizumab (Keytruda®) for untreated advanced renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA858 – Jan 2023
RED	Lenvatinib (with sorafenib)	(Lenvima® (used with Nexavar®))	NHSE	Progressive, locally advanced or metastatic differentiated thyroid cancer - as per NICE TA 535	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA535 - Aug 18
RED	Lenvatinib ▼ (with everolimus)	(Kispplx® ▼)	NHSE	Previously treated advanced renal cell carcinoma in adults who have had 1 previous vascular endothelial growth factor (VEGF)-targeted therapy - as per NICE TA 498	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA498 - Jan 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Leronlimab		NHSE	HIV	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Lesinurad ▼ (with a xanthine oxidase inhibitor)	<i>(Zurampic® ▼)</i>	ICB	Chronic hyperuricaemia in people with gout whose serum uric acid is above the target level despite an adequate dose of a xanthine oxidase inhibitor alone	Not commissioned. No NHS prescribing in primary or secondary care	TA506 - Feb 18
RED	Letermovir	<i>(Prevymis®)</i>	NHSE	Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT) - NHSE responsibility	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA591 - Jul 19
ADVICE	Letrozole	<i>(Femara®)</i>	ICB	Adjuvant treatment of early oestrogen-receptor-positive breast cancer in postmenopausal women	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG81 - Nov 06
ADVICE	Leuprorelin acetate	<i>(Prostap®; Lutrate®)</i>	ICB	Prostate cancer	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
SCA	Leuprorelin acetate	<i>(Prostap® SR)</i>	ICB	Management of endometriosis; pre-operative management of uterine fibroids	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG73 - Sep 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Levocetirizine	(Xyzal®)	ICB	Symptomatic relief of allergy such as hay fever, urticaria	Not recommended for routine use	NICE has not issued any guidance.
Double Red	Levodopa	(Generic / various)	ICB	Management of dystonia in adults with cerebral palsy - as per NG 119 - NICE Do Not Do (Not a licensed indication).	Not recommended for routine use	NG119 - Jan 19
RED	Levofloxacin (inhaled)	Quinsair®	NHSE	Cystic fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Levoketoconazole		NHSE	Cushing's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Lidocaine / Prilocaine Spray	(Fortacin®)	ICB	Primary premature ejaculation in adult men	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Lidocaine 5% medicated plasters	(Versatis®)	ICB	Localised neuropathic pain when first line systemic therapies are ineffective or not tolerated as per the local Neuropathic Pain Pathway	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Specialist to prescribe first month supply	CG173 - Nov 13
RED	Lidocaine/Hydrocortisone mouthwash	n/a	NHSE	restricted specialist prescribing only for mouth pain and inflammation in autoimmune diseases and oncology	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Lift products including juice shots and chew tabs	(previously Glucojuice)	ICB	hypoglycaemia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Linezolid	(Zyvox®)	ICB	Pneumonia, complicated skin and soft tissue infections caused by G+ve bacteria (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLUE	Linzagolix	Yselty®	ICB	moderate to severe symptoms of uterine fibroids	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available	TA996 – August 2024
BLACK	Liothyronine	(Generics)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG90 - Oct 09
BLACK	Liothyronine / L-tri-iodothyronine sodium (T3)	(Cytomel, Triostat (U.S.))	ICB	ROUTINE use of liothyronine as monotherapy or in combination with levothyroxine to treat hypothyroidism	Not commissioned. No NHS prescribing in primary or secondary care	RMOC guidance - June 2019
RED	Liothyronine / L-tri-iodothyronine sodium (T3)	(Cytomel, Triostat (U.S.))	ICB	Niche, short-term use for up to three months in patients awaiting surgery pre-cancer therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	RMOC guidance - June 2019

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Liothyronine / L-tri-iodothyronine sodium (T3)	(Cytomel / Triostat (U.S.))	ICB	RESTRICTED use for long term treatment in rare cases of levothyroxine-induced liver injury, and are assessed by an NHS consultant as requiring treatment - as per RMOG guidance	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 3 months for new patients.	RMOG guidance - June 2019
ADVICE	Liothyronine / L-tri-iodothyronine sodium (T3)	(Cytomel, Triostat (U.S.))	ICB	RESTRICTED use for patients in place of levothyroxine who continue to suffer with symptoms despite adequate biochemical correction, and are assessed by an NHS consultant as requiring treatment	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 3 months for new patients.	RMOG guidance - June 2019
BLACK	Liothyronine/L-tri-iodothyronine sodium (T3)	(Cytomel, Triostat (US))	ICB	Resistant depression - as per RMOG guidance	Not commissioned. No NHS prescribing in primary or secondary care	RMOG guidance - June 2019
RED	Liothyronine/L-tri-iodothyronine sodium (T3)	(Cytomel, Triostat (US))	ICB	Patients with thyroid cancer following thyroid surgery, pre- and post radio iodine ablation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	RMOG guidance - June 2019
RED	Liposomal cytarabine-daunorubicin	(Vyxeos®)	NHSE	Untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults - as per NICE TA 552	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA552 - Dec 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Liraglutide	(Victoza®)	ICB	Adjunctive use in Type 2 diabetes	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA203 - Oct 10
BLACK	Liraglutide	(Saxenda® ▼)	ICB	managing obesity in people aged 12 to 17 years (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA749 – December 2021
BLACK	Liraglutide	(Victoza®)	ICB	1.8 mg dose for Type 2 diabetes mellitus	Not commissioned. No NHS prescribing in primary or secondary care	NG28 - Dec 15
RED	Liraglutide (marketed as Saxenda®)▼	(Saxenda® ▼)	ICB	Treatment of obesity	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA664 - Dec 2020
SCA	Lisdexamfetamine Mesilate ▼	(Elvanse®)	ICB	Attention Deficit Hyperactivity Disorder in adults (if continued from childhood)	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NG87 - Mar 18
SCA	Lisdexamfetamine Mesilate ▼ (currently under review)	(Elvanse® ▼)	ICB	ADHD in children aged 6 years and over, up to 17 years when response to previous methylphenidate treatment is considered clinically inadequate	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG87 - Mar 18
BLACK	Lisocabtagene maraleucel		n/a	relapsed or refractory aggressive B-cell non-Hodgkin lymphoma	Not for prescribing in primary or secondary care	TA987 – July 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Lithium	<i>(Various - prescribe branded only)</i>	ICB	Treatment and prophylaxis of mania, bipolar disorder, and recurrent depression; aggressive or self-mutilating behaviour	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	NICE has not issued any guidance.
ADVICE	Lixisenatide	<i>(Lyxumia®)</i>	ICB	Treatment of Type 2 diabetes, HbA1c ≥ 58mmol/mol (7.5%), BMI ≥35 kg/m2	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Lixivaptan (Unlicensed drug)	<i>((unlicensed drug))</i>	NHSE	Hyponatraemia and other endocrine uses - NHSE responsibility	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lomitapide	<i>(Lojuxta®)</i>	NHSE	Homozygous familial hypercholesterolemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lomustine	<i>(CCNU®)</i>	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Lonafarnib	<i>(Sarasar®)</i>	NHSE	Hepatitis D infection (with ritonavir)	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Loncastuximab tesirine	Zynlonta®	NHSE	for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA947 – January 2024
RED	Lopinavir (with ritonavir)	(Kaletra®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Lorlatinib	(Lorviqua®)	NHSE	previously treated ALK-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA628 – May 2020
BLACK	Lorlatinib	Lorviqua®	NHSE	untreated ALK-positive advanced non-small-cell lung cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA909 – July 2023
BLACK	Loxapine inhalation	(Adasuve®)	ICB	Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA286 - May 14
BLACK	Lumacaftor-ivacaftor ▼	(Orkambi® ▼)	NHSE	For treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Not commissioned. No NHS prescribing in primary or secondary care	TA398 - Jul 16
RED	Lumasiran	Oxlumo®	NHSE	hyperoxaluria type 1	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST25 – April 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Lurasidone ▼	<i>Latuda</i> ®	ICB	Third antipsychotic option for schizophrenia in adults aged 18 years and over	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Lurasidone ▼	<i>Latuda</i> ®	ICB	Treatment of schizophrenia in adults aged 18 years and over - third-line option under the Early Intervention Treatment Pathway	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 4 weeks.	NICE has not issued any guidance.
BLACK	Lurasidone ▼	<i>Latuda</i> ®	ICB	Off-label use to manage hallucinations/aggression relating to dementia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Luspatercept		NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Luspatercept	n/a	NHSE	anaemia caused by beta-thalassaemia (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA843 – November 2022
BLACK	Luspatercept	n/a	NHSE	anaemia caused by myelodysplastic syndromes (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA844 – November 2022
RED	Lusutrombopag	<i>MULPLEO</i> ®	ICB	Treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure as per TA617	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA617 - Jan 20

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Lutetium(177Lu) oxodotreotide	<i>(Lutathera®)</i>	NHSE	Unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours in adults as per NICE TA 539	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA539 - Aug 18
BLACK	Lutetium-177 vipivotide tetraxetan	Pluvicto®	NHSE	PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments	Not commissioned. No NHS prescribing in primary or secondary care	TA930 – November 2023
RED	Macimorelin	<i>(Macrilen®)</i>	NHSE	Growth hormone deficiency in adults (diagnostic test)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Macitentan	<i>(Opsumit®)</i>	NHSE	Pulmonary Arterial Hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Magnesium lactate MR (prescribe as Magnalac SR 84mg tabs)	Magnalac SR 84mg tabs	ICB	Gitelman's syndrome	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance
BLACK	Malaria prophylaxis	<i>(Choroquine Malarone® Mefloquine Primaquine Proguan)</i>	ICB	Malaria chemoprophylaxis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Mannitol (dry powder for inhalation)	<i>(Bronchitol®)</i>	NHSE	(Adjunctive) treatment of cystic fibrosis (CF)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA266 - Nov 12
RED	Maralixibat		NHSE	Alagille syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Maraviroc	<i>(Celsentri®)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Maribavir	<i>Livtenicity®</i>	NHSE	refractory cytomegalovirus infection after transplant	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA860 – Jan 2023
RED	Maribavir	<i>Livtenicity®</i>	NHSE	CMV	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Masitinib	<i>(Masipro®)</i>	NHSE	Pancreatic cancer / GIST	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Mavacamten	Camzyos®	NHSE	symptomatic obstructive hypertrophic cardiomyopathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA913 – September 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Mecasermin		NHSE	Growth failure	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Melanorm-HC®	<i>(Melanorm-HC®)</i>	ICB	Melasma / Chloasma	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Melatonin	SLENYTO®	ICB	Various indications	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Melatonin	<i>(Colonis®, Ceyesto®, Syncrodin®)</i>	ICB	Jet lag (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
SCA	Melatonin	Standard release - Adaflex®, Ceyesto® Prolonged release - Circadin®, Film coated - Syncrodin® Melatonin 2mg modified release tablets (generic)	ICB	Management of sleep disorders in children	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	NICE has not issued any guidance.
Double Red	Melatonin liquid preparations	<i>Various</i>	ICB	Only for use in patients with fine bore enteral feeding tubes or where there is risk of tube occlusion. Only to be prescribed in secondary care. Not commissioned for use in primary care	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Melatonin Prolonged Release (Circadin)	(Circadin®)	ICB	Monotherapy in short term management of primary insomnia characterised by poor quality of sleep in patients aged 55 years or over whilst at the Julian Hospital, Norwich	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Melatonin prolonged-release tablets ▼ (Circadin) ▼	(Circadin® ▼)	ICB	Management of sleep disorders in adults aged 18-55	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Melatonin prolonged-release tablets ▼ (Circadin) ▼	(Circadin® ▼)	ICB	Short term treatment of primary insomnia in adults aged 55 years and over	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Melphalan	(Alkeran®)	NHSE	haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA822 – September 2022
BLACK	Melphalan flufenamide	Alkeran®	NHSE	with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA968 – April 2024
SCA	Memantine	(Ebixa® (generics also available))	ICB	Moderate to severe dementia in Alzheimer's Disease - as per NICE TA 217	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	TA217 - Mar 11
RED	Mepolizumab	Nucala®	NHSE	Severe eosinophilic asthma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA671 – February 2021
BLACK	Mepolizumab	Nucala	ICB	eosinophilic granulomatosis with polyangiitis (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA845 – November 2022
BLACK	Mepolizumab	Nucala	ICB	severe hypereosinophilic syndrome (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA846 – November 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Mepolizumab	Nucala	ICB	severe chronic rhinosinusitis with nasal polyps (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA847 – November 2022
RED	Mepolizumab ▼	<i>(Nucala® ▼)</i>	ICB	Severe refractory eosinophilic asthma in adults - as per NICE TA 431	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA431 - Jan 17
BLACK	Meptazinol	Meptid	ICB	pain relief	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Mercaptopurine	<i>(Puri-Nethol®)</i>	NHSE	Acute leukaemias and chronic myeloid leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Mercaptopurine 50mg tablets	<i>(Puri-Nethol®)</i>	ICB	Steroid-sparing effect in ulcerative colitis and Crohn's disease (Not a licensed indication).	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.
RED	Mesenchymal stem cells (Prochymal®)	<i>(Prochymal®)</i>	NHSE	Acute Graft vs Host Disease (GVHD) & other indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Methadone	various	ICB	pain relief in palliative care	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Methadone	various	ICB	refractory neuropathic pain, severe, iatrogenic opioid dependence patients, patients with chronic pain response to doses of strong opioid	Formulary - suitable for prescribing in primary care following specialist advice from a Pain Management Service	NICE has not issued any guidance.
ADVICE	Methenamine	Hiprex®	ICB	prophylaxis of uncomplicated lower urinary tract infections	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Methotrexate (Oral and injectable))	()	NHSE	High doses used in malignant disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Methotrexate (oral)	(Matrex® - generics are available)	ICB	Rheumatoid Arthritis, Juvenile Arthritis, Connective Tissue Disease, Felty's Syndrome, Psoriasis, Crohn's Disease and Sarcoidosis	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG100 - Jul 18
SCA	Methotrexate (Parenteral)	(Metoject/Nordi met pens; Zlatal syringes)	ICB	Rheumatoid Arthritis, Juvenile Arthritis, Connective Tissue Disease, Felty's Syndrome, Psoriasis, Crohn's Disease and Sarcoidosis	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG100 - Jul 18
RED	Methoxy polyethylene glycol-epotein beta ▼	(Mircera® ▼)	NHSE	Symptomatic anaemia associated with Chronic Kidney Disease (dialysis patients only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG114 - Nov 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Methylnaltrexone bromide ▼	(Relistor® ▼)	ICB	Opioid-induced bowel dysfunction in palliative care - as per NICE TA 468 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA468 - Aug 17
SCA	Methylphenidate HCl	(see Shared Care Agreement)	ICB	Narcolepsy in adults - All patients will be initiated by specialist centre in Cambridge. No new initiations in Norfolk and Waveney	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.
SCA	Methylphenidate HCl	(Various - see Shared Care Agreement)	ICB	ADHD in adults who had previously been treated, or who had symptoms identified, in childhood or adolescence	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NG87 - Mar 18
SCA	Methylphenidate HCl (currently under review)	(Various - see Shared Care Agreement)	ICB	Attention Deficit Hyperactivity Disorder in Children and Adolescents	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG87 - Mar 18
Double Red	Methylphenidate Hydrochloride	(Various)	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG53 - Aug 07
RED	Metreleptin	(Myalepta®)	NHSE	Dyslipidaemia - Generalised lipodystrophy and partial lipodystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST14 - Feb 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Metyrapone	Metopirone®)	ICB	Cushing's syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Mexiletine	Namuscla®	NHSE	symptoms of myotonia in non-dystrophic myotonic disorders	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA748 – December 2021
RED	Mexiletine (imported generic) unlicensed in the UK	<i>(Unlicensed generic product in the UK)</i>	ICB	Ventricular tachycardia only (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Mexiletine (imported generic) unlicensed in the UK	<i>(Unlicensed in the UK)</i>	ICB	NOT recommended for any indication (EXCEPT ventricular tachycardia - Hospital / Specialist use only) (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Mexiletine (Namuscla®)	<i>(Namuscla®)</i>	ICB	NOT recommended for any indication (EXCEPT myotonia in adults with non-dystrophic myotonic disorders - as per NHSE commissioning policy - Hospital / Specialist use only)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Mexiletine (Namuscla®)	<i>(Namuscla® (licensed High Cost Drug))</i>	NHSE	Treatment of myotonia in adults with non-dystrophic myotonic disorders (NDMD) - as per NHSE policy - specialist use only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Micafungin	<i>(Mycamine®)</i>	NHSE	Systemic fungal infections	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Midodrine	(Bramox®, Midotense®)	ICB	Treatment of severe orthostatic hypotension due to autonomic dysfunction - second line use after fludrocortisone	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Midostaurin	(Rydapt®)	NHSE	Untreated FLT3-mutation-positive acute myeloid leukaemia in adults - as per NICE TA 523	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA523 - July 2018
RED	Midostaurin	Rydapt®	NHSE	advanced systemic mastocytosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA728 – September 2021
RED	Mifamurtide	(Mepact®)	NHSE	Treatment of osteosarcoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA235 - Oct 11
RED	Migalastat ▼	(Galafold® ▼)	NHSE	Fabry disease in people over 16 years of age with an amenable mutation, and only if enzyme replacement therapy (ERT) (with agalsidase alfa or agalsidase beta) would otherwise be offered - as per NICE HST4	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST4 - Feb 17
RED	Miglustat ▼	(Zavesca® ▼)	NHSE	Mild to moderate type I Gaucher's disease for whom enzyme replacement therapy is unsuitable / Niemann-Pick	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Mineralocorticoids (such as fludrocortisone)	<i>(Generic s are available)</i>	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do (x).	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
Double Red	Minocycline	<i>(Acnamino®, Minocin®, Sebomin®)</i>	ICB	Acne vulgaris	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Minoxidil	<i>(Regaine®)</i>	ICB	Androgenetic alopecia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Mirikizumab	Omvo®	ICB	moderately to severely active ulcerative colitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA925 – October 2023
BLACK	Mitapivat	Pyrukynd®	NHSE	pyruvate kinase deficiency (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA867 – February 2023
RED	Mitotane	<i>(Lysodren®)</i>	NHSE	Adrenocortical carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Mobocertinib	EXKIVITY®	NHSE	EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA855 – Jan 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Modafinil	(<i>Provigil</i> ®)	ICB	All unlicensed indications, including excess sleepiness in MS, Parkinson's Disease, obstructive sleep apnoea, or chronic shift work sleep disorder. (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG186 - Oct 14
SCA	Modafinil	(see <i>Shared Care Agreement</i>)	ICB	Narcolepsy in adults - All patients will be initiated by specialist centre in Cambridge. No new initiations in Norfolk and Waveney	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.
RED	Mogamulizumab	Poteligeo®	NHSE	previously treated mycosis fungoides and Sézary syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA754 – December 2021
RED	Molgramostim (rhGM-CSF)	(<i>Molgradex</i> ®)	ICB	Autoimmune (acquired) pulmonary alveolar proteinosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Momelotinib	()	NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Momelotinib	Omjjara®)	NHSE	myelofibrosis-related splenomegaly or symptoms	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA957 – March 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Monoamine oxidase inhibitors (MAOIs)	(Various)	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
BLACK	Mosunetuzumab	Lunsumio®	NHSE	relapsed or refractory follicular lymphoma	Not commissioned. No NHS prescribing in primary or secondary care	TA892 – May 2023
RED	Motavizumab	(Numax®)	NHSE	Respiratory syncytial virus (RSV) prophylaxis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Moxifloxacin	(Avelox®)	NHSE	Respiratory infection, including resistant TB	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Mycophenolate Mofetil	(Generic)	ICB	For use as an immunosuppressive agent in the treatment of connective tissue disease and other autoimmune conditions managed by Rheumatology, Gastroenterology, Dermatology, Neurology and Nephrology (Not a licensed indication).	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG100 - Jul 18
SCA	Mycophenolate mofetil / Mycophenolic acid	(Arzip®, CellCept® / Myfortic®)	ICB	Immunosuppression in adult solid organ transplant patients - as per NICE TA 481	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	TA481 - Oct 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Mycophenolate sodium	(<i>Ceptava®</i> , <i>Myfortic®</i>)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17
BLACK	Mycophenolate sodium	(<i>Ceptava®</i> , <i>Myfortic®</i>)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17
RED	Nabilone	(<i>Nabilone®</i>)	NHSE	Pain and spasticity in Multiple Sclerosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	N-acetylcysteine	()	ICB	Idiopathic pulmonary fibrosis (Not a licensed indication).	Not recommended for routine use	NG115 - Dec 18
ADVICE	Naftidrofuryl oxalate	(<i>Praxilene®</i> (<i>generic available</i>))	ICB	Treatment of intermittent claudication in people with peripheral arterial disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA223 - May 11
BLACK	Nail lacquer- Amorolfine & Ticonazole	(<i>Loceryl®</i> & <i>Trosyl®</i>)	ICB	Fungal nail infections	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLUE	Naldemedine	Rizmoic®	ICB	Opioid-induced constipation	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA651 - Sept 2020
RED	Nalmefene	(<i>Selincro</i> ®)	PHE	Reduction of alcohol consumption in those aged ≥18 years with alcohol dependence that have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. Prescribing of treatments for alcohol misuse, including acamprosate and disulfiram (and also nalmefene) are the responsibility of the specialist since local alcohol misuse services are not commissioned from GPs practices	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA325 - Nov 14
RED	Naltrexone	(<i>Nalorex</i> ® / <i>Opizone</i> ®)	ICB	Alcohol misuse disorder - controlled drinking (continued use) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
SCA	Naltrexone	(Nalorex® / Opizone®)	ICB	Alcohol Use Disorder - maintenance of abstinence only (under an approved shared care agreement) (Not a licensed indication).	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	CG115 - Feb 11
RED	Naltrexone	(Nalorex® / Opizone®)	PHE	Management of opioid dependence. Commissioned by Public Health England/other health and social care departments eg Norfolk County Council - Specialist Prescribing Only. Not for GP prescribing	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA115 - Jan 07
BLACK	Naltrexone - low dose	(Several low strength options available)	ICB	Use of a Low Dose in Multiple Sclerosis (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Naltrexone and Bupropion (Mysimba®) ▼	(Mysimba® ▼)	ICB	Treatment of obesity	Not commissioned. No NHS prescribing in primary or secondary care	TA494 - Dec 17
RED	Natalizumab ▼	(Tysabri® ▼)	NHSE	Highly active relapsing-remitting multiple sclerosis in adults - as per NHS England policy and NICE TA 127	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA127 – August 2007, updated May 2024
BLACK	NBTXR-3	n/a	NHSE	treating advanced soft tissue sarcoma	Not commissioned. No NHS prescribing in primary or secondary care	TA745 – November 2021
BLACK	Necitumumab ▼	(Portrazza® ▼)	NHSE	Adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy - as per NICE TA 411	Not commissioned. No NHS prescribing in primary or secondary care	TA411 - Sep 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Needle free injection devices	<i>(Insujet® and Injex®)</i>	ICB	Insulin needle free injection device	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Nefopam	Acupan	ICB	pain relief	Not recommended for routine use.	NICE has not issued any guidance.
RED	Nelarabine	<i>(Atriance®)</i>	NHSE	Cancer - lymphoblastic leukaemia - as per Cancer Drug Fund policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Neratinib	<i>(Nerlynx®)</i>	NHSE	Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA612 - Nov 19
RED	Nevirapine	<i>(Viramune®)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Nicotinic acid (niacin) and derivatives	<i>(Various)</i>	ICB	All indications including prevention in CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG181 - Jul 14
RED	Nilotinib	<i>(Tasigna®)</i>	NHSE	Untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults - as per NICE TA 426	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA426 - Dec 16
RED	Nilotinib ▼	<i>(Tasigna® ▼)</i>	NHSE	Chronic myeloid leukaemia in adults resistant or intolerant to imatinib as per NICE TA 425	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA425 - Dec 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nintedanib	Ofev®	NHSE	progressive fibrosing interstitial lung diseases	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA747 – November 2021
RED	Nintedanib	(Vargatef®)	NHSE	Ovarian cancer (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nintedanib	Ofev®	NHSE	idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA864 – February 2023
RED	Nintedanib ▼	(Vargatef® ▼)	NHSE	Previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer - as per NICE TA 347	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA347 - Jul 15
RED	Nintedanib ▼	(Ofev® ▼)	NHSE	Idiopathic pulmonary fibrosis - as per NICE TA 379	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA379 - Jan 16
RED	Niraparib	Zejula®	NHSE	Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemo	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA673 – February 2021
RED	Niraparib	(Zejula®)	NHSE	Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - as per NICE TA784	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA784 – April 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nitazoxanide	(Alinia®)	NHSE	Viral Hepatitis C (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nitisinone	(Nitisinone Dipharma®, Orfadin®)	NHSE	Hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nitisinone	(Nitisinone Dipharma®, Orfadin®)	NHSE	Alkaptonuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nitric oxide	()	NHSE	Pulmonary Arterial Hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Nivolumab	(Opdivo®)	NHSE	Locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - as per NICE TA 530	Not commissioned. No NHS prescribing in primary or secondary care	TA530 - Jul 18
RED	Nivolumab	(Opdivo®)	NHSE	Adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease - as per NICE TA 558	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA558 - Jan 19
RED	Nivolumab	(Opdivo®)	NHSE	advanced squamous non-small-cell lung cancer after chemotherapy as per TA655	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA655 – October 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nivolumab	Opdivo®	NHSE	adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA684 – March 2021
RED	Nivolumab	Opdivo®	NHSE	previously treated unresectable advanced or recurrent oesophageal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA707 – June 2021
RED	Nivolumab	Opdivo®	NHSE	advanced non-squamous non-small-cell lung cancer after chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA713 – July 2021
RED	Nivolumab	Opdivo®	NHSE	recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA736 – October 2021
RED	Nivolumab	Opdivo®	NHSE	with ipilimumab for untreated advanced renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA780 – March 2022
RED	Nivolumab	Opdivo®	NHSE	adjuvant treatment of invasive urothelial cancer at high risk of recurrence	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA817 – August 2022
RED	Nivolumab	Opdivo®	NHSE	with ipilimumab for untreated unresectable malignant pleural mesothelioma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA818 – August 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nivolumab	Opdivo®	NHSE	with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA857 – Jan 2023
RED	Nivolumab	Opdivo®	NHSE	with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA865 – February 2023
BLACK	Nivolumab	Opdivo®	n/a	adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over	Not commissioned. No NHS prescribing in primary or secondary care	TA980 – June 2024
RED	Nivolumab	Opdivo®	NHSE	adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA746 – November 2021
BLACK	Nivolumab	Opdivo	NHSE	with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) as per TA785	Not commissioned. No NHS prescribing in primary or secondary care	TA785 – April 2022
RED	Nivolumab	Opdivo®	NHSE	chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA876 – March 2023
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	Advanced (unresectable or metastatic) melanoma - as per NICE TA 384	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA384 - Feb 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	Previously treated advanced renal cell carcinoma in adults - as per NICE TA 417	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA417 - Nov 16
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	Relapsed or refractory classical Hodgkin lymphoma in adults after autologous stem cell transplant and treatment with brentuximab vedotin - as per NICE TA 462	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA462 - Jul 17
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	For previously treated local advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy only if nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression - as per NICE TA 483	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA483 - Nov 17
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	For previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if their tumours are PD L1 positive and nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA484 - Nov 17
RED	Nivolumab ▼	(Opdivo® ▼)	NHSE	Squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA490 - Nov 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Nivolumab ▼ in combination with ipilimumab	<i>(Opdivo® ▼ in combination with Yervoy®)</i>	NHSE	Advanced (unresectable or metastatic) melanoma in adults, only when the company provides ipilimumab with discount agreed under PAS - as per NICE TA 400	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA400 - Jul 16
RED	Nivolumab relatlimab	Opdualag®	NHSE	untreated unresectable or metastatic melanoma in people 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA950 – February 2024
RED	Nivolumab with ipilimumab	Opdivo and Yervoy®	NHSE	previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA716 – July 2021
BLACK	Nivolumab with ipilimumab	Opdivo® with Yervoy®	NHSE	and chemo for untreated metastatic non-small-cell lung cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA724 – September 2021
RED	Nonacog alpha	()	NHSE	Haemophilia - as per BCSH Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nonacog beta pegol	<i>(Refixia®)</i>	NHSE	Haemophilia B (congenital factor IX deficiency).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Nusinersen	<i>(Spinraza®)</i>	NHSE		Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA588 - Jul 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Obeticholic acid ▼	(Ocaliva® ▼)	NHSE	Primary biliary cholangitis - as per NICE TA 443	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA443 - Apr 17
RED	Obinutuzumab	(Gazyvaro®)	NHSE	Untreated advanced follicular lymphoma - as per NICE TA 513	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA513 - Mar 18
RED	Obinutuzumab ▼	(Gazyvaro® ▼)	NHSE	For untreated chronic lymphocytic leukaemia for adults who have comorbidities that make full-dose fludarabine based therapy unsuitable for them - as per NICE TA 343	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA343 - Jun 15
RED	Obinutuzumab ▼	(Gazyvaro® ▼)	NHSE	(with bendamustine, then as maintenance) for follicular lymphoma in adults that did not respond or progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen - as per NICE TA 472 Updated to TA629 in May 2020	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA629 – May 2020
BLACK	Occlusive dressings and dry bandages	(Various)	ICB	Treatment of infected atopic eczema in children - as per NICE CG 57 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG57 - Dec 07
RED	Ocrelizumab ▼	(Ocrevus® ▼)	NHSE	Relapsing-remitting multiple sclerosis in adults in line with NICE TA 533	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA533 - Jul 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ocrelizumab ▼	(Ocrevus® ▼)	NHSE	Multiple sclerosis in adults - as per NHS England policy (under review post NICE 533)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ocriplasmin intravitreal injection ▼	(Jetrea® ▼)	ICB	Treatment of vitreomacular traction in adults - as per NICE TA 297	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA297 - Oct 13
RED	Octocog alfa	(Advate®, Kogenate Bayer®)	NHSE	Haemophilia A (congenital factor VIII deficiency)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Octreotide	(Sandostatin® - Generics are available)	NHSE	Congenital hyperinsulinism (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Octreotide	(Sandostatin®)	ICB	Reducing vomiting in terminal bowel obstruction (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Octreotide	(Sandostatin®)	NHSE	Carcinoid and other neuroendocrine tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Octreotide	(Sandostatin®)	NHSE	Acromegaly	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Octreotide (Oral) Octreolin®	(Octreolin®)	ICB	Acromegaly	Not recommended for routine use	NICE has not issued any guidance.
RED	Odevixibat	Bylvay	NHSE	progressive familial intrahepatic cholestasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST17 - Feb 2022
RED	Ofatumumab	(Arzerra®)	NHSE	For untreated chronic lymphocytic leukaemia in combination with chlorambucil or bendamustine - as per NICE TA 344	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA344 - Jun 15
BLACK	Ofatumumab	(Arzerra®)	NHSE	Chronic lymphocytic leukaemia (with chemotherapy) - as per NICE TA 470 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA470 - Aug 17
RED	Ofatumumab	Kesimpta®	NHSE	treating relapsing multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA699 – May 2021
RED	Ofatumumab ▼	(Arzerra® ▼)	NHSE	Treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA202 - Oct 10

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Olanzapine	(Zalasta®, Zyprexa®, ZypAdhera® IM)	ICB	Schizophrenia - 1st line	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of three months.	TA43 - Jun 02
ADVICE	Olanzapine	(Zalasta®, Zyprexa®, ZypAdhera® IM)	ICB	Maintenance in Bipolar Mania	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of three month.	NICE has not issued any guidance.
BLACK	Olanzapine	(Zalasta®, Zyprexa®, ZypAdhera® IM)	ICB	For hallucinations and delusions in Parkinson's disease, where no cognitive impairment (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
RED	Olaparib	LYNPARZA®	NHSE	for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer as per TA620	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA620 - Jan 20
BLACK	Olaparib	N/A	NHSE	maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA750 – December 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Olaparib	N/A	NHSE	BRCA mutation-positive HER2-negative metastatic breast cancer after chemo (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA762 – February 2022
BLACK	Olaparib	Lynparza®	NHSE	previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA831 – October 2022
RED	Olaparib	Lynparza®	NHSE	adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA886 – May 2023
RED	Olaparib	Lynparza®	NHSE	maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA908 – July 2023
RED	Olaparib	Lynparza®	NHSE	with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA946 – January 2024
RED	Olaparib	Lynparza®	NHSE	with abiraterone for untreated hormone-relapsed metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA951 – February 2024
RED	Olaparib	Lynparza®	NHSE	previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA887 – May 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Olaparib (replaced TA598)	(Lynparza®)	NHSE	Maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA962 – March 2024
RED	Olaparib (with bevacizumab)	Lynparza®	NHSE	maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA693 – April 2021
RED	Olaparib ▼	(Lynparza® ▼)	NHSE	Maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA381 - Jan 16
RED	Olaratumab ▼	(Lartruvo® ▼)	NHSE	(in combination with duxorubicin) for treating advanced soft tissue sarcoma in adults - as per NICE TA 465	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA465 - Aug 17
RED	Olesoxime	()	NHSE	Spinal muscular atrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Olipudase alfa	(Xenpozyme®)	NHSE	Acid Sphingomyelinase deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Olopatadine and Mometasone furoate nasal spray	Ryaltris®	ICB	moderate to severe seasonal and perennial rhinitis if monotherapy with antihistamine or corticosteroid is inadequate	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Omalizumab	(Xolair®)	NHSE	Severe persistent allergic asthma in patients aged 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA133 - Nov 07
RED	Omalizumab	(Xolair®)	NHSE	Treatment of severe persistent allergic asthma in children aged 6 to under 12 years	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA278 - Apr 13
RED	Omalizumab	(Xolair®)	ICB	For previously treated severe chronic spontaneous urticaria in adults and young people aged 12 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA339 - Jun 15
BLACK	Omalizumab	N/A	ICB	Chronic rhinosinusitis with nasal polyps (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA678 – February 2021
RED	Ombitasvir-paritaprevir-ritonavir ▼	(Viekirax® ▼)	NHSE	Genotype 1 or 4 chronic hepatitis C in adults (with or without dasabuvir (Exviera®) as per NICE TA 365	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA365 - Nov 15
RED	Onasemnogene abeparvovec	Zolgensma®	NHSE	spinal muscular atrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST15 – July 2021, updated April 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Onasemnogene abeparvovec	Zolgensma®	NHSE	presymptomatic spinal muscular atrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST24 – April 2023
ADVICE	Ondansetron (generic plain tablets)	<i>(Generic plain tablets)</i>	ICB	Second line option in hyperemesis gravidarum (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Ondansetron (generic plain tablets)	<i>(Generic plain tablets)</i>	ICB	Drug-induced nausea and vomiting in palliative care (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Ondansetron + other 5HT3 antagonists	<i>(Zofran®, various)</i>	ICB	Nausea & vomiting associated with chemotherapy and other hospital-led treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Opicapone ▼	<i>(Ongentys® ▼)</i>	ICB	Adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease (PD) and end-of-dose motor fluctuations who cannot be stabilised on those combinations	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Orlistat	<i>(Xenical®)</i>	ICB	Identification, assessment and management of overweight and obesity in children (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG189 - Nov 14

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Orphenadrine	<i>(Generics available)</i>	ICB	NICE Do Not Do - Dyskinesia and/or motor fluctuations in Parkinson's disease - as per NG 71	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
Double Red	Oscillating Positive Expiratory Pressure devices	<i>(eg Acapella/Flutter /Lung flute/Pari O-PEP/RCCornet)</i>	ICB	Mucus clearance in Chronic Bronchitis, Bronchiectasis, Emphysema, Asthma, Cystic Fibrosis	Not recommended for routine use	NICE has not issued any guidance.
RED	Osilodrostat	<i>()</i>	NHSE	Cushing's Disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Osimertinib	TAGRISSE®	NHSE	Untreated EGFR mutation-positive non small-cell lung cancer as per TA654	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA654 – October 2020
RED	Osimertinib	Tagrisso®	NHSE	adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA761 – January 2022
RED	Osimertinib ▼	<i>(Tagresso® ▼)</i>	NHSE	Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only after first-line treatment with an EGFR tyrosine kinase inhibitor	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA416 - Oct 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Osimertinib ▼	(Tagresso® ▼)	NHSE	treating EGFR T790M mutation-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA653 – October 2020
Double Red	Ospemifene	(Senshio®)	ICB	Moderate to Severe Symptomatic Vulvar And Vaginal Atrophy (VVA) In Post-Menopausal Women Who Are Not Candidates For Local Vaginal Oestrogen Therapy	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Ostomy underwear	(Various)	ICB	Any use other than for parastomal hernia assessed by a specialist	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Ostomy underwear	(Various)	ICB	Support following stoma surgery for parastomal hernia	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Oxaliplatin	(Eloxatin®)	NHSE	Colorectal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA93 - Aug 05
ADVICE	Oxcarbazepine	(Trileptal®)	ICB	Epilepsy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Oxycodone / Naloxone (Targinact®) ▼	(Targinact® ▼)	ICB	Pain / opioid-induced constipation	Not commissioned. No NHS prescribing in primary or secondary care	CG140 - July 12

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Ozanimod	Zeposia®	NHSE	relapsing–remitting multiple sclerosis	Not commissioned. No NHS prescribing in primary or secondary care	TA706 – June 2021
RED	Ozanimod	Zeposia®	ICB	moderately to severely active ulcerative colitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA828 – October 2022
BLACK	Paclitaxel	(<i>Abraxane</i> ®)	NHSE	For untreated non-small-cell lung cancer (as albumin-bound nanoparticles with carboplatin) (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA362 - Oct 15
RED	Paclitaxel	(<i>Taxol</i> ®)	NHSE	In combination with platinum or as monotherapy for treatment of advanced recurrent ovarian cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA389 - Apr 16
RED	Paclitaxel	(<i>Abraxane</i> ®)	NHSE	As albumin-bound nanoparticles in combination with gemcitabine (<i>Gemzar</i> ®) for previously untreated metastatic adenocarcinoma of the pancreas in adults - as per NICE TA 476	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA476 - Sep 17
RED	Paclitaxel	(<i>Taxol</i> ®)	NHSE	Non-small cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Paclitaxel	(<i>Taxol</i> ®)	NHSE	Lymph node positive breast cancer	Not commissioned. No NHS prescribing in primary or secondary care	CG80 - Feb 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Paclitaxel albumin	(Abraxane®)	NHSE	As monotherapy for metastatic breast cancer in patients who have not or are unlikely to tolerate first-line treatment with standard taxanes	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pacritinib	(Einpaxiq®)	NHSE	Myelofibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Padeliporfin	(Tookad®)	NHSE	Untreated localised (unilateral, low-risk) prostate cancer - as per NICE TA 546	Not commissioned. No NHS prescribing in primary or secondary care	TA546 - Nov 18
RED	Palbociclib	Ibrance®	NHSE	with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA836 – October 2022
RED	Palbociclib (with fulvestrant)	(Ibrance® ▼)	NHSE	with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA619 - Jan 20
RED	Palbociclib ▼ (with an aromatase inhibitor)	(Ibrance® ▼)	NHSE	Previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA495 - Nov 17
RED	Palforzia	n/a	ICB	peanut allergy in children and young people	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA769 – February 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Paliperidone	Invega	ICB	mental health conditions - injections and oral formulations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Palivizumab	(Synagis®)	NHSE	Prevention of Respiratory Syncytial Virus (RSV) in infants	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Palovarotene		NHSE	Fybrodysplasia ossificans progressiva	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Panitumumab	(Vectibix®)	NHSE	Treatment of metastatic colorectal cancer after first-line chemotherapy	Not commissioned. No NHS prescribing in primary or secondary care	TA242 - Jan 12
RED	Panitumumab	(Vectibix®)	NHSE	Previously untreated metastatic colorectal cancer (with chemo)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA439 - Mar 17
RED	Panobinostat ▼	(Farydak® ▼)	NHSE	Treatment of multiple myeloma (in combination with bortezomib and dexamethasone) after at least 2 previous treatments, including bortezomib and an immunomodulatory agent.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA380 - Jan 16
RED	Para-aminosalicylic acid		NHSE	Multi drug resistant TB	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Parathyroid hormone	(Natpar®)	NHSE	Specialist endocrinology conditions	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Paravit CF		ICB	for use when recommended by specialists for patients with cystic fibrosis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Parenteral nutrition		NHSE	Intestinal failure	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Paricalcitol		NHSE	Hyperparathyroidism	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Paritaprevir-ombitasvir-ritonavir ▼	(Viekirax®)	NHSE	Genotype 1 or 4 chronic hepatitis C in adults (with or without dasabuvir (Exviera®) as per NICE TA 365	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA365 - Nov 15
BLACK	Paroxetine	(Generics available)	ICB	Depression in children and young people - as per NICE CG 28 "Do Not Do" (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG28 - Sep 17
RED	Pasireotide	(Signifor®)	NHSE	Acromegaly	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pasireotide	(Signifor®)	NHSE	Cushing's Disease - as per NHS England Policy 16052/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Path Finder laser shoe attachment	(Path Finder)	ICB	Walking aid for freezing of gait in Parkinson's disease	Not commissioned. No NHS prescribing in primary or secondary care	MIB170 - Jan 19
RED	Patiiran		NHSE	Amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLUE	Patiromer	VELTASSA®	ICB	Hyperkalaemia	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA623 - Feb 20
RED	Patisiran	Onpattro	NHSE	hereditary transthyretin amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST10 - Aug 2019
RED	Pazopanib	(Votrient®)	NHSE	First-line treatment of advanced renal cell carcinoma (A licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA215 - Feb 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Pegaptanib sodium	(Macugen®)	ICB	Neovascular (wet) age-related macular degeneration	Not commissioned. No NHS prescribing in primary or secondary care	TA155 - Aug 08
RED	Pegaspargase ▼	(Oncaspar® ▼)	NHSE	Acute lymphoblastic leukaemia in children, young people and adults only when they have untreated newly diagnosed disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA408 - Sep 16
RED	Pegcetacoplan	Aspaveli®	NHSE	paroxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA778 – March 2022
RED	Pegfilgrastim	(Neulasta®)	ICB	Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Peginterferon alfa	(Pegasys®, PegIntron®, ViraferonPeg®)	NHSE	Treatment of mild chronic hepatitis C (with ribavirin)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA106 - Aug 06
RED	Peginterferon alfa	(Pegasys®, PegIntron®, ViraferonPeg®)	NHSE	Treatment of chronic hepatitis C (with ribavirin)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA200 - Sep 10
RED	Peginterferon alfa	(Pegasys® /ViraferonPeg®)	NHSE	Treating children and young people with chronic hepatitis C (with ribavirin)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA300 - Nov 13

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Peginterferon alfa-2a	(Pegasys, ViraferonPeg)	NHSE	Chronic Hepatitis B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG165 - Jun 13
RED	Peginterferon Beta-1a	(Plegridy®)	NHSE	Treating relapsing–remitting multiple sclerosis as per TA624	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA624 - Feb 20
RED	Peginterferon Beta-1a	(Plegridy®)	NHSE	Multiple sclerosis - as per NHS England policy SSC1534	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Peginterferon Lambda-1a	()	NHSE	Hepatitis C .	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Pegloticase	(Krystexxa®)	NHSE	Severe debilitating chronic tophaceous gout	Not commissioned. No NHS prescribing in primary or secondary care	TA291 - Jun 13
RED	Pegunigalsidase alfa		NHSE	Fabry's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pegunigalsidase alfa	Elfabrio®	NHSE	Fabry disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA915 – October 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pegvaliase		NHSE	Phenylketonuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pegvisomant	(Somavert®)	NHSE	Acromegaly (where other treatments failed / not tolerated) - as per NHS England Policy 16050/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pegylated liposomal doxorubicin	Caelyx	NHSE	Cancer - as per NHS England / Cancer Drug Fund policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Pegylated liposomal irinotecan	(Onivyde®)	NHSE	For treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy	Not commissioned. No NHS prescribing in primary or secondary care	TA440 - Apr 17
BLACK	Pelvic floor muscle toning devices	(Incl. PelvicToner®, Kegel8®, Aquaflex®)	ICB	Pelvic floor muscle training	Not commissioned. No NHS prescribing in primary or secondary care	NG123 - Apr 19
RED	Pembrolizumab	(Keytruda®)	NHSE	Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - as per NICE TA 519	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA519 - Apr 18
RED	Pembrolizumab	(Keytruda®)	NHSE	Untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - as per NICE TA 522	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA522 - Jul 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pembrolizumab	(Keytruda®)	NHSE	Untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-positive mutations - as per NICE TA 557	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA557 - Jan 19
BLACK	Pembrolizumab	(Keytruda®)	NHSE	For treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy - as per NICE TA 570 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA570 - Mar 19
RED	Pembrolizumab	Keytruda®	NHSE	untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA709 – June 2021
RED	Pembrolizumab	Keytruda®	NHSE	adjuvant treatment of completely resected stage 3 melanoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA766 – February 2022
RED	Pembrolizumab	Keytruda®	NHSE	adjuvant treatment of resected stage 2B or 2C melanoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA837 – October 2022
RED	Pembrolizumab	Keytruda®	NHSE	plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA885 – May 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pembrolizumab	Keytruda®	NHSE	with lenvatinib for previously treated advanced or recurrent endometrial cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA904 – June 2023
RED	Pembrolizumab	Keytruda®	NHSE	previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA914 – September 2023
RED	Pembrolizumab	Keytruda®	NHSE	plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA939 – December 2023
BLACK	Pembrolizumab	(Keytruda®)	N/A	with gemcitabine and cisplatin for untreated advanced biliary tract cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA966 – April 2024
BLACK	Pembrolizumab	(Keytruda®)	NHSE	Relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin - as per NICE TA 540	Not commissioned. No NHS prescribing in primary or secondary care	TA540 - Sept 18 - updated May 2024
RED	Pembrolizumab	(Keytruda®)	NHSE	relapsed or refractory classical Hodgkin lymphoma in people 3 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA967 – May 2024
BLACK	Pembrolizumab	(Keytruda®)	NHSE	with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA966 – April 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pembrolizumab	Keytruda®	NHSE	with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA737 – October 2021, updated Aug 2024
RED	Pembrolizumab	Keytruda®	NHSE	platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA997 - August 2024
BLACK	Pembrolizumab	N/A	NHSE	untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA674 – February 2021
RED	Pembrolizumab	Keytruda®	NHSE	with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA683 – March 2021
BLACK	Pembrolizumab	Keytruda®	NHSE	locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	Not commissioned. No NHS prescribing in primary or secondary care	TA692 – April 2021
RED	Pembrolizumab	Keytruda®	NHSE	with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA770 – February 2022
RED	Pembrolizumab	Keytruda®	NHSE	relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA772 – February 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pembrolizumab	Keytruda®	NHSE	plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA801 - June 2022
RED	Pembrolizumab	Keytruda®	NHSE	adjuvant treatment of renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA830 – October 2022
RED	Pembrolizumab	Keytruda®	NHSE	neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA851 – December 2022
BLACK	Pembrolizumab	Keytruda®	NHSE	with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma	Not commissioned. No NHS prescribing in primary or secondary care	TA983 – June 2024
RED	Pembrolizumab	Keytruda®	NHSE	with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1017 – November 2024
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	Advanced melanoma after disease progression with ipilimumab in adults - as per NICE TA 357	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA357 - Oct 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	Advanced (unresectable or metastatic) melanoma in adults not previously treated with ipilimumab as per NICE TA 366	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA366 - Nov 15
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after chemotherapy - as per NICE TA 428	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA428 - Jan 17
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	Untreated PD-L1-positive metastatic non-small-cell lung cancer - as per NICE TA 447	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA447 - Jun 17
RED	Pembrolizumab ▼	(Keytruda®)	NHSE	untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA531 - Jul 18
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	with axitinib for untreated advanced renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA650 – September 2020
RED	Pembrolizumab ▼	(Keytruda® ▼)	NHSE	untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA661 – November 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pemetrexed	(Alimta®)	NHSE	Treatment of malignant pleural mesothelioma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA135 - Jan 08
RED	Pemetrexed	(Alimta®)	NHSE	First-line treatment of non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA181 - Aug 07
RED	Pemetrexed	(Alimta®)	NHSE	Non-small-cell lung cancer - patients who have had prior chemotherapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA181 - Aug 07
RED	Pemetrexed	(Alimta®)	NHSE	Maintenance treatment of non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA190 - Aug 17
RED	Pemetrexed	(Alimta®)	NHSE	Maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) following induction therapy with pemetrexed and cisplatin	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA402 - Aug 16
RED	Pemigatinib	Pemaryze®	NHSE	relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA722 – August 2021
BLACK	Pen needle and remover (Unifine Pentips Plus)	(Unifine® Pentips® Plus)	ICB	Insulin administration	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Penicillamine	(Distamine®)	ICB	Wilson's disease (as recommended by a specialist centre - Cambs Universty Hospitals /Addenbrooke's Hospital)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pentosan polysulfate sodium 100mg capsules	(Elmiron®)	ICB	Bladder pain syndrome / Interstitial Cystitis characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Pentoxifylline (Oxpentifylline)	(Trental®)	ICB	Treatment of intermittent claudication in people with peripheral arterial disease	Not commissioned. No NHS prescribing in primary or secondary care	TA223 - May 11
RED	Peptide receptor radionucleotide therapy	()	NHSE	Cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Perampanel	(Fycompa®)	ICB	Second line adjunctive treatment of patients over the age of 12 years with partial seizures with or without secondary generalisation	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script until the dose is stable.	NICE has not issued any guidance.
BLACK	Pergolide	()	ICB	First-line use in Parkinson's disease	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Pergolide	()	ICB	Pharmacological neuroprotective therapy in Parkinson's disease (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Perindopril arginine	(Coversyl® Arginine tablets)	ICB	All indications	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Pertuzumab	(Perjeta®)	NHSE	In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA424 - Dec 16
RED	Pertuzumab	(Perjeta®)	NHSE	(with trastuzumab and docetaxel) for treating HER2-positive breast cancer - as per NICE TA 509	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA509 - Mar 18
RED	Pertuzumab	(Perjeta®)	NHSE	For adjuvant treatment of HER2-positive early stage breast cancer in adults, only if they have lymph node-positive disease - as per NICE TA 569 (NHSE commissioning responsibility)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA569 - Mar 19
BLACK	Phenothiazines (see list of drugs in TAG Guidance)	(Various)	ICB	NICE Do Not Do - Use in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Pholcodine linctus	generic	ICB	Cough suppressant	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Phytomenadione (Vitamin K Nutritional Supplement)	NeoKay Oral Drops	ICB	Limited to use in preterm-born babies (<37 weeks gestation) who are cared for in NNUH (mainly NICU but will include some preterm babies cared for on postnatal ward) and who are discharged home breastfeeding	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Pibrentasvir	(Maviret® (Combi product with glecaprevir))	NHSE	Chronic hepatitis C - as per NICE TA 499	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA499 - Jan 18
ADVICE	Pimecrolimus 1% Cream	(Elidel® cream)	ICB	Option for 2nd line treatment of moderate atopic eczema on the face and neck in children aged 2 to 16 years not controlled by topical steroids or where there is serious risk of important ADRs from further use of topical steroids - as per NICE CG 57	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG57 - Aug 04
Double Red	Pindolol	(Visken®)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG90 - Oct 09
RED	Pirfenidone	(Esbriet®)	NHSE	Idiopathic Pulmonary Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA504 - Feb 18
BLACK	Pitolisant hydrochloride	Ozawade®	ICB	excessive daytime sleepiness caused by obstructive sleep apnoea	Not commissioned. No NHS prescribing in primary or secondary care	TA776 – March 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pixantrone ▼	(Pixuvri® ▼)	NHSE	Monotherapy treatment of multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA306 - Feb 14
ADVICE	Plantar pressure offloading devices	(Various)	ICB	Prevention and management of diabetic foot problems	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Plerixafor	(Mozobil®)	NHSE	Mobilisation of stem cells in Bone Marrow Transplant	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Polatuzumab vedotin	Polivy®	NHSE	with rituximab and bendamustine - relapsed or refractory diffuse large B-cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA649 – September 2020
RED	Polatuzumab vedotin	Polivy®	NHSE	combination for untreated diffuse large B-cell lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA874 – March 2023
BLACK	Pomalidomide	(Imnovid®)	NHSE	With bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma	Not commissioned. No NHS prescribing in primary or secondary care	TA602 - Sep 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Pomalidomide ▼	(<i>Imnovid</i> ® ▼)	NHSE	In combination with dexamethasone - treatment of relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib as per NICE TA 427	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA427 - Jan 17
RED	Pomalidomide ▼	(<i>Imnovid</i> ▼)	NHSE	Myelofibrosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ponatinib ▼	(<i>Iclusig</i> ® ▼)	NHSE	Chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults - as per NICE TA 451	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA451 - Jun 17
RED	Ponesimod	()	NHSE	Multiple sclerosis (x).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ponesimod	Ponvory®	NHSE	relapsing–remitting multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA767 – February 2022
RED	Poractant alfa	(<i>Curosurf</i> ®)	NHSE	Respiratory distress syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Posaconazole	(Noxafil®)	NHSE	Systemic fungal infections - as per Trust Guidelines & NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Potassium aminobenzoate (capsules and powder)	(Potaba®)	ICB	Peyronie's disease, Scleroderma	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Potassium bicarbonate slow release–potassium citrate	n/a	ICB	distal renal tubular acidosis (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA838 – November 2022
BLACK	Potassium hydroxide solution 5%	Molludab / Molutrex	ICB	Molluscum contagiosum (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Pralsetinib	Gavreto®	NHSE	RET fusion-positive advanced non-small-cell lung cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA812 – August 2022
BLACK	Pramipexole	()	ICB	Pharmacological neuroprotective therapy in Parkinson's disease (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
ADVICE	Pramipexole - Immediate Release	(Mirapexin®)	ICB	Idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Pramipexole - Prolonged Release	(Mirapexin® Prolonged Release)	ICB	Idiopathic Parkinson's disease - alone or with levodopa, for patients initiated on treatment prior to mid March 2011 only - no new patients to be started on Pramipexole PR after this date.	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for all scripts.	NICE has not issued any guidance.
BLACK	Pramipexole - Prolonged Release	(Mirapexin® Prolonged Release)	ICB	Idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa - Not commissioned from mid March 2011 onwards	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Prasterone	INTRAROSA®	ICB	Vulvar and vaginal atrophy (in post-menopausal women with moderate to severe symptoms)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Prasugrel	(Efient®)	ICB	Targeted use in diabetics: In combination with aspirin, prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing primary or delayed percutaneous coronary intervention (PCI)	Not commissioned. No NHS prescribing in primary or secondary care	TA182 - Oct 09
ADVICE	Prasugrel	(Efient®)	ICB	In combination with aspirin: Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with known intolerance to clopidogrel or who have restenosed whilst on clopidogrel.	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA317 - Jul 14
BLACK	PredictSure-IBD prognostic tool	(PredictSure-IBD)	ICB	Prediction of prognosis in Inflammatory bowel disease	Not commissioned. No NHS prescribing in primary or secondary care	MIB178 - Mar 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Pregabalin	(Lyrica®; generic also available)	ICB	Generalised anxiety disorder (GAD) - for use only where all other options have failed.	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Pregabalin	(Lyrica®, generic also available)	ICB	Control of epilepsy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
Double Red	Pretomanid	()	NHSE	Multi drug resistant tuberculosis (TB)	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Pridinol	Myopridin	ICB	central and peripheral muscle spasms, lumbar pain, torticollis and general muscle pain in adults	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Procarbazine	()	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Pro-gest cream	(Pro-gest®)	ICB	Hormone replacement therapy (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Progestogens (oral)	(Various)	ICB	(given during the luteal phase only) for treatment of Heavy Menstrual Bleeding - as per NICE CG 44 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG144 - Aug 16
BLACK	Prolonged release oxycodone (Onexila XL)	(Onexila® XL)	ICB	Analgesia	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Prontoderm bacterial decolonisation foam/nasal gel	<i>(Prontoderm® foam and Prontoderm® nasal gel)</i>	ICB	Topical decolonisation of MRSA carriers	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Propafenone	Arythmol	ICB	cardiovascular indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Prosource Jelly	<i>(Prosource® Jelly)</i>	ICB	hypoproteinaemia	Not recommended for routine use.	NICE has not issued any guidance.
RED	Protein C concentrate	<i>(Ceprotrin®)</i>	NHSE	Congenital protein C deficiency - as per B(C)SH Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Protein Kinase Inhibitors	<i>(Various)</i>	NHSE	Endocrinology non-malignant conditions (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Prothrombin Complex	<i>(Beriplex®, Octaplex®)</i>	NHSE	As per B(C)SH Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Pyridostigmine	Mestinon®	ICB	Myasthenia gravis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Quetiapine	<i>(Generics are available)</i>	ICB	Schizophrenia - 1st line	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of three months	CG82 - Mar 09
BLACK	Quetiapine	<i>(Seroquel)</i>	ICB	Generalised anxiety disorder (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Quizartinib	Vanflyta®	NHSE	induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1013 – October 2024
BLACK	Rabbit anti-human thymocyte immunoglobulin	<i>(Thymoglobuline®)</i>	NHSE	INITIAL treatments to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 and 482 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17
BLACK	Rabbit anti-human thymocyte immunoglobulin	<i>(Thymoglobuline®)</i>	NHSE	INITIAL treatments to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 and 482 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17
RED	Radium-223 dichloride ▼	<i>(Xofigo® ▼)</i>	NHSE	Hormone-relapsed prostate cancer with bone metastases.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA412 - Sep 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Raloxifene	(Evista®)	ICB	Primary prevention of osteoporotic fragility fractures in postmenopausal women	Not commissioned. No NHS prescribing in primary or secondary care	TA160 - Oct 08
ADVICE	Raloxifene	(Evista®)	ICB	Chemoprophylaxis for no more than 5 years for pre- or post-menopausal women at either high or moderate risk of developing breast cancer (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG164 - Jun 13
RED	Raltegravir	(Isentress®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Raltitrexed	(Tomudex®)	Clinical Trial	Advanced colorectal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA93 - Aug 05
BLACK	Ramucirumab	(Cyramza®)	NHSE	Unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA609 - Oct 19
BLACK	Ramucirumab (with erlotinib)	(Cyramza® ▼)	NHSE	untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA635 – June 2020
BLACK	Ramucirumab ▼	(Cyramza® ▼)	NHSE	Advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.	Not commissioned. No NHS prescribing in primary or secondary care	TA378 - Jan 16
BLACK	Ramucirumab ▼ in combination with doxetaxel	(Cyramza® ▼)	NHSE	Locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed after platinum-based chemotherapy	Not commissioned. No NHS prescribing in primary or secondary care	TA403 - Aug 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Ranibizumab	(Lucentis®)	ICB	treating diabetic retinopathy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA637 – June 2020
RED	Ranibizumab	(Lucentis®)	ICB	Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NG82 - Jan 18
RED	Ranibizumab	(Lucentis®)	ICB	Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ranibizumab	(Lucentis®)	ICB	Visual impairment due to diabetic macular oedema	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA274 - Feb 13 updated Oct 2023
RED	Ranibizumab	(Lucentis®)	ICB	Neovascular (wet) age-related macular degeneration	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA155 - Aug 08 - updated May 2024
RED	Ranibizumab	(Lucentis®)	ICB	Treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (RVO)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA283 - May 13 - updated May 2024
RED	Ranibizumab	(Lucentis®)	ICB	Choroidal neovascularisation associated with pathological myopia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA298 - Nov 13 - updated May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ranolazine	(Ranexa®)	ICB	Adjunctive use in stable angina unresponsive to other treatments	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG126 - Jul 11
ADVICE	Rasagiline	(Azilect®)	ICB	Idiopathic Parkinson's Disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Rasagiline	(Generics available)	ICB	NICE Do Not Do - Pharmacological neuroprotective therapy in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
RED	Rasburicase	(Fasturtec®)	NHSE	Prophylaxis & treatment of acute hyperuricaemia to prevent renal failure in patients with high tumour burden who are at risk of tumour lysis syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ravulizumab	Ultomiris®	NHSE	paroxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA698 – May 2021
RED	Ravulizumab	Ultomiris®	NHSE	Parxysmal nocturnal haemoglobinuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Ravulizumab	N/A	N/A	generalised myasthenia gravis	Not commissioned. No NHS prescribing in primary or secondary care	TA940 – December 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Ravulizumab	N/A	N/A	AQP4 antibody-positive neuromyelitis optica spectrum disorder	Not commissioned. No NHS prescribing in primary or secondary care	TA941 – December 2023
RED	Ravulizumab	Ultomiris®	NHSE	treating atypical haemolytic uraemic syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA710 – June 2021
RED	Raxibacumab		NHSE	Inhaled anthrax	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Reagent Pad (Neuropad)	<i>(Neuropad)</i>	ICB	Diagnostic test for peripheral neuropathy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Recombinant human parathyroid hormone	Natpar® s/c injection)	NHSE	Hypoparathyroidism as per TA625 (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA625 - Mar 20
RED	Refenalin		NHSE	Prevention of delayed graft function	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Regorafenib	<i>(Stivarga®)</i>	NHSE	Previously treated advanced hepatocellular carcinoma - as per NICE TA 514	Not commissioned. No NHS prescribing in primary or secondary care	TA514 - Mar 18
RED	Regorafenib	<i>(Stivarga®)</i>	NHSE	Advanced unresectable hepatocellular carcinoma in adults who have had sorafenib - as per NICE TA 555	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA555 - Jan 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Regorafenib	Stivarga®	NHSE	previously treated metastatic colorectal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA866 – February 2023
BLACK	Regorafenib ▼	(Stivarga® ▼)	NHSE	Metastatic colorectal cancer after treatment for metastatic disease	Not commissioned. No NHS prescribing in primary or secondary care	TA334 - Feb 15
RED	Regorafenib ▼	(Stivarga® ▼)	NHSE	Previously treated unresectable or metastatic gastrointestinal stromal tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA488 - Nov 17
RED	Relugolix	Orgovyx®	NHSE	hormone-sensitive prostate cancer	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA995 – August 2024
ADVICE	Relugolix–estradiol–norethisterone acetate	Ryeqo®	ICB	moderate to severe symptoms of uterine fibroids	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of three months	TA832 – October 2022
RED	Remdesivir	Veklury	ICB	for use in hospitalised patients with covid-19 who meet the criteria defined in the NICE TA	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA971 – May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Repaglinide	PRANDIN®	ICB	To treat CF patients who have diabetes, as an alternative to insulin	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Reparixin		NHSE	Prevention of delayed graft function	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Reslizumab ▼	(Cinqaero® ▼)	NHSE	Treatment of severe eosinophilic asthma inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug - as per NICE TA 479	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA479 - Oct 17
BLACK	RESPeRATE®	(RESPeRATE®)	ICB	Device used to lower BP by changing breathing rates	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Reveglucosidase alfa	()	NHSE	Pompe Disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ribavirin	(Copegus®, Rebetol®)	NHSE	Chronic hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA200 - Sep 10
RED	Ribociclib (with fulvestrant)	Kisqali®	NHSE	hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA687 – March 2021

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ribociclib with fulvestrant	(Kisqali®)	NHSE	Hormone receptor-positive, HER2-negative, advanced breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA593 - Aug 19
RED	Ribociclib ▼ (with an aromatase inhibitor)	(Kisqali® ▼)	NHSE	Previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA496 - Dec 17
ADVICE	Rifampicin	various	ICB	Non-TB related mycobacterium infections	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	NICE has not issued any guidance.
RED	Rifaximin	(Targaxan®)	ICB	Treatment and prophylaxis of secondary hepatic encephalopathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA337 - Mar 15
BLACK	Rifaximin	(Xifaxanta®)	ICB	For treatment of traveller's diarrhoea	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Rifaximin	((Targaxan® / Xifaxanta®))	ICB	Chronic diarrhoea in G-I disorders (including Crohn's disease, Ulcerative Colitis, Diverticular disease, IBS, recurrent C. diff infection, small intestinal bacterial overgrowth)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rifaximin	((<i>Targaxan</i> ® / <i>Xifaxanta</i> ®))	ICB	UC with pouchitis only when other treatment options have failed	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rigosertib	(<i>Estybon</i> ®)	NHSE	Refractory myelodysplastic syndromes (MDS), high-risk / Pancreatic cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rilpivirine	(<i>Edurant</i> ®)	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Riluzole	(<i>Rilutek</i> ®)	NHSE	Amyotrophic Lateral Sclerosis (Motor Neurone Disease)	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	NICE has not issued any guidance.
ADVICE	Rimegepant	Vydura	ICB	preventing migraine	Specialist will initiate and provide the first 12 weeks of medication to the patient.	TA906 - July 2023
RED	Rimeporide		NHSE	Duchenne muscular dystrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Riociguat ▼	(<i>Adempas</i> ® ▼)	NHSE	Treatment chronic thromboembolic Pulmonary Hypertension in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Ripretinib	Qinlock®	NHSE	advanced gastrointestinal stromal tumour after 3 or more treatments	Not commissioned. No NHS prescribing in primary or secondary care	TA881 – May 2023
RED	Risankizumab	(Skyrizi®)	ICB	Psoriasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA596 - Aug 19
RED	Risankizumab	(Skyrizi®)	ICB	active psoriatic arthritis after inadequate response to DMARDs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA803 – July 2022
RED	Risankizumab	Skyrizi®	ICB	moderately to severely active ulcerative colitis	Red/Hospital - Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA998 – August 2024
RED	Risankizumab (updated from blue)	Skyrizi®	ICB	previously treated moderately to severely active Crohn's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA888 – May 2023
RED	Risdiplam	Evrysdi®	NHSE	spinal muscular atrophy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA755 – December 2021 updated Dec 2023
RED	Risperidone	(Risperdal® (tablets))	ICB	Unresponsive conduct disorder in ADHD	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG158 - Mar 13

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Risperidone (Depot injection) ▼	(Risperdal Consta® ▼)	ICB	Schizophrenia and other psychoses in patients tolerant to risperidone by mouth.	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLUE	Ritlecitinib	Litfulo®	ICB	severe alopecia areata in people 12 years and over	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA958 – March 2024
RED	Ritonavir	(Norvir®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ritonavir-paritaprevir-ombitasvir ▼	(Viekirax®)	NHSE	Genotype 1 or 4 chronic hepatitis C in adults (with or without dasabuvir (Exviera®) as per NICE TA 365	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA365 - Nov 15
RED	Rituximab	(MabThera®)	NHSE	Relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA137 - Feb 08

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab	(MabThera®)	NHSE	Option for first-line treatment of chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA174 - Jul 09
RED	Rituximab	(MabThera®)	NHSE	Treatment of relapsed or refractory chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA193 - Jul 10
RED	Rituximab	(MabThera®)	NHSE	1st-line maintenance treatment of follicular non-Hodgkin's lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA226 - Jun 11
RED	Rituximab	(MabThera®)	NHSE	1st-line treatment of stage III-IV follicular lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA243 - Jan 12
RED	Rituximab	(Mabthera®)	NHSE	Splenic B cell non Hodgkin's lymphoma (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®, Rixathon®, Truxima®)	ICB	Option for treatment of Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera)	NHSE	Splenic marginal zone (B cell non Hodgkin) lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab	(MabThera®)	NHSE	Aggressive non-Hodgkin's lymphoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Connective tissue disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Treatment for relapsing Steroid Sensitive Nephrotic Syndrome (SSNS) in children (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Treatment of Steroid Resistant Nephrotic Syndrome (SRNS) in paediatric patients (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Membranous nephropathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Focal segmental glomerulosclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Myasthenia gravis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab	(MabThera®)	NHSE	Anti-nmdar autoimmune encephalitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera®)	NHSE	Dermatomyositis and polymyositis (adults)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab	(MabThera & biosimilars)	NHSE	Steroid sensitive nephrotic syndrome - as per NHS England policy E03/P/c and b (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab - subcutaneous injection	(MabThera®)	NHSE	Follicular Lymphoma maintenance - NHS England policy Lymphoma maintenance	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	ICB	Rheumatoid arthritis - with MTX after DMARDs including a TNF inhibitor	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA195 - Aug 10
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Anti-neutrophil cytoplasmic antibody-associated (ANCA) vasculitis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA308 - Mar 14
RED	Rituximab (biosimilar)	(Truxima®, Rithaxon®)	NHSE	RhF +ve Poly-Articular Juvenile Idiopathic Arthritis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	ICB	treatment of autoimmune haemolytic anaemia (AIHA) in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	ANCA associated vasculitis - as per NICE TA 308 and NHS England policy A13/P/a (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Eradication of inhibitors in patients with Acquired Haemophilia (2nd line option) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Nephritis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Connective tissue disease - interstitial lung disease (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Primary Sjogren's syndrome (PSS) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Chronic inflammatory demyelinating polyneuropathy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Immunoglobulin G4 related disease - as per NHS England policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Myositis - as per NHS England Policy 16035/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Pemphigus Vulgaris - as per NHS England policy 16035/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truxima®, Rixathon®)	NHSE	Cytopenia complicating primary immunodeficiency - as per NHS England policy 16044/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Systemic Lupus Erythematosus (SLE) - as per NHS England Policy A13/PS/a (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Neuromyelitis optica (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rituximab (biosimilar)	(Truximab®, Rithaxon®)	NHSE	Graft versus host disease -as per Policy NHS England Policy 16069/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rituximab (biosimilar)	(<i>Truximab</i> ®, <i>Rithaxon</i> ®)	NHSE	ABO-incompatible kidney transplants - as per specification - Specialist centres only (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rivaroxaban	(<i>Xarelto</i> ®)	ICB	Prevention of adverse outcomes after acute management of acute coronary syndrome in people with elevated cardiac biomarkers (as per NICE TA 335)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA335 - Mar 15
ADVICE	Rivaroxaban	(<i>Xarelto</i> ®)	ICB	For preventing atherothrombotic events in people with coronary or peripheral artery disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA607 - Oct 19
Double Red	Rivaroxaban	(<i>Xarelto</i> ®)	ICB	Combined use with dual antiplatelet therapy in people who otherwise need anticoagulation, who have had an MI - as per NICE CG 172 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG172 - Nov 13
RED	Rivaroxaban ▼	(<i>Xarelto</i> ® ▼)	ICB	Prevention of venous thromboembolism in adults after total hip or total knee replacement (as per NICE TA 170)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA170 - Apr 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Rivaroxaban ▼	(Xarelto® ▼)	ICB	Treatment of deep vein thrombosis (except calf vein DVT) and prevention of recurrent DVT in specified patient groups	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of 3 weeks.	TA261 - Jul 12
ADVICE	Rivaroxaban ▼	(Xarelto® ▼)	ICB	Treatment and prevention of pulmonary embolism as per NICE TA 261 (where warfarin is not appropriate - see Full Guidance)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA261 - Jul 12
RED	Rivaroxaban ▼	(Xarelto® ▼)	ICB	Treatment of calf vein deep vein thrombosis (as per NICE TA 261)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA261 - Jul 12
SCA	Rivastigmine	(Exelon®)	ICB	Mild to moderate dementia in Alzheimer's Disease - as per NICE TA 217	Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review	TA217 - Mar 11
ADVICE	Rivastigmine	(Use cost-effective generic oral preparations)	ICB	Mild to moderate dementia in Parkinson's disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should recommend, but GP can take responsibility for all scripts 6 weeks.	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Rivipansel sodium		NHSE	Hepatic veno-occlusive disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Rivipansel sodium		NHSE	Sickle Cell Disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Roflumilast ▼	(Daxas® ▼)	ICB	Adjunct to bronchodilators for maintenance in chronic obstructive pulmonary disease in adults with chronic bronchitis and a history of frequent exacerbations - as per NICE 461	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of one month.	TA461 - Jul 17
RED	Romiplostim	(Nplate®)	NHSE	Chronic immune (idiopathic) thrombocytopenic purpura	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA221 - Apr 11
RED	Romosozumab	EVENTITY®	ICB	severe osteoporosis	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA791 – May 2022
RED	Ropeginterferon alfa 2b	()	NHSE	Hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ropinirole	(Adartrel®, Requip®)	ICB	Parkinson's Disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Ropinirole	()	ICB	Pharmacological neuroprotective therapy in Parkinson's disease (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
ADVICE	Rotigotine	(Neupro® patches)	ICB	Monotherapy for early and adjunct to levodopa in advanced stage Parkinson's disease	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Rotigotine	()	ICB	Pharmacological neuroprotective therapy in Parkinson's disease (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Rotigotine	n/a	ICB	restless legs syndrome	Not commissioned. No NHS prescribing in primary or secondary care	NICE CKS - July 2022
RED	Roxadustat	()	NHSE	Dialysis induced anaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Roxadustat	Evrenzo®	ICB	symptomatic anaemia in chronic kidney disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA807 – July 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	RT300 (functional electrical stimulation system)	(RT300)	ICB	Spinal cord injury rehabilitation - as per MIB 169	Not commissioned. No NHS prescribing in primary or secondary care	MIB169 - Jan 19
BLACK	Rubefaciants	(Various -)	ICB	Osteoarthritis - as per NICE CG 59 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG59 - Feb 08
RED	Rucaparib	(Rubraca®)	NHSE	Maintenance of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1007 – September 2024
BLACK	Rupatadine	(Generic)	ICB	Symptomatic relief of allergic rhinitis and urticaria	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Rurioctocog alfa pegol		NHSE	Haemophilia A	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ruxolitinib	(Jakavi®)	NHSE	Disease-related splenomegaly or symptoms in adults with myelofibrosis - as per NICE TA 386	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA386 - Mar 16
BLACK	Ruxolitinib	Jakavi	NHSE	acute graft versus host disease refractory to corticosteroids (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA839 – November 2022
BLACK	Ruxolitinib	Jakavi	NHSE	chronic graft versus host disease refractory to corticosteroids (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA840 – November 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ruxolitinib	(<i>Jakavi</i> ®)	NHSE	Polycythaemia vera	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA921 – October 2023
RED	Ruzasvir		NHSE	Hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sacituzumab govitecan	Trodelvy®	NHSE	unresectable triple-negative advanced breast cancer after 2 or more therapies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA819 – August 2022
RED	Sacrosidase		NHSE	Congenital sucrase isomaltase deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Sacubitril / Valsartan ▼	(<i>Entresto</i> ® ▼)	ICB	Symptomatic chronic heart failure with reduced ejection fraction in adults	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	TA388 - Apr 16
Double Red	Safety needles (insulin)	(<i>BD-Autoshields, Mylife Clickfine Autoprotect etc</i>)	ICB	Insulin administration	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Safety needles (insulin)	(BD- Autoshields, Mylife Clickfine Autoprotect etc)	ICB	Insulin administration	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Safinamide	(Xadago®)	ICB	Idiopathic Parkinson's disease where existing oral agents are contra-indicated or have failed to improve motor fluctuations/dyskinesia	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Safinamide ▼	(Xadago® ▼)	ICB	NICE Do Not Do - Pharmacological neuroprotective therapy in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
RED	Sapropterin	Kuvan®	NHSE	hyperphenylalaninaemia in phenylketonuria	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA729 – September 2021
RED	Sapropterin (Tetrahydrobiopterin (BH4, THB))	(Kuvan® ▼)	NHSE	Management of Phenylketonuria (PKU) only during pregnancy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sapropterin (Tetrahydrobiopterin (BH4, THB))	(Kuvan®)	NHSE	Treatment of children with phenylketonuria (PKU)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Sargramostim (GM-CSF)	(Leukine® (import))	NHSE	Antibody-positive pulmonary alveolar proteinosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sarilumab	Kevzara®	NHSE	Critically ill patients with COVID-19 pneumonia (adults))	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	ES34 – January 2021
RED	Sarilumab ▼	(Kevzara® ▼)	ICB	Treatment of moderate to severe active rheumatoid arthritis in adults (with and without methotrexate) - as per NICE 485	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA485 - Nov 17
RED	Satraliumab		NHSE	Neuromyelitis optica	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Satralizumab	Enspryng	N/A	preventing relapses in neuromyelitis optica spectrum disorders	Not commissioned. No NHS prescribing in primary or secondary care	TA960 – March 2024
RED	Sebelipase alfa	(Kanuma®)	NHSE	Lysosomal acid lipase deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sebelipase alfa	Kanuma®	NHSE	Wolman disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST30 – January 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Sebelipase alfa	Kanuma®	NHSE	lysosomal acid lipase deficiency that is not Wolman disease	Not commissioned. No NHS prescribing in primary or secondary care	TA961 – March 2024
RED	Secukinumab	Cosentyx®	ICB	non-radiographic axial spondyloarthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA719 – July 2021
RED	Secukinumab	(Cosentyx®)	NHSE	Paediatric indications (where adult TA available) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Secukinumab	Cosentyx®		moderate to severe hidradenitis suppurativa	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA935 – December 2023
RED	Secukinumab	Cosentyx®	NHSE	moderate to severe plaque psoriasis in children and young people	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA734 – October 2021
RED	Secukinumab ▼	(Cosentyx® ▼)	ICB	Treatment of moderate to severe plaque psoriasis - as per NICE TA 350 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA350 - Jul 15
RED	Secukinumab ▼	(Cosentyx® ▼)	ICB	Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors - as per NICE TA 407 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA407 - Sep 16

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Secukinumab ▼ (with or without MTX)	(<i>Consentyx</i> ® ▼)	ICB	Active psoriatic arthritis after inadequate response to DMARDs as per NICE TA 445 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA445 - May 17
RED	Selective internal radiation therapies	QuiremSpheres®	NHSE	hepatocellular carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA688 – March 2021, updated July 2024
RED	Selective internal radiation therapies	QuiremSpheres®	NHSE	unresectable advanced hepatocellular carcinoma	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA985 – July 2024
BLACK	Selegiline	(<i>Eldepryl</i> ®, <i>Zelapar</i> ®)	ICB	NICE Do Not Do - Pharmacological neuroprotective therapy in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
RED	Selexipag	(<i>Uptravi</i> ®)	NHSE	Pulmonary arterial hypertension - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Selinexor	Nexpovio®	NHSE	with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA970 – May 2024
RED	Selinexor	Nexpovio®	NHSE	with bortezomib and dexamethasone for previously treated multiple myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA974 – May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Selpercatinib	Retsevmo®	NHSE	advanced thyroid cancer with RET alterations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA742 – November 2021
RED	Selpercatinib	Retsevmo®	NHSE	untreated RET fusion-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA911 – July 2023
RED	Selpercatinib	Retsevmo®	NHSE	previously treated RET fusion-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA760 – January 2022
RED	Selumetinib	Koselugo	NHSE	symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST20 - May 2022
ADVICE	Semaglutide	(<i>Ozempic®</i>)	ICB	Adults with insufficiently controlled type 2 diabetes mellitus	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Semaglutide	(<i>Ozempic®</i>)	ICB	For adults with insufficiently controlled type 2 diabetes mellitus as adjunct to diet and exercise - monotherapy (if metformin inappropriate) or in combination with other antidiabetic drugs as per local Diabetes Formulary guidance - 3rd line option	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Semaglutide	Wegovy®	ICB	managing overweight and obesity (adults)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care Only to be supplied via Tier 3 service	TA875 – March 2023
BLACK	Semaglutide	Wegovy®	ICB	managing overweight and obesity in young people aged 12 to 17 years	Not commissioned. No NHS prescribing in primary or secondary care	TA910 – July 2023
ADVICE	Semaglutide oral preparations	Rybelsus®	ICB	Diabetic patients where GLP1 analogue is indicated but oral preparation is more suitable	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Setmelanotide	Imcivree	NHSE	obesity caused by LEPR or POMC deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST21 - July 2022
RED	Setmelanotide	Imcivree®	NHSE	obesity and hyperphagia in Bardet-Biedl syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST31 – May 2024
Double Red	Setrobuvir	()	NHSE	Viral Hepatitis C - as per NHSE policy	Not recommended for routine use	NICE has not issued any guidance.
RED	Setrusumab		NHSE	Osteogenesis imperfecta	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Sevelamer	(Renage®)	ICB	Hyperphosphataemia in chronic renal failure in patients on haemodialysis	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Sialic acid	()	NHSE	Myopathy - as per NHSE policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sildenafil	(Generic)	ICB	Connective tissue diseases (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Sildenafil	(Generic)	ICB	Use of regular, daily doses for penile rehabilitation in prostate cancer/post radical prostatectomy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Sildenafil (generic plain tablets only)	(Generic plain tablets)	ICB	Digital ulceration in severe secondary Raynaud's phenomenon associated with systemic sclerosis (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation GP can initiate and take responsibility for all scripts 1 month or stable dose.	NICE has not issued any guidance.
RED	Sildenafil (Revatio®)	(Revatio®)	NHSE	Pulmonary Arterial Hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Silicone gel sheet dressing	<i>various</i>	ICB	Reduce and prevent hypertrophic and keloid scarring	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Silk garments	<i>(Various)</i>	ICB	Dermatology	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Simeprevir	<i>(Olysio®)</i>	NHSE	Treatment of genotypes 1 and 4 chronic hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA331 - Feb 15
BLACK	Simeprevir	<i>(Olysio®)</i>	NHSE	For treating genotype 1 or 4 chronic hepatitis C in combination with sofosbuvir (Sovaldi®) (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA361 - Oct 15
RED	Simeprevir / Peginterferon + Ribavirin	<i>(Olysio® / Various)</i>	NHSE	Hepatitis C - as per NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Siponimod	Mayzent®	NHSE	secondary progressive multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA656 – November 2020
BLACK	Sipuleucel-T	<i>(Provenge®)</i>	NHSE	Treatment of adults with asymptomatic or minimally symptomatic metastatic hormone relapsed prostate cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA332 - Mar 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Sirolimus	(Rapamune®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17
BLACK	Sirolimus	(Rapamune®)	NHSE	Initial treatment to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 & 482 (Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17
SCA	Sirolimus	(Rapamune®)	NHSE	Immunosuppression in adult solid organ transplantation - as per NICE TA 481	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	TA481 - Oct 17
BLACK	Sirolimus	Rapamune®	NHSE	facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA972 – May 2024
RED	Sirukumab	(Plivensia®)	NHSE	Paediatric indications (where adult TA available) - as per NHSE policy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Smart One (portable spirometer)	(Smart One (portable spirometer))	ICB	Measuring lung function	Not commissioned. No NHS prescribing in primary or secondary care	MIB96 - Feb 17
BLACK	Smartinhaler	(Smartinhaler)	ICB	Asthma	Not commissioned. No NHS prescribing in primary or secondary care	MIB90 - Jan 17
BLACK	Sodium Chloride (Hypertonic 3-7%) as a mucolytic	(Various including MucoClear®, Nebusal®)	ICB	Prevent exacerbations in people with stable chronic obstructive pulmonary disease (COPD) - as per NICE CG 101 - Do Not Do (x).	Not commissioned. No NHS prescribing in primary or secondary care	CG101 - Jul 10

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Sodium Chloride (Hypertonic 3-7%) for inhalation	<i>(MucoClear®, Nebusal®)</i>	NHSE	Clearance of mucosal secretions in Cystic Fibrosis and Bronchiectasis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Sodium chloride nasal appliance	<i>(Sterimar isotonic & hypertonic, Aqua maris)</i>	ICB	Nasal congestion and sinusitis	Not recommended for routine use	NG79 - Oct 17
ADVICE	Sodium Clodronate	<i>(Bonefos®/Loron®)</i>	ICB	Bone pain associated with bony metastases	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	NICE has not issued any guidance.
RED	Sodium oxybate	<i>(Xyrem®)</i>	ICB	Cataplexy associated with narcolepsy in adults aged ≥19 years (under specialist supervision) (A licensed indication). Updated July 2020 following PAC guidance in March 2020	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sodium oxybate	<i>(Xyrem®)</i>	NHSE	Management of narcolepsy with cataplexy in children aged <19 years (specialist centre use only - commissioned by NHS England) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sodium Phenylbutyrate	<i>(Ammonaps®, Pheburane®)</i>	NHSE	Acute hyperammonaemia due to urea cycle disorders (specialist use only)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
Double Red	Sodium valproate ▼ / semisodium ▼	(<i>Epilim®</i> , <i>Episenta®</i> , <i>Depakote®</i>)	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not recommended for routine use	CG90 - Oct 09
RED	Sodium zirconium cyclosilicate (now includes moderate as well as severe)	(<i>Lokelma®</i>)	ICB	moderate (K>6.0) and severe (K>6.5) hyperkalaemia in adults - emergency care	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA599 - Sep 19
ADVICE	Sodium zirconium cyclosilicate (updated from black)	(<i>Lokelma®</i>)	ICB	Hyperkalaemia in adults - persistent use	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should initiate treatment	TA599 - Sep 19
RED	Sofosbuvir ▼	(<i>Sovaldi®</i> ▼)	NHSE	Treatment of chronic hepatitis C in adults - as per NICE TA 330 and NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA330 - Feb 15
RED	Sofosbuvir-velpatasvir ▼	(<i>Epclusa®</i> ▼)	NHSE	Chronic hepatitis C in adults - as per NICE TA 430 and NHSE policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA430 - Jan 17
RED	Sofosbuvir-velpatasvir-voxilaprevir ▼	(<i>Vosevi®</i> ▼)	NHSE	Chronic hepatitis C in adults	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA507 - Feb 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Solriamfetol	Sunosi®	ICB	excessive daytime sleepiness caused by obstructive sleep apnoea	Not commissioned. No NHS prescribing in primary or secondary care	TA777 – March 2022
RED	Solriamfetol	Sunosi®	ICB	excessive daytime sleepiness caused by narcolepsy as per TA758	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA758 – January 2022
RED	Somatrogon	Ngenla®	ICB	growth disturbance in children and young people aged 3 years and over	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA863 – February 2023
RED	Somatropin (Growth hormone)	<i>(Various (lowest cost preparation))</i>	ICB	Adults: Profound growth hormone deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA64 - Aug 03
RED	Somatropin (Growth hormone)	<i>(Various - Omnitrope®, Genotropin®, Norditropin®)</i>	ICB	Children with growth failure with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome and chronic renal insufficiency - as per NICE TA 188 and East of England PAC policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA188 - Jul 10
RED	Somatropin (Growth Hormone)	<i>(Various - Omnitrope®, Genotropin®, Norditropin®)</i>	ICB	Growth disturbance in children born small for gestational age - as per NICE TA 188 and East of England PAC policy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA188 - Jul 10
RED	Sorafenib	<i>(Nexavar®)</i>	NHSE	Treatment of advanced hepatocellular carcinoma as per NICE TA 474 / treatment of papillary or follicular thyroid cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA474 - Sep 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Sorafenib (with lenvatinib) ▼	<i>(Nexavar® (with Lenvima®) ▼)</i>	NHSE	Treatment of progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine - as per NICE TA 535	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA535 - Aug 18
BLACK	Sotagliflozin	<i>(Generics)</i>	ICB	Type 1 diabetes as per NICE TA622	Not commissioned. No NHS prescribing in primary or secondary care	TA622 - Feb 20
RED	Sotorasib	Lumykras®	NHSE	previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA781 – March 2022
RED	Sotrovimab	<i>(Xevudy®)</i>	ICB	for use in patients with covid-19	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA878 – March 2023, updated June 2023
BLACK	Spatone	<i>(Spatone Iron-Plus sachets / products)</i>	ICB	Iron supplement	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	SQ HDM SLIT	n/a	ICB	allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA834 – October 2022
ADVICE	SSRI antidepressants	<i>(Various)</i>	ICB	Use for depression in children and young people (only with talking therapies) - as per NICE CG 28 (Not a licensed indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG28 - Mar 15

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	St Mark's solution (ready made)	<i>(Ready made sachets from unlicensed specials)</i>	ICB	Oral rehydration solution (ORS) which is used in the management of Short Bowel Syndrome (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Stiripentol	<i>(Diacomit®)</i>	ICB	For SCN1A related and Severe Myoclonic Epilepsies in Infancy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Strimvelis	<i>(Strimvelis)</i>	NHSE	Adenosine deaminase deficiency - severe combined immunodeficiency (ADA-SCID) - as per NICE HST 7	Not commissioned. No NHS prescribing in primary or secondary care	HST7 - Feb 18
RED	Sucroferric oxyhydroxide	<i>(Velphoro®)</i>	NHSE	Control serum phosphorus in dialysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Sulfasalazine	<i>(Generics are available)</i>	ICB	Inflammatory Arthritis and Inflammatory Bowel Disease	Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG	NG100 - Jul 18
SCA	Sulfasalazine	<i>(Generics are available)</i>	ICB	Inflammatory Arthritis and Inflammatory Bowel Disease	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG100 - Jul 18
BLACK	Sumatriptan (as Imigran RADIS®)	<i>(Imigran RADIS®)</i>	ICB	Acute migraine; cluster headaches	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Sunitinib	(<i>Sutent</i> ®)	NHSE	First-line for advanced and/or metastatic renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA169 - Mar 09
BLACK	Sunitinib	(<i>Sutent</i> ®)	NHSE	Second-line treatment of advanced and/or metastatic renal cell carcinoma	Not commissioned. No NHS prescribing in primary or secondary care	TA178 - Aug 09
RED	Sunitinib	(<i>Sutent</i> ®)	NHSE	Treatment of gastrointestinal stromal tumours	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA179 - Sep 09
RED	Sunitinib	(<i>Sutent</i> ®)	NHSE	Unresectable or metastatic neuroendocrine tumours in people with progressive disease in adults as per NICE TA 449	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA449 - Jun 17
RED	Susoctocog alfa	(<i>Obizur</i> ®)	NHSE	Antihaemorrhagics, blood coagulation factor VIII	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Sutimlimab		NHSE	Primary cold agglutinin disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tabalumab	()	NHSE	Systemic Lupus Erythematosus (SLE)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Tabelecleucel	n/a	NHSE	post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA923 – October 2023
SCA	Tacrolimus (oral)	<i>(Generic option to be used)</i>	NHSE	Induction of remission, in combination with steroids, in patients with mild-moderate Ulcerative Colitis which is unresponsive to steroids and 5-ASA preparations (Not a licensed indication).	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	CG166 - Jun 13
SCA	Tacrolimus (oral)	<i>(Various)</i>	NHSE	Immunosuppression in adult solid organ transplantation - as per NICE TA 481	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	TA481 - Oct 17
RED	Tacrolimus (oral) - immediate release	<i>(Various)</i>	NHSE	Immunosuppressive therapy to prevent organ rejection in kidney transplant in children and young people - as per NICE TA 482	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA482 - Oct 17
BLACK	Tacrolimus (oral) - prolonged release	<i>(Advagraf®, Envarsus®)</i>	NHSE	Initial treatments to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 and 482	Not commissioned. No NHS prescribing in primary or secondary care	TA481 - Oct 17
BLACK	Tacrolimus (oral) - prolonged release	<i>(Advagraf®, Envarsus®)</i>	NHSE	Initial treatments to prevent organ rejection in adults, children and young people having a kidney transplant - as per NICE TAs 481 and 482	Not commissioned. No NHS prescribing in primary or secondary care	TA482 - Oct 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Tacrolimus 0.03% Ointment ▼	(Protopic® ointment ▼)	ICB	Option for 2nd line treatment of moderate to severe atopic eczema in adults and children over 2 years not controlled by topical steroids where there is serious risk of important ADRs further topical steroid use - as per NICE CG 57	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 3-4 months (1st review).	CG57 - Aug 04
RED	Tadalafil (Adcirca)	(Adcirca®)	NHSE	Pulmonary Arterial Hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tadalafil (Adcirca)	(Adcirca®)	ICB	Raynaud's disease or connective tissue diseases (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Tadalafil (Cialis)	(Cialis®)	ICB	Treatment of symptoms associated with benign prostatic hyperplasia (Not a licensed indication) (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA273 - Jan 13
BLACK	Tadalafil (Cialis)	(Cialis®)	ICB	Use of regular, daily doses for penile rehabilitation in prostate cancer/post radical prostatectomy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Tadalafil taken once every day	(Cialis®)	ICB	Erectile dysfunction/penile rehabilitation	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Tafamidis	(Vyndaqel®)	NHSE	Amyloidosis - Treatment of transthyretin familial amyloid polyneuropathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tafamidis	Vyndaqel®	NHSE	transthyretin amyloidosis with cardiomyopathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA984 – June 2024
BLACK	Tafasitamab	Minjuvi®	NHSE	relapsed or refractory diffuse large B-cell lymphoma	Not commissioned. No NHS prescribing in primary or secondary care	TA883 – May 2023
BLACK	Tagraxofusp	n/a	NHSE	blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA782 – March 2022
RED	Talazoparib	Talzenna®	NHSE	HER2-negative advanced breast cancer with germline BRCA mutations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA952 – February 2024
RED	Taliglucerase alfa	(Eleyso®)	NHSE	Gaucher's Disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Talimogene laherparepvec ▼	(Imlygic® ▼)	NHSE	Unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs, only if treatment with systemically administered immunotherapies is not suitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA410 - Sep 16
ADVICE	Tamoxifen	()	ICB	Chemoprophylaxis for no more than 5 years for pre- or post-menopausal women at either high or moderate risk of developing breast cancer (Not a licenced indication).	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG164 - Jun 13

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Tapentadol (immediate-release)	<i>various</i>	ICB	Management of moderate to severe pain in adults, where opioid analgesia is necessary	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Tapentadol (modified-release)	<i>various</i>	ICB	Severe chronic pain in adults with intolerance to m-r morphine, which can be adequately managed only with opioid analgesics	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	CG140 - Jul 12
RED	Targeted-release budesonide	(Kinpeygo®)	ICB	primary IgA nephropathy	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA937 – December 2023
Double Red	Taribavirin (viramidine)		NHSE	Viral Hepatitis C	Not recommended for routine use	NICE has not issued any guidance.
RED	Teclistamab	Tecvayli®	NHSE	relapsed and refractory multiple myeloma after 3 or more treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1015 – November 2024
RED	Teduglutide	(Revestive®)	NHSE	Short bowel syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Teduglutide	Revestive®	NHSE	short bowel syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA804 – July 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tegafur with uracil	(Uftoral®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA61 - May 03
RED	Teicoplanin	(Targocid®)	ICB	Intravenous treatment at home	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Teicoplanin	(Targocid®)	ICB	Intramuscular treatment at home	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script.	NICE has not issued any guidance.
RED	Telaprevir	(Incivo®)	NHSE	Treatment of genotype 1 chronic hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA252 - Apr 12
RED	Temozolomide	(Temodal®)	NHSE	Malignant glioma (brain cancer)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA121 - Jun 07
RED	Temozolomide	(Temodal®)	NHSE	Endocrinology, non-malignant conditions	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Temsirolimus	(Torisel®)	NHSE	First-line treatment of advanced and/or metastatic renal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA178 - Aug 09
BLACK	Temsirolimus	(Torisel®)	NHSE	Treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA207 - Oct 10
RED	Tenecteplase	Metalyse	ICB	acute ischaemic stroke	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA990 - July 2024
RED	Tenofovir alafenamide fumarate	(Vemlidy®)	NHSE	HIV alone or in combination with other anti-retroviral drugs - as per NHS England Policy 16043/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Tenofovir alafenamide fumarate ▼	(Vemlidy® ▼)	NHSE	Chronic Hepatitis B (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA435 - March 2017
RED	Tenofovir disoproxil	(Viread®)	NHSE	Treatment of chronic hepatitis B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA173 - Jul 09
RED	Tepotinib	Tepmetko®	NHSE	advanced non-small-cell lung cancer with MET gene alterations	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA789 – May 2022

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Teprasiran		NHSE	Prevention of delayed graft function	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Teriflunomide ▼	(Aubagio® ▼)	NHSE	Relapsing remitting multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA303 - Jan 14
RED	Teriparatide	(Forsteo®)	ICB	Secondary prevention of osteoporotic fragility fractures in postmenopausal women	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA161 - Oct 08
RED	Teriparatide	(Forsteo®)	NHSE	Osteogenesis imperfecta - as per NHS England Policy 16002/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Teriparatide	(Forsteo®)	NHSE	Male and juvenile osteoporosis (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
SCA	Testosterone	Sustanon 250® Restandol® Testocaps®	ICB	Boys in Infancy and Adolescence	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Testosterone	various	ICB	off-label testosterone in women for hypoactive sexual disorder during the menopause	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
BLACK	Testosterone - transdermal patches	()	ICB	Hormone replacement in androgen deficiency	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Testosterone - various formulations except patches	(Various)	ICB	Androgen deficiency / treatment of transgender patients requiring virilising endocrine therapy	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Tetrabenazine tablets	Xenazine® 25	ICB	hyperkinetic motor disorders with Huntington's chorea	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation. Specialist will initiate and retain patient until stable	NICE has not issued any guidance
RED	Tetrahydrobiopterin (BH4, THB) - aka Sapropterin	(Sapropterin (Kuvan®))	NHSE	Phenylketonuria (PKU) - Specialist centres only - Highly specialised criteria only (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tezacaftor	(Symkevi® (with ivacaftor))	NHSE	Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tezacaftor, Ivacaftor and Elexacaftor	Kaftrio®	NHSE	patients 6 years and over who have cystic fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tezepelumab	Tezspire®	ICB	severe asthma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA880 – April 2023
RED	Thalidomide	<i>(Thalidomide Celgene®)</i>	NHSE	Multiple myeloma (first-line)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA228 - Jul 11
RED	Thrombin	<i>(Various)</i>	NHSE	Pseudoaneurysm - as per NICE IPG060	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	IPG060 - Nov 04
BLACK	Thyroxine (Levothyroxine sodium)	<i>(Generics are available)</i>	ICB	Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do	Not commissioned. No NHS prescribing in primary or secondary care	CG53 - Aug 07
Double Red	Thyroxine (Levothyroxine sodium) / Liothyronine	<i>(Generics)</i>	ICB	Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do (Not a licensed indication).	Not recommended for routine use	NG90 - Oct 09

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Ticagrelor	(Brilique®)	ICB	(With aspirin) to prevent atherothrombotic events in patients with ACS as per NICE TA 236	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script.	TA236 - Oct 11
ADVICE	Ticagrelor	(Brilique®)	ICB	In combination with aspirin for preventing atherothrombotic events who had a myocardial infarction and who are at high risk of a further event as per NICE TA 420	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA420 - Dec 16
RED	Tildrakizumab	(Ilumetri®)	ICB	Moderate to severe plaque psoriasis in adults - as per NICE TA 575 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA575 - Apr 19
RED	Tioguanine	(Lanvis®)	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tipranavir	(Aptivus®)	NHSE	HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Tirbanibulin	Klisyri®	ICB	actinic keratosis	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tirofiban	(Aggrastat®)	ICB	Prevention of MI in unstable angina	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA47 - Sep 02
ADVICE	Tirzepatide	Mounjaro®	ICB	type 2 diabetes	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA924 – October 2023
BLUE	Tirzepatide	Mounjaro®	ICB	managing overweight and obesity	NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required	TA1026 - Dec 2024
RED	Tisagenlecleucel	(Kymriah®)	NHSE	For treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - as per NICE 567 (NHSE commissioning responsibility)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA567 - Mar 19
BLACK	Tisagenlecleucel	N/A	N/A	relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies	Not commissioned. No NHS prescribing in primary or secondary care	TA933 – November 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tisagenlecleucel	Kymriah®	NHSE	relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA975 – May 2024
BLACK	Tisagenlecleucel	Kymriah®	NHSE	follicular lymphoma after 2 or more therapies (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA842 – November 2022
RED	Tivozanib	(<i>Fotivda</i> ®)	NHSE	Advanced renal cell carcinoma - as per NICE TA 512	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA512 - Mar 18
BLACK	Tixagevimab plus cilgavimab	Evusheld®	ICB	for use in patients with covid-19	Not commissioned. No NHS prescribing in primary or secondary care	TA971 – May 2024
RED	Tobramycin (nebulised)	(<i>Tobi</i> ®, <i>Bramitob</i> ®)	NHSE	Pseudomonas aeruginosa infection in patients with Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tobramycin Dry Powder Inhaler	(<i>Tobi Podhaler</i> ®)	NHSE	Pseudomonas lung infection in Cystic Fibrosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA276 - Mar 13
RED	Tocilizumab	(<i>RocActemra</i> ®)	ICB	Systemic juvenile idiopathic arthritis - as per NICE TA 238	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA238 - Dec 11

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tocilizumab	RoActemra®	NHSE	Critically ill patients with COVID-19 pneumonia (adults)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	ES33 – January 2021
RED	Tocilizumab	(RoActemra®)	NHSE	Adult onset Stills Disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tocilizumab	(RoActemra®)	ICB	for use in patients with covid-19	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA878 – March 2023, updated June 2023
RED	Tocilizumab (monotherapy)	(RoActemra®)	ICB	Option for use as per recommended pathway for moderate to severe rheumatoid arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tocilizumab (with methotrexate)	(RoActemra®)	ICB	Rheumatoid arthritis in adults - as per NICE TA 247	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA247 - Feb 12
RED	Tocilizumab IV	(RoActemra® for infusion)	NHSE	Juvenile arthritis paediatric - as per NHS England Policy E03/P/d & NICE TA 373 (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA373 - Dec 15
RED	Tocilizumab IV	(RoActemra® for infusion)	NHSE	Treatment of giant cell arteritis - as per NHS England Policy 16019/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA518 - Apr 18

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tocilizumab IV	(RoActemra® for infusion)	NHSE	Takayasu arteritis - as per NHS England policy 16056/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tocilizumab IV	(RoActemra® for infusion)	NHSE	Juvenile arthritis paediatric (where adult TA available - as per TA 247 & 375)) (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tofacitinib	(Xeljanz®)	ICB	Active psoriatic arthritis in adults after inadequate response to DMARDs under certain conditions - as per NICE TA 543 and local business application	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA543 - Oct 18
RED	Tofacitinib	(Xeljanz®)	ICB	Moderately to severely active ulcerative colitis in adults - as per NICE TA 547 (option after biosimilar adalimumab	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA547 - Nov 18
RED	Tofacitinib	Xeljanz®	NHSE	juvenile idiopathic arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA735 – October 2021
RED	Tofacitinib	Xeljanz®	ICB	active ankylosing spondylitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA920 – October 2023
RED	Tofacitinib ▼	(Xeljanz® ▼)	ICB	Treatment of moderate to severe active rheumatoid arthritis in adults (with and without methotrexate) - as per NICE TA 480 and local pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA480 - Oct 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Tolvaptan	(Jinarc®, Samsca®)	NHSE	Hyponatraemia in cancer - as per NHS England Policy 16051/P (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tolvaptan ▼	(Jinarc®, Samsca® ▼)	ICB	Autosomal dominant polycystic kidney disease in adults - NICE TA 358	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA358 - Oct 15
RED	Topotecan	(Hycamtin®)	NHSE	Advanced ovarian cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA28 - May 05
RED	Topotecan	(Hycamtin®)	NHSE	Treatment of recurrent and stage IVB cervical cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA183 - Oct 09
BLACK	Topotecan	(Hycamtin®)	NHSE	Treatment of advanced recurrent ovarian cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA389 - Apr 16
RED	Topotecan (oral)	(Hycamtin®)	NHSE	Treatment of relapsed small-cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA184 - Nov 09
BLACK	Toripalimab	n/a	n/a	with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA1024 – December 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Total parenteral nutrition	(Various)	NHSE	Various	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Trabectedin	(Yondelis®)	NHSE	Treatment of advanced soft tissue sarcoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA185 - Feb 10
BLACK	Trabectedin	(Yondelis®)	NHSE	(In combination with pegylated liposomal doxorubicin HCl) for relapsed ovarian cancer	Not commissioned. No NHS prescribing in primary or secondary care	TA389 - Apr 16
RED	Tralokinumab	Adtralza®	NHSE	Asthma (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Tralokinumab	Adtralza®	ICB	moderate to severe atopic dermatitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA814 – August 2022
BLACK	Tramadol & paracetamol combination	(Tramacet®)	ICB	Moderate to severe pain	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Trametinib	(Mekinist®)	NHSE	(with dabrafenib (Tafinlar®)) for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer - as per NICE TA 564	Not commissioned. No NHS prescribing in primary or secondary care	TA564 - Feb 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Trametinib ▼	(<i>Mekinist</i> ® ▼)	NHSE	Unresectable or metastatic melanoma in adults with a BRAF V600 mutation (with dabrafenib)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA396 - Jun 16
RED	Tranexamic Acid mouthwash	Unlicensed special	ICB	Oral bleeds. Restricted to use by local hospital trusts only	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Transanal irrigation /Rectal Irrigation appliances	(<i>Peristeen</i> ®, <i>Qufora</i> ®, <i>Aquaflush</i> ®, <i>IryPump S</i> ®)	ICB	Bowel dysfunction; Chronic constipation; Faecal incontinence. Initiation by hospital consultants for adults acro	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Transanal irrigation/Rectal Irrigation appliances	(<i>Peristeen</i> ®, <i>Qufora</i> ®, <i>IryPump S</i> ®)	ICB	Chronic Constipation and Faecal Incontinence (as recommended by the NCH&C Adult Continence Service only) - as an option as per agreed treatment pathways	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
ADVICE	Transanal irrigation/Rectal Irrigation appliances	(<i>Peristeen</i> ®, <i>Qufora</i> ®)	ICB	Chronic Constipation and Faecal Incontinence in Paediatrics (as recommended by the NNUH Paediatrics Service) - as per agreed treatment pathway	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Trastuzumab	(<i>Herceptin</i> ®)	NHSE	Advanced breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA34 - Mar 02

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Trastuzumab	<i>(Herceptin®)</i>	NHSE	Adjuvant treatment of early-stage HER2-positive breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA107 - Feb 09
RED	Trastuzumab	<i>(Herceptin®)</i>	NHSE	HER2-positive metastatic gastric cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA208 - Nov 10
BLACK	Trastuzumab	<i>(Herceptin®)</i>	NHSE	In combination with an aromatase inhibitor, 1st-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2	Not commissioned. No NHS prescribing in primary or secondary care	TA257 - Jun 12
RED	Trastuzumab deruxtecan	Enhertu®	NHSE	HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA704 – May 2021
RED	Trastuzumab deruxtecan	Enhertu®	NHSE	HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA862 – February 2023
BLACK	Trastuzumab deruxtecan	Enhertu®	NHSE	HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment	Not commissioned. No NHS prescribing in primary or secondary care	TA879 – April 2023
BLACK	Trastuzumab deruxtecan	Enhertu®	NHSE	HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA976 – May 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Trastuzumab deruxtecan	Enhertu®	NHSE	HER2-low metastatic or unresectable breast cancer after chemotherapy	Not for prescribing in primary or secondary care	TA992 – July 2024
RED	Trastuzumab emtansine ▼	(Kadcyla® ▼)	NHSE	HER2-positive, unresectable locally advanced or metastatic breast cancer, after treatment with trastuzumab and a taxane (paclitaxel or docetaxel) as per NICE TA 458	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA458 - Jul 17
RED	Trastuzumab emtansine ▼	(Kadcyla® ▼)	NHSE	adjuvant treatment of HER2-positive early breast cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA632 – June 2020
RED	Trenonacog alpha	(IXinity®)	NHSE	Haemophilia B	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Treosulfan	Trecondi®	NHSE	with fludarabine for malignant disease before allogeneic stem cell transplant	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA640 – August 2020
RED	Treosulfan	Trecondi®	NHSE	All indications	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Treosulfan	N/A	NHSE	with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA945 – January 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Treprostinil	<i>(Tyvaso (EU), Remodulin (U.S))</i>	NHSE	Peripheral Arterial Hypertension	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Treprostinil diethanolamine	<i>(Orenitram (US))</i>	NHSE	Pulmonary Arterial Hypertension (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Treprostinil sodium	<i>(Trevyent®)</i>	NHSE	Pulmonary Arterial Hypertension - as per NHS England policy A11/P/c	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Triamcinolone and Erythromycin mouthwash	Knox mouthwash	ICB	Oral lichen planus	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance
RED	Trientine dihydrochloride	<i>(Metalite® (Japanese import))</i>	NHSE	Wilson's Disease (where penicillamine not tolerated)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Trifluridine–tipiracil	Lonsurf®	NHSE	metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA852 – December 2022
RED	Trifluridine–tipiracil	Lonsurf®	NHSE	with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1008 – September 2024

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Trifluridine-tipiracil ▼	(Lonsurf® ▼)	NHSE	For previously treated metastatic colorectal cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA405 - Aug 16
RED	Triheptanoin		NHSE	Pyruvate carboxylase deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Trihexyphenidyl hydrochloride	(Generics available)	ICB	NICE Do Not Do - Dyskinesia and/or motor fluctuations in Parkinson's disease - as per NG 71	Not commissioned. No NHS prescribing in primary or secondary care	NG71 -Sep 17
BLACK	Tri-Luma®	(Tri-Luma®)	ICB	Melasma (Chloasma)	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Trimetazidine	N/A	ICB	refractory angina	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Trimipramine	(Generics available)	ICB	Treatment of depressive illness, especially where sleep disturbance, anxiety or agitation are presenting symptoms	Not recommended for routine use	NICE has not issued any guidance.
SCA	Triptorelin	(Decapeptyl® SR)	ICB	Treatment of precocious puberty, menorrhagia and dysmenorrhoea in children	Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly	NICE has not issued any guidance.
SCA	Triptorelin	(Decapeptyl® SR; Gonapeptyl® Depot)	ICB	Management of endometriosis; pre-operative management of uterine fibroids	Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly	NG73 - Sep 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Triptorelin acetate	(Decapeptyl®; Gonapeptyl®)	ICB	Prostate cancer	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	NICE has not issued any guidance.
RED	Tucatinib	TUKYSA®	NHSE	with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA786 – April 2022
RED	Ublituximab	Briumvi®	NHSE	relapsing multiple sclerosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1025 – December 2024
RED	Ulipristal ▼ (Esmya®)	(Esmya® ▼)	ICB	First line option for treatment of symptoms of fibroids ≥ 3cm and with Hb ≤102g/L	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ulipristal acetate ▼ (Esmya®)	(Esmya® ▼)	ICB	Pre-operative treatment of moderate to severe symptoms of uterine fibroids	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Unloading Knee Braces	Various	ICB	Support for knee joint	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Upadacitinib	Rinvoq®	ICB	Severe rheumatoid arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA665 – December 2020

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Upadacitinib	Rinvoq®	ICB	previously treated moderately to severely active Crohn's disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA905 – June 2023
RED	Upadacitinib	Rinvoq®	ICB	moderate rheumatoid arthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA744 – November 2021
RED	Upadacitinib	Rinvoq®	ICB	active psoriatic arthritis after inadequate response to DMARDs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA768 – February 2022
RED	Upadacitinib	Rinvoq®	ICB	active ankylosing spondylitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA829 – October 2022
RED	Upadacitinib	Rinvoq®	ICB	active non-radiographic axial spondyloarthritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA861 – February 2023
RED	Upadacitinib	Rinvoq®	ICB	moderate to severe atopic dermatitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA814 – August 2022
RED	Upadacitinib	Rinvoq®	ICB	moderately to severely active ulcerative colitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA856 – Jan 2023

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Uprifosbuvir		NHSE	Hepatitis C	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Uroshield Catheter Device	()	ICB	Preventing catheter-related urinary infections	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Ustekinumab	(Stelara®)	ICB	Treatment of adults with moderate to severe psoriasis - as per NICE TA 180 and CG153	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA180 - Oct 12
RED	Ustekinumab	(Stelara®)	ICB	Treatment of active psoriatic arthritis, as monotherapy or in combination with methotrexate, following inadequate response to previous non-biological DMARDs - as per NICE TA 340 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA340 - Jul 15
RED	Ustekinumab	(Stelara®)	NHSE	Plaque psoriasis in children and young people - as per NICE TA 455	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA455 - Jul 17
RED	Ustekinumab	(Stelara®)	ICB	2nd line (biologic) option for moderately to severely active Crohn's disease after previous treatment - as per NICE 456 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA456 - Jul 17
RED	Ustekinumab	(Stelara®)	ICB	Treating moderately to severely active ulcerative colitis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA633 - Jun 20

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Ustekinumab	(Stelara®)	NHSE	Treatment of psoriasis and psoriatic arthritis in Paediatrics (where an adult NICE guidance is available - TAs 180, 340) - NHSE policy (Not a licenced indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Ustekinumab	(Stelara®)	ICB	Dose escalation in the treatment of severe psoriasis which has responded inadequately to the initial ustekinumab dosage regimen	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Vacuum dressings	(Vacuum Assisted Closure (VAC dressings).)	ICB	Healing of chronic wounds	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Vacuum pumps / devices for erectile dysfunction	(Various)	ICB	Erectile dysfunction	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Vadadustat	()	NHSE	Anaemia in chronic kidney disease in dialysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Vaginal dilators or trainers	(Femmax®, Ameille Care® and Ameille Comfort®)	ICB	Following vaginal reconstruction surgery or following pelvic radiotherapy when recommended by an appropriate Secondary Care Specialist	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Valganciclovir	(Valcyte®)	NHSE	Prevention of CMV disease following solid organ transplantation	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
ADVICE	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	epilepsy and bipolar in women of childbearing potential	Formulary - Secondary care clinician to initiate and stabilise before transfer to primary care	NICE has not issued any guidance.
RED	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	epilepsy and bipolar - in women of childbearing potential where the conditions of PREVENT are not met	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	epilepsy and bipolar - use in pregnancy	Not recommended for routine use	NICE has not issued any guidance.
BLACK	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	Migraine - all women under 55 of childbearing potential	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	Migraine - women over 55	Formulary - Secondary care clinician to initiate and stabilise before transfer to primary care	NICE has not issued any guidance.
BLACK	Valproate-containing products	Sodium Valproate, Valproic Acid and Valproate Semisodium	ICB	All other indications in women of childbearing potential	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
Double Red	Valsartan / Amlodipine	(Exforge®)	ICB	Hypertension	Not recommended for routine use	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Vandetanib	(<i>Caprelsa®</i>)	NHSE	For treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease - as per NICE TA 550	Not commissioned. No NHS prescribing in primary or secondary care	TA550 - Dec 18
BLACK	Vardenafil	(<i>Levitra®</i>)	ICB	Use of regular, daily doses for penile rehabilitation in prostate cancer/post radical prostatectomy	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
ADVICE	Varenicline	(<i>Champix®</i>)	PHE	Adjunct to smoking cessation in combination with motivational support - Public Health England commissioning responsibility - as per NICE TA 123 GP prescribable after consultant/specialist recommendation where the specialist is a smoking cessation adviser (level 2 or 3)	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation	TA123 - Jul 07
RED	Vatiquinone		NHSE	Friedreichs ataxia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Vedolizumab	(<i>Entyvio®</i>)	ICB	chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA826 – September 2022
RED	Vedolizumab	(<i>Entyvio®</i>)	NHSE	Paediatric indications (where an adult NICE TA is available - TAs 342 & 352)) - Specialist Centre only (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Vedolizumab ▼	(<i>Entyvio</i> ® ▼)	ICB	3rd line (biologic) treatment option for moderately to severely active ulcerative colitis in adults - as per NICE TA 342 and the local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA342 - Jun 15
RED	Vedolizumab ▼	(<i>Entyvio</i> ® ▼)	ICB	3rd line biologic treatment option for moderately to severely active Crohn's disease - as per NICE TA 352 and local treatment pathway	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA352 - August 2015
RED	Velaglucerase alfa	(<i>VPRIV</i> ®)	NHSE	Type I Gaucher's disease (specialist use only) - as per NHS England specification	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Velcalcetide (aka Etelcalcetide)	(<i>Parsabiv</i> ®)	NHSE	Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Velmanase alfa	Lamzede®	NHSE	alpha-mannosidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST29 – December 2023
RED	Vemurafenib	(<i>Zelboraf</i> ®)	NHSE	Melanoma (BRAF V600 mutation positive, unresectable metastatic)	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA269 - Dec 13
RED	Venetoclax	(<i>Venclyxto</i> ®)	NHSE	(with rituximab) for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy - as per NICE TA 561	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA561 - Feb 19

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Venetoclax	(Venclyxto®)	NHSE	with obinutuzumab for untreated chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA663 – December 2020
RED	Venetoclax	Venclyxto®	NHSE	with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA765 – February 2022
RED	Venetoclax	Venclyxto®	NHSE	with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA787 – April 2022
RED	Venetoclax	Venclyxto®	NHSE	chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA796 – June 2022
BLACK	Venlafaxine	(Generics / Various)	ICB	Depression in children and young people - as per NICE CG 28 "Do Not Do" (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	CG28 - Sep 17
BLACK	Vericiguat	N/A	ICB	chronic heart failure with reduced ejection fraction (terminated)	Not commissioned. No NHS prescribing in primary or secondary care	TA731 – September 2021
BLACK	Vernakalant	N/A	ICB	Rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA675 – February 2021
RED	Verteporfin	(Visudyne®)	ICB	With photodynamic therapy (PDT) - Chronic Central Serous Chorio-Retinopathy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Vestronidase Alfa		NHSE	Mucopolysaccharidosis VII	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Vibegron	Obgemsa®	ICB	symptoms of overactive bladder syndrome	Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA999 – September 2024
BLACK	Vinflunine	(<i>Javlor®</i> ▼)	NHSE	Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract - as per NICE TA 272	Not commissioned. No NHS prescribing in primary or secondary care	TA272 - Jan 13
RED	Vinorelbine	(<i>Navelbine®</i> , <i>Navelbine® Capsules</i> ▼)	NHSE	Non-small cell lung cancer	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA26 - Jun 01
RED	Vinorelbine	(<i>Navelbine®</i> , <i>Navelbine® Capsules</i> ▼)	NHSE	Advanced breast cancer - as per NICE 81	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	CG81 - Feb 09
BLACK	Virulite electronic cold sore device	(<i>Virulite</i>)	ICB	Electronic cold sore device (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Vismodegib ▼	(<i>Erivedge®</i> ▼)	NHSE	Basal cell carcinoma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA489 - Nov 17

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Vitamin B Co / Co Strong tablets	()	ICB	Time-limited use (10 days) only in re-feeding syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
BLACK	Vitamin E	(Various)	ICB	NICE Do Not Do - Pharmacological neuroprotective therapy in Parkinson's disease - as per NG 71 (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NG71 - Sep 17
RED	Voclosporin	Lupkynis®	NHSE	with mycophenolate mofetil for treating lupus nephritis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA882 – May 2023
RED	Volanesorsen	Waylivra	NHSE	Familial chylomicronemia syndrome	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST13 - Oct 2020
RED	Von Willebrand factor, recombinant - Factor VIII	(Von Willebrand factor (recombinant))	NHSE	Von Willebrand's disease / factor VIII deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Vonicog Alfa	(Veyvont®)	NHSE	Von Willebrand Deficiency	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Voretigene Neparvovec	Luxturna	NHSE	Inherited Retinal Dystrophies	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	HST11 - Oct 2019

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Voriconazole	(Vfend®)	NHSE	Systemic fungal infections	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Voxelotor	Oxbryta®	NHSE	haemolytic anaemia caused by sickle cell disease	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA981 – June 2024
RED	Vutrisiran	Amvuttra®	NHSE	hereditary transthyretin-related amyloidosis	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA868 – February 2023
RED	VX-210		NHSE	Spinal cord Injury	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
Double Red	Warfarin	(Generics available)	ICB	Routine use in combination with prasugrel or ticagrelor to people who need anticoagulation who have had an MI - as per NICE CG 172 - Do Not Do	Not recommended for routine use	CG172 - Nov 13
RED	Wasp / Bee venom extract (Pharmalgen®)	(Pharmalgen® Wasp / Bee venom extract)	ICB	Wasp / Bee venom allergy - as per NICE TA 246	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA246 - Feb 12
BLACK	Waterproof dressing protectors	LimbO, Seal-Tight and all related brands/devices	ICB	Waterproof protectors to wear in shower/bath to protect casts, dressings and PICC lines.	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
BLACK	Yasmin	(Yasmin®)	ICB	Contraception	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
BLACK	Yohimbine	(eg Prowess, Aphrodyne, Dayto Himbin, Yocon, Yohime s)	ICB	Erectile dysfunction (Not a licensed indication).	Not commissioned. No NHS prescribing in primary or secondary care	NICE has not issued any guidance.
RED	Zanubrutinib	Brukinsa®		chronic lymphocytic leukaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA931 – November 2023
BLACK	Zanubrutinib	Brukinsa®	NHSE	with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)	Not commissioned. No NHS prescribing in primary or secondary care	TA978 – May 2024
RED	Zanubrutinib	Brukinsa®	NHSE	marginal zone lymphoma after anti-CD20-based treatment	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA1001 – September 2024
RED	Zanubrutinib	Brukinsa®	NHSE	Waldenstrom's macroglobulinaemia	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	TA833 – October 2022
RED	Ziconotide	(Prialt®)	NHSE	Intrathecal analgesia for severe chronic pain - as per NHS England Policy 16011/P	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.

Traffic Light Classification	Drug Name	Brand Name	Commissioner	Indication (assume licenced unless stated)	Instructions for Prescriber	NICE Guidance
RED	Zidovudine (also with lamivudine and Abacavir)	<i>(Retrovir® / Combivir® / Trizivir® / Generics)</i>	NHSE	HIV infection in combination with other antiretroviral drugs	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Zoledronic Acid	<i>(Various)</i>	ICB	To prolong survival and prevent skeletal-related events (SREs) in patients with plasma cell myeloma	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
RED	Zoledronic acid	<i>(Various)</i>	ICB	6-monthly infusions for 2 years to improve survival in post-menopausal women with breast cancer receiving chemotherapy (Not a licensed indication).	Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care	NICE has not issued any guidance.
ADVICE	Zonisamide	<i>(Zonegran®)</i>	ICB	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 18 years and older	Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of one month.	NICE has not issued any guidance.